WO2015015318A2 - Novel quinazolinones as bromodomain inhibitors - Google Patents

Novel quinazolinones as bromodomain inhibitors Download PDF

Info

Publication number
WO2015015318A2
WO2015015318A2 PCT/IB2014/002510 IB2014002510W WO2015015318A2 WO 2015015318 A2 WO2015015318 A2 WO 2015015318A2 IB 2014002510 W IB2014002510 W IB 2014002510W WO 2015015318 A2 WO2015015318 A2 WO 2015015318A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amino
cancer
disease
mmol
Prior art date
Application number
PCT/IB2014/002510
Other languages
French (fr)
Other versions
WO2015015318A3 (en
WO2015015318A4 (en
Inventor
John Frederick QUINN
Vladimir Khlebnikov
Original Assignee
Zenith Epigenetics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/908,898 priority Critical patent/US9855271B2/en
Priority to CA2919948A priority patent/CA2919948C/en
Priority to JP2016530632A priority patent/JP6542212B2/en
Priority to KR1020167005227A priority patent/KR20160038008A/en
Priority to CN201480053771.5A priority patent/CN105593224B/en
Priority to EP14832298.5A priority patent/EP3027604B1/en
Priority to EA201690087A priority patent/EA201690087A1/en
Priority to AU2014298051A priority patent/AU2014298051B2/en
Application filed by Zenith Epigenetics Corp. filed Critical Zenith Epigenetics Corp.
Publication of WO2015015318A2 publication Critical patent/WO2015015318A2/en
Publication of WO2015015318A3 publication Critical patent/WO2015015318A3/en
Publication of WO2015015318A4 publication Critical patent/WO2015015318A4/en
Priority to IL243479A priority patent/IL243479B/en
Priority to HK16106581.4A priority patent/HK1218547A1/en
Priority to US15/821,454 priority patent/US10500209B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention provides novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions associated with bromodomain and extra terminal domain (BET) proteins.
  • BET bromodomain and extra terminal domain
  • PTMs Post-translational modifications
  • Histone acetylation at specific lysine residues is a PTM that is regulated by histone acetylases (HATs) and deacetylases (HDACs).
  • HATs histone acetylases
  • HDACs deacetylases
  • bromodomain and extra terminal domain (BET) proteins comprises Brd2, Brd3, Brd4, and BrdT, each of which contains two bromodomains in tandem that can independently bind to acetylated lysines, as reviewed in S. Wu and C. Chiang, “The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation,” J Biol Chem 282(18): 13141-5 (2007).
  • BET domain co-regulators in obesity, inflammation and cancer, " Nat Rev Cancer 12(7):465-77 (2012).
  • BET inhibitors are believed to be useful in the treatment of diseases or conditions related to systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis, and the prevention and treatment of viral infections.
  • R. Prinjha et al. "Place your BETs: the therapeutic potential of bromodomains, " Trends Pharmacol Sci 33(3): 146-53 (2012).
  • BET inhibitors are expected to have anti-inflammatory and immunomodulatory properties.
  • BET inhibitors have been shown to have a broad spectrum of antiinflammatory effects in vitro including the ability to decrease expression of pro-inflammatory cytokines such as IL- ⁇ , MCP-1, TNF- ⁇ , and I L-6 in activated immune cells.
  • pro-inflammatory cytokines such as IL- ⁇ , MCP-1, TNF- ⁇ , and I L-6 in activated immune cells.
  • the mechanism for these anti-inflammatory effects may involve BET inhibitor disruption of Brd4 co-activation of NF-KB-regulated pro-inflammatory cytokines and or displacement of BET proteins from cytokine promoters, including EL-6.
  • BET inhibitor disruption of Brd4 co-activation of NF-KB-regulated pro-inflammatory cytokines and or displacement of BET proteins from cytokine promoters, including EL-6.
  • a BET inhibitor has been shown to ameliorate inflammation and kidney injury in HIV-1 transgenic mice, an animal model for HIV-associated nephropathy, in part through inhibition of Brd4 interaction with NF-kappaB.
  • the utility of BET inhibition in autoimmune disease was demonstrated in a mouse model of multiple sclerosis, where BET inhibition resulted in abrogation of clinical signs of disease, in part, through inhibition of IL-6 and IL-17.
  • BET inhibitors may be useful in the treatment of a variety of chronic autoimmune inflammatory conditions.
  • one aspect of the invention provides compounds, compositions, and methods for treating autoimmune and/or inflammatory diseases by administering one or more compounds of the invention or pharmaceutical compositions comprising one or more of those compounds.
  • autoimmune and inflammatory diseases, disorders, and syndromes that may be treated using the compounds and methods of the invention include but are not limited to, inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis (G.
  • BET inhibitors may be useful in the treatment of a wide variety of acute inflammatory conditions.
  • one aspect of the invention provides compounds, compositions, and methods for treating inflammatory conditions including but not limited to, acute gout, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement, such as glomerulonephritis, vasculitis, including giant cell arteritis, Wegener's granulomatosis, polyarteritis nodosa, Behcet's disease, Kawasaki disease, and Takayasu's arteritis.
  • BET inhibitors may be useful in the prevention and treatment of diseases or conditions that involve inflammatory responses to infections with bacteria, viruses, fungi, parasites, and their toxins, such as, but not limited to sepsis, sepsis syndrome, septic shock (E.
  • one aspect of the invention provides compounds, compositions, and methods for treating these inflammatory responses to infections with bacteria, viruses, fungi, parasites, and their toxins described herein.
  • Cancer is a group of diseases caused by dysregulated cell proliferation.
  • Cancer cells accumulate genetic and epigenetic changes that alter cell growth and metabolism, promoting cell proliferation and increasing resistance to programmed cell death, or apoptosis. Some of these changes include inactivation of tumor suppressor genes, activation of oncogenes, and modifications of the regulation of chromatin structure, including deregulation of histone PTMs. J. Watson "Giring 'incurable' cancer,” Cancer Discov l(6):477-80 (2011); R. Morin et al., "Frequent mutation of histone-modifying genes h non-Hodgkin lymphoma” Nature 476(7360):298- 303 (2011).
  • One aspect of the invention provides compounds, compositions, and methods for treating human cancer, including, but not limited to, cancers that result from aberrant translocation or overexpression of BET proteins (e.g., NUT midline carcinoma (NMC) (C. French “NUT midline carcinoma,” Cancer Genet Cytogenet 203(l):16-20 (2010) and B- cell lymphoma (R. Green wald et al., "E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia,” Blood 103(4): 1475-84 (2004)).
  • NMC tumor cell growth is driven by a translocation of the Brd4 or Brd3 gene to the nutlin 1 gene.
  • cancers include Burkitt's lymphoma, acute myelogenous leukemia, multiple myeloma, and aggressive human medulloblastoma. M. Vita and M. Henriksson, Semin Cancer Biol 16(4):318-30 (2006). Cancers in which c-myc is overexpressed may be particularly susceptible to BET protein inhibition; it has been shown that treatment of tumors that have activation of c-myc with a BET inhibitor resulted in tumor regression through inactivation of c-myc transcription. M. Dawson et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature, 2011. 478(7370): p. 529-33; J.
  • Embodiments of the invention include methods for treating human cancers that rely on BET proteins and pTEFb (Cdk9/CyclinT) to regulate oncogenes (S. Wang, and P. Fischer, "Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol Sci 29(6):302-13 (2008)), and cancers that can be treated by inducing apoptosis or senescence by inhibiting Bcl2, cyclin-dependent kinase 6 (CDK6) (M. Dawson et al., Nature 478 (7370):529-33 (2011)), or human telomerase reverse transcriptase (hTERT). J. Delmore et al., Cell 146(6):904-17 (2010); M. Ruden and N. Puri, “Novel anticancer therapeutics targeting telomerase,” Cancer Treat Rev (2012).
  • BET inhibitors may be useful in the treatment of cancers including, but not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryob 1 astic leukemia, acute monocytic leukemia, acute myeloid leukemia (M. Dawson et al., Nature 478(7370):529-33 (2011); J. Mertz, et al., Proc Natl Acad Sci USA 108(40): 16669-74 (2011); J. Zuber et al., Nature
  • adenomatoid odontogenic tumor adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angi oimmunob I astic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell acute lymphoblastic leukemia(C.
  • breast cancer brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small
  • fibroblastoma giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor,
  • gynandroblastoma gallbladder cancer, gastric cancer, hairy cell leukemia,
  • hemangioblastoma head and neck cancer
  • hemangiopericytoma hematological
  • malignancy hepatoblastoma, hepatospienic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia (Mertz, J.A., et al., Proc Natl Acad Sci USA 108(40): 16669-74 (2011)), chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell
  • muscle tissue neoplasm mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, NUT- midline carcinoma (P. Filippakopoulos et al., Nature 468(7327): 1067-73 (2010)), ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath
  • meningioma optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma,
  • pituicytoma pituitary adenoma, pituitary tumor, plasmacytoma, polyerabryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial
  • BET inhibitors may be useful in the treatment of benign proliferative and fibrotic disorders, including benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, juvenile polyposis syndrome, idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma, and cardiac fibrosis.
  • one aspect of the invention provides compounds, compositions, and methods for treating such benign proliferative and fibrotic disorders.
  • Cardiovascular disease is the leading cause of mortality and morbidity in the United States. V. Roger et al., "Heart disease and stroke statistics-2012 update: a report from the American Heart Association,” Circulation 125(l):e2-e220 (2012).
  • Atherosclerosis an underlying cause of CVD, is a multifactorial disease characterized by dyslipidemia and inflammation. BET inhibitors are expected to be efficacious in
  • BET inhibitors bind directly to BET proteins and inhibit their binding to acetylated bistones at the ApoA-1 promoter, suggesting the presence of a BET protein repression complex on the ApoA-1 promoter, which can be functionally disrupted by BET inhibitors. It follows that, BET inhibitors may be useful in the treatment of disorders of lipid metabolism via the regulation of ApoA-I and HDL such as
  • one aspect of the invention provides compounds, compositions, and methods for treating cardiovascular disorders by upregulation of ApoA-1.
  • BET inhibitors may be useful in the prevention and treatment of conditions associated with ischemia-reperfusion injury such as, but not limited to, myocardial infarction, stroke, acute coronary syndromes (R. Prinjha et al. Trends Pharmacol Sci 33(3): 146-53
  • one aspect of the invention provides compounds, compositions, and methods for prevention and treatment of conditions described herein that are associated with ischemia-reperfusion injury.
  • Obesity-associated inflammation is a hallmark of type II diabetes, insulin resistance, and other metabolic disorders.
  • one aspect of the invention provides compounds, compositions, and methods for treatment and prevention of metabolic disorders, including but not limited to obesity-associated inflammation, type II diabetes, and insulin resistance.
  • Host-encoded BET proteins have been shown to be important for transcriptional activation and repression of viral promoters.
  • Brd4 interacts with the E2 protein of human papilloma virus (HPV) to enable E2 mediated transcription of E2- target genes.
  • HPV human papilloma virus
  • KSHV latent nuclear antigen 1
  • KSHV Kaposi's sarcoma-associated herpes virus
  • a BET inhibitor has been shown to inhibit the Brd4-mediated recruitment of the transcription elongation complex pTEFb to the Epstein-Barr virus (EBV) viral C promoter, suggesting therapeutic value for EBV-associated malignancies.
  • EBV Epstein-Barr virus
  • Palermo et al, "RNA polymerase ⁇ stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus," PLoSPathog 7(10):el002334 (2011).
  • a BET inhibitor reactivated HTV in models of latent T cell infection and latent monocyte infection, potentially allowing for viral eradication by complementary anti-retroviral therapy. J.
  • BET bromodomain inhibition activates transcription via a transient release of P-TEFb from 7SK snR P
  • J Biol Chem (2012) J Biol Chem (2012)
  • Z. Li et al. "The BET bromodomain inhibitor JQ1 activates HTV latency through antagonizing Brd4 inhibition of Tat-transactivation” Nucleic Acids Res (2012).
  • BET inhibitors may be useful in the prevention and treatment of episome- based DNA viruses including, but not limited to, human papillomavirus, herpes virus, Epstein-Barr virus, human immunodeficiency virus (A. Belkina and G.
  • the invention also provides compounds, compositions, and methods for treatment and prevention of episome-based DNA virus infections described herein.
  • CNS diseases are characterized by disorders in epigenetic processes. Brd2 haplo-insufFiciency has been linked to neuronal deficits and epilepsy.
  • L. Velisek et al. "GABAergic neuron deficit as an idiopathic generalized epilepsy mechanism: the role of BRD2 haploinsufficiency in juvenile myoclonic epilepsy," PLoS One 6(8): e23656 (2011) SNPs in various bromodomain-containing proteins have also been linked to mental disorders including schizophrenia and bipolar disorders.
  • Prinjha et al. Trends Pharmacol Sci 33(3):146-53 (2012).
  • one aspect of the invention provides compounds, compositions, and methods for treating such CNS diseases and disorders.
  • BRDT is the testis-specific member of the BET protein family which is essential for chromatin remodeling during spermatogenesis. J. Gaucher et al.,
  • Monocyte chemotactic protein- 1 (MCP-1, CCL2) plays an important role in cardiovascular disease. J. Niu and P. Kolattukudy, "Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications," Clin Sci (Lond) 117(3):95-109 (2009). MCP-1, by its chemotactic activity, regulates recruitment of monocytes from the arterial lumen to the subendothelial space, where they develop into macrophage foam cells, and initiate the formation of fatty streaks which can develop into atherosclerotic plaque. J.
  • CHD patients with among the highest levels of MCP-1 are those with acute coronary syndrome (ACS).
  • ACS acute coronary syndrome
  • MCP-1 has been shown to be involved in plaque rupture, ischemic/reperfusion injury, restenosis, and heart transplant rejection.
  • MCP- also promotes tissue inflammation associated with autoimmune diseases including rheumatoid arthritis (RA) and multiple sclerosis (MS).
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • MCP-1 plays a role in the infiltration of macrophages and lymphocytes into the joint in RA, and is overexpressed in the synovial fluid of RA patients.
  • A. Koch et al. "Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis," J Clin Invest 90(3):772-9 (1992).
  • MCP-1 monocyte chemoattractant protein 1
  • MCP-1 is overexpressed by a variety of cell types in the brain during disease progression and contributes to the infiltration of macrophages and lymphocytes which mediate the tissue damage associated with MS. Genetic depletion of MCP-1 or CCR2 in the experimental autoimmune
  • EAE encephalomyelitis
  • one aspect of the invention provides compounds, compositions, and methods for treating cardiovascular, inflammatory, and autoimmune conditions associated with MCP-1 and CCR2.
  • the invention provides compounds that are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising one or more of those compounds, and use of these compounds or compositions in the treatment and prevention of diseases and conditions, including, but not limited to, cancer, autoimmune, and cardiovascular diseases.
  • the first aspect of the invention includes compounds of Formula I and methods of administering a therapeutically effective amount of those compounds to a mammal (e.g., a human) in need thereof:
  • Wi is selected from N and CRi;
  • W2 is selected from N and CR 2 ;
  • W3 is selected from N and CR3;
  • W4 is selected from N and CR ;
  • X is selected from N and CH;
  • Y is selected from -S(O)-, -C(0>, -NH-, -NHCH 2 -, -NHCH 2 CH 2 -, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(C]-C3), halogen, hydroxyl, or amino;
  • R] R 2 , R3, and R4 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen; two adjacent substituents selected from Ri, R 2 , R3, and R* may be connected in a 5- or 6-membered ring to form a bicyclic carbocycle or bicyclic heterocycle;
  • Rs is selected from amino, S- and 6- membered carbocycies and heterocycles
  • R $ is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl;
  • R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
  • Another aspect of the invention includes compounds of Formula la and methods of administering a therapeutically effective amount of those compounds to a mammal (e.g., a human) in need thereof:
  • X is selected from N and CH;
  • Y is selected from -S(0)-, -C(0 , -NH-, -IMHCH2-, -NHCH 2 CH 2 -, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(Cj-C3), halogen, hydroxyl, or amino;
  • Ri and R3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen
  • R5 is selected from amino, aminoalkyl, 5- and 6- membered carbocycies and heterocycles optionally substituted with halogen, amino, amide, alky Ci-Ce), or alkox fCj- Q) for example, the structures Ra
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF 3 , -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, - C(0)NH 2 , -C(0)CH(OH)CH 3 , -C(0)C(0)OMe, -CF 3 , -CH 2 CH 2 OH, -CH 2 CH 2 amino, and - CH 2 C3 ⁇ 4C(Me) 2 OH;
  • R « is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl
  • R 7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
  • a pharmaceutical composition comprising a compound of Formula I or Formula la, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients is provided.
  • cardiac disease refers to diseases, disorders and conditions of the heart and circulatory system that are mediated by BET inhibition.
  • Exemplary cardiovascular diseases include, but are not limited to, acute coronary syndrome, angina, arteriosclerosis, atherosclerosis, carotid atherosclerosis, cerebrovascular disease, cerebral infarction, congestive heart failure, congenital heart disease, coronary heart disease, coronary artery disease, coronary plaque stabilization, dyslipidemias, dyslipoproteinemias, endothelium dysfunctions, familial hypercholesterolemia, familial combined hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hyperbetalipoproteinemi a, hypercholesterolemia, hypertension, hyperlipidemia, intermittent claudication, ischemia, ischemia reperfusion injury, ischemic heart diseases, cardiac ischemia, metabolic syndrome, multi-infarct dementia, myocardial infarction, obesity, peripheral vascular disease, reperfusion injury, restenosis, renal artery atherosclerosis, rheumatic heart disease, stroke, thrombotic disorder, transit
  • inflammatory diseases refers to diseases, disorders, and conditions that are mediated by BET inhibition.
  • exemplary inflammatory diseases include, but are not limited to, arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post
  • cancer refers to diseases, disorders, and conditions that are mediated by BET inhibition.
  • exemplary cancers include, but are not limited to, chronic lymphocytic leukemia and multiple myeloma, follicular lymphoma, diffuse large B cell lymphoma with germinal center phenotype, Burkitt's lymphoma, Hodgkin's lymphoma, follicular lymphomas and activated, anaplastic large cell lymphoma, neuroblastoma and primary neuroectodermal tumor, rhabdomyosarcoma, prostate cancer, breast cancer, NMC (NUT-midline carcinoma), acute myeloid leukemia (AML), acute B lymphoblastic leukemia (B-ALL), Burkitt's Lymphoma, B-cell lymphoma, melanoma, mixed lineage leukemia, multiple myeloma, pro-myelocytic leukemia (PML), non-Hodg
  • Subject refers to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful for both human therapy and veterinary applications. In one embodiment, the subject is a human.
  • treatment refers to an amelioration of a disease or disorder, or at least one discernible symptom thereof.
  • treatment refers to an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient
  • treatment or “treating” refers to inhibiting the progression of a disease or disorder, either physically, e.g., stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both.
  • treatment or “treating” refers to delaying the onset of a disease or disorder. For example, treating a cholesterol disorder may comprise decreasing blood cholesterol levels.
  • prevention or “preventing” refers to a reduction of the risk of acquiring a given disease or disorder.
  • a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
  • -CONH 2 is attached through the carbon atom.
  • hydrate refers to a crystal form with either a stoichiometric or non-stoichiometric amount of water is incorporated into the crystal structure.
  • alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C2-Cg)a]kenyl.
  • alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, and 4-(2-methyl-3-butene)- pentenyL
  • alkoxy refers to an alkyl group attached to an oxygen (-O-alkyl-).
  • Alkoxy also include an alkenyl group attached to an oxygen (“alkenyloxy”) or an alkynyl group attached to an oxygen (“alkynyloxy”) groups.
  • alkoxy groups include, but are not limited to, groups with an alkyl, alkenyl or alkynyl group of 1-8 carbon atoms, referred to herein as (Ci-Cg)alkoxy.
  • Exemplary alkoxy groups include, but are not limited to methoxy and ethoxy.
  • alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-8 carbon atoms, referred to herein as (C).Cg)alkyL
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl- 1 -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-l-butyl, 2- methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl- 1 -pentyl, 3-methyl-l-pentyi, 4-methyl-l- pentyl, 2-methyl-2-pentyl, 3 -methy 1-2-pentyl , 4-methyl-2-pentyl, 2,2-dimethyl- 1 -butyl, 3,3- dimethyl-l-butyl, 2-ethyl-l -butyl
  • alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C2.Cg)alkynyl.
  • alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl- 1 -butyny 1 , 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl.
  • amide refers to the form -N a OXRb)- or
  • R ⁇ , R3 ⁇ 4 and Rc are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen.
  • the amide can be attached to another group through the carbon, the nitrogen, R3 ⁇ 4, or R Q .
  • the amide also may be cyclic, for example R 0 and Rc, may be joined to form a 3- to 8-membered ring, such as 5- or 6-membered ring.
  • amide encompasses groups such as sulfonamide, urea, ureido, carbamate, carbamic acid, and cyclic versions thereof.
  • amide also encompasses an amide group attached to a carboxy group, e.g., -amide-COOH or salts such as -amide-COONa, an amino group attached to a carboxy group (e.g., -amino- COOH or salts such as -amino-COONa).
  • amine or “amino” as used herein refers to the form -NR ⁇ Rg or
  • Rj and Rg are independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, carbamate, cycloalkyl, haloalkyl, heteroaryl, heterocycle, and hydrogen.
  • the amino can be attached to the parent molecular group through the nitrogen.
  • the amino also may be cyclic, for example any two of and Re may be joined together or with the N to form a 3- to 12-membered ring (e.g., morpholino or piperidinyl).
  • the term amino also includes the corresponding quaternary ammonium salt of any amino group.
  • Exemplary amino groups include alkylamino groups, wherein at least one of R ⁇ j or is an alkyl group.
  • Rd and Re each may be optionally substituted with hydroxyl, halogen, alkoxy, ester, or amino.
  • aryl refers to a mono-, bi-, or other
  • the aryl group can optionally be fused to one or more rings selected from aryls, cycloalkyls, and heterocyclyls.
  • the aryl groups of this present disclosure can be substituted with groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone.
  • Exemplary aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl.
  • Exemplary aryl groups also include, but are not limited to a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as n (C6)aryl.”
  • arylalkyl refers to an alkyl group having at least one aryl substituent (e.g., -aryl-alkyl-).
  • exemplary arylalkyl groups include, but are not limited to, arylalkyls having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as B ( )arylalkyl.
  • R g ⁇ R3 ⁇ 4 and Rj are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen.
  • Exemplary carbamates include, but are not limited to, arylcarbamates or heteroaryl carbamates (e.g., wherein at least one of Rg ⁇ R n and Rj are independently selected from aryl or heteroaryl, such as pyridine, pyridazine, pyrimidine, and pyrazine).
  • Carbocycle refers to an aryl or cycloalkyl group.
  • carboxy refers to -COOH or its corresponding carboxylate salts (e.g., -COONa).
  • carboxy also includes "carboxycarbonyl,'' e.g. a carboxy group attached to a carbonyl group, e.g., -C(0)-COOH or salts, such as -C(O)- COONa.
  • cyano refers to -CN.
  • cycloalkoxy refers to a cycloalkyl group attached to an oxygen.
  • cycloalkyl refers to a saturated or unsaturated cyclic, bicyclic, or bridged bicyclic hydrocarbon group of 3-12 carbons, or 3-8 carbons, referred to herein as "(C3-Cg)cycloalkyl,” derived from a cycloalkane.
  • exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclohexenes, cyclopentanes, and cyclopentenes.
  • Cycloalkyl groups may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Cycloalkyl groups can be fused to other cycloalkyl saturated or unsaturated, aryl, or heterocyclyl groups.
  • dicarboxylic acid refers to a group containing at least two carboxylic acid groups such as saturated and unsaturated hydrocarbon dicarboxylic acids and salts thereof.
  • Exemplary dicarboxylic acids include alkyl dicarboxylic acids.
  • Dicarboxylic acids may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
  • Dicarboxylic acids include, but are not limited to succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, maleic acid, phthalic acid, aspartic acid, glutamic acid, malonic acid, fumaric acid, (+V(-)-malic acid, (+)/(-) tartaric acid, isophthalic acid, and terephthalic acid.
  • Dicarboxylic acids further include carboxylic acid derivatives thereof, such as anhydrides, imides, hydrazides (for example, succinic anhydride and succinimide).
  • ester refers to the structure -C(0)0-, -C(0)0-Rj_, -RkC(0)0-Rj_, or -RkCiC O-, where O is not bound to hydrogen, and Rj and Rfc can independently be selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, cycloalkyl, ether, haloalkyl, heteroaryl, and heterocyclyl.
  • Rfc can be a hydrogen atom, but Rj cannot be a hydrogen atom.
  • the ester may be cyclic, for example the carbon atom and Rj, the oxygen atom and Rfc or Rj and Rfc may be joined to form a 3- to 12-membered ring.
  • esters include, but are not limited to, alkyl esters wherein at least one of Rj or Rk is alkyl, such as -0-C(0)-alkyl, -C(0>0-alkyl-, and -alkyl-C(0)-0-alkyl-.
  • Exemplary esters also include aryl or heteoraryl esters, e.g. wherein at least one of Rj or Rk is a heteroaryl group such as pyridine, pyridazine, pyrimidine and pyrazine, such as a nicotinate ester.
  • Exemplary esters also include reverse esters having the structure -Rj f C(0)0-, where the oxygen is bound to the parent molecule.
  • Exemplary reverse esters include succinate, D- argininate, L-argininate, L-lysinate and D-lysinate.
  • Esters also include carboxyiic acid anhydrides and acid halides.
  • halo or halogen as used herein refer to F, CI, Br, or 1.
  • haloalkyl refers to an alkyl group substituted with one or more halogen atoms. "Haloalkyls” also encompass alkenyl or alkynyl groups substituted with one or more halogen atoms.
  • heteroaryl refers to a mono-, bi-, or multi-cyclic, aromatic ring system containing one or more heteroatoms, for example 1-3 heteroatoms, such as nitrogen, oxygen, and sulfur.
  • Heteroaryls can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxy., ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Heteroaryls can also be fused to non-aromatic rings.
  • heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (l,2,4)-triazolyl, pyrazinyl, pyrimidilyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl.
  • heteroaryl groups include, but are not limited to, a monocyclic aromatic ring, wherein the ring comprises 2-5 carbon atoms and 1-3 heteroatoms, referred to herein as "(C 2 - C 5 )heteroaryl"
  • heterocycle refers to a saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered ring containing one, two, or three heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Heterocycles can be aromatic (heteroaryls) or non-aromatic.
  • Heterocycles can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
  • Heterocycles also include bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings
  • heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyi, indolyl, isoquino!yl, isotbiazolidinyl, isotbiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyL piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyr
  • hydroxyalkyl refers to a hydroxy attached to an alkyl group.
  • hydroxyary refers to a hydroxy attached to an aryl group.
  • ketone refers to the structure -C(0)-Rn (such as acetyl, -C(0)CH 3 ) or -R n .C(0 R 0 _.
  • the ketone can be attached to another group through Rn or R Q .
  • R j , or R Q can be alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl, or or R Q can be joined to form a 3- to 12-membered ring.
  • monoester refers to an analogue of a dicarboxylic acid wherein one of the carboxylic acids is functionalized as an ester and the other carboxylic acid is a free carboxylic acid or salt of a carboxylic acid.
  • monoesters include, but are not limited to, to monoesters of succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, oxalic and maleic acid.
  • phenyl refers to a 6-membered carbocyclic aromatic ring.
  • the phenyl group can also be fused to a cyclohexane or cyclopentane ring.
  • Phenyl can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylaJkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
  • thioalkyl refers to an alkyl group attached to a sulfur (-S-alkyl-).
  • alkyl can be optionally substituted with or interrupted by or branched with at least one group selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carbonyl, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxy!, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, thioketone, ureido and N.
  • the substituents may be branched to form a substituted or unsubstituted heterocycle or cycloalkyl.
  • a suitable substitution on an optionally substituted substituent refers to a group that does not nullify the synthetic or pharmaceutical utility of the
  • substitutions include, but are not limited to: -g alkyl, alkenyl or alkynyl; Ci-6 aryl, C2-5 heteroaryl; C37 cycloalkyl; C alkoxy; Ce aryloxy; -CN; -OH; oxo; halo, carboxy; amino, such as -NH(C alkyl), -N(Ci-g alkyl)2, -NH((C6)aryl), or
  • compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
  • composition refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
  • prodrugs as used herein represents those prodrugs of the compounds of the present disclosure that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present disclosure.
  • a discussion is provided in Higuchi et al., "Prodrugs as Novel Delivery Systems ? ACS Symposium Series, Vol. 14, and in Roche,
  • salts refers to salts of acidic or basic groups that may be present in compounds used in the present compositions.
  • Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfate, citrate, matate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicorinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate and pamoate (i.
  • Compounds included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
  • Compounds included in the present compositions, that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
  • the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
  • stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom.
  • Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated "( ⁇ )" in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
  • Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
  • Stereoisomers can also be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
  • Geometric isomers can also exist in the compounds of the present disclosure.
  • the present disclosure encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
  • Substituents around a carbon-carbon double bond are designated as being in the "Z” or "E” configuration wherein the terms "Z” and "E” are used in accordance with IUPAC standards.
  • structures depicting double bonds encompass both the E and Z isomers.
  • the invention is directed to a compound according to Formula I:
  • Wi is selected from N and CRj;
  • W2 is selected from N and CR2;
  • W3 is selected from N and CR 3 ;
  • W 4 is selected from N and CR ;
  • X is selected from N and CH;
  • Y is selected from -S(0)-, -C(0>, -NH-, -NHCH 2 -, -NHC3 ⁇ 4CH 2 -, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(Ct-C3), halogen, hydroxy I, or amino;
  • Ra, R3, and R4 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino (such as, e.g., aminoalkyl), aryloxy, aryl, hydroxyl, and halogen;
  • Ri, R2, R3, and R4 may be connected in a 5- or 6-membered ring to form a bicyclic carbocycle or bicyclic heterocycle;
  • Rs is selected from amino and 5- and 6- membered carbocycles and heterocycles
  • Re is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl;
  • R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
  • Another aspect of the invention is directed to a compound according to Formula la:
  • X is selected from N and CH;
  • Y is selected from -S(0)-, -C(0 , -NH-, -NHCH 2 -, -NHCH 2 CH 2 -, and - HCH 2 CH 2 CH 2 -, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(Ci-C3), halogen, hydroxyl, or amino;
  • R] and R3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen;
  • Rs is selected from amino, aminoalkyl, S- and 6- membered carbocycles and heterocycles optionally substituted with halogen, amino, amide, alkyl(Ci-C6), or alkoxy(Ci- C3 ⁇ 4) for example, the structures
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF 3 , -C(0)-tBu, -C(0)NHiPr, -C(0)NMe 2 , -C(0)NHEt, - C(0)NH 2 , -C(0)CH(OH)CH 3 , -C(0)C(0)OMe, -CF 3 , -CH 2 CH 2 OH, -CH 2 CH 2 amino, and - CH ⁇ CCMe ⁇ OH;
  • Re is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl;
  • R 7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
  • each of Ri , R2, R3, and R are independently selected from hydrogen, alkyl, alkoxy, amino, and halogen.
  • each of Ri and R 3 are independently selected from hydrogen, alkyl, alkoxy, amino, and halogen.
  • each of Ri , R2, R3, and R4, if present, are independently selected from hydrogen, alkyl, and alkoxy, each of which may be optionally substituted with hydroxyl, amino, or halogen.
  • each of Ri and R3 are independently selected from hydrogen, alkyl, and alkoxy, each of which may be optionally substituted with hydroxyl, amino, or halogen.
  • each of Ri, R2, R3, and R is independently selected from aryl and aryloxy, each of which may be optionally substituted with halogen, alkoxy, or amino.
  • each of Rj and R3 are independently selected from aryl and aryloxy, each of which may be optionally substituted with halogen, alkoxy, or amino.
  • Wi is CRi
  • W3 is CR 3
  • Rj and R3 are each independently an alkoxy group, for example mefhoxy, ethoxy, isopropoxy, and propoxy.
  • Ri and R3 are each independently an alkoxy group, for example methoxy, ethoxy, isopropoxy, and propoxy.
  • Wt is CRi
  • W2 is CR2
  • W3 is CR3
  • W is CR4, and Rj and R3 are each alkoxy and R2 and R4 are each hydrogen.
  • i is CRi
  • W2 is CR2
  • W3 is N
  • W is CR4
  • Ri and R3 are each alkoxy and R2 is hydrogen.
  • Wi is CRj
  • W2 is CR 2
  • W3 is CR3
  • W is CR4
  • Ri and R3 are each methoxy and R 2 and R4 are each hydrogen.
  • R] and R3 are each methoxy.
  • Wj is CRj
  • W2 is CR2
  • W 3 is CR3
  • W4 is CR 4
  • Ri is methoxy
  • R 3 is amino or aminoalkyl
  • R 2 and R are each hydrogen.
  • Ri is methoxy and R is amino or aminoalkyl.
  • R5 is aminoalkyl
  • Y is selected f om -NH-, -NHCH 2 -, -NHCH 2 CH 2 -, and -NHCH 2 CH 2 CH 2 -, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with F, Me, OMe, and CL
  • Y is -
  • X is N.
  • X is CH.
  • R5 is selected from amino, aminoalkyl, and 5- and 6- membered carbocyc!es and heterocycles optionally substituted with halogen, amino, urea, ester, carbamate, amide, alkyl(C
  • Rj is selected from -NHRa and 5- and 6-membered carbocycles and heterocycles optionally substituted with halogen, amino, urea, ester, carbamate, amide, alkyl(CrC «), alkoxy(Cj-C6), or aryl, for example, the structures
  • Ra is selected from hydrogen, alkyl, alkenyl, aryl, -C(0)Alkyl(Ci-C ), -C(0)Amino, -C(0)Oalkyl(C,-C4), and benzyl.
  • R 5 is selected from -NHRa and 5- and 6-membered carbocycles and heterocycles optionally substituted with halogen, amino, amide, alkyl(C]-C6), or alkoxy(C
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, - C(0)NH 2 , -C(0)CH(OH)CH 3 , -C(0)C(0)OMe, -CF 3 , -C3 ⁇ 4CH 2 OH, -CH 2 CH 2 amino, and - CH 2 CH 2 C(Me) 2 OH.
  • R$ is selected from hydrogen, alkyl, alkoxy, aminoalkyl, and thioalkyl, each of which may be optionally substituted with halogen, amino, hydroxyl, or alkoxy.
  • R$ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
  • R « is selected from hydrogen, methyl, and methoxy.
  • 3 ⁇ 4 is selected from groups represented by Formula ⁇ :
  • D and E are independently selected from O, N, and S;
  • 3 ⁇ 4 is selected from hydrogen and alkyl, and Rg is present only if D is N;
  • R 9 and Rio are independently selected from hydrogen, alkyl, and cycloalkyl, and only one of R9 and Rio is present if E is O or S;
  • R9 and Rio may be connected to form a carbocycle or a heterocycle containing one or more heteroatoms; and n is selected from 1, 2, and 3.
  • D is O and E is N;
  • n 1;
  • R- 9 and Rio are independently selected from hydrogen, alkyl, and carbocycle.
  • R 7 is selected from hydrogen, methoxy, ethoxy, propoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, and -OCF 3 .
  • W is CR ! ;
  • W 2 is CR2
  • W 3 is CR 3 ;
  • Wij is CRt
  • Ri and R3 are each alkoxy
  • R 2 and R4 are each hydrogen
  • Y is selected from-NH-, -MHCH 2 -, - HCH2CH2-, and - HCH2CH2CH2-, with the nitrogen attached to the B ring;
  • R 5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF 3 , -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C ⁇ 0)NHEt, -C(0)NH 2 , -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF 3 , -CH 2 CH 2 OH, -CH 2 CH 2 amino, and -CH 2 CH 2 C(Me)20H; and
  • R$ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
  • R] and R3 are each alkoxy
  • Y is selected from-NH-, -NHCH 2 -, -NHCH 2 CH 2 -, and -NHCH 2 CH 2 CH 2 -, with the nitrogen attached to the B ring;
  • R 5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0) e, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF 3 , -C(0)-tBu, -C(0)NHiPr, -C(0)NMe 2 , -C(0)NHEt, -C(0)NH 2 , -C(0)CH(OH)CH 3 , -C(0)C(0)OMe, -CF 3 , -CH 2 CH 2 OH, -CH 2 CH 2 amino, and -CH ⁇ H ⁇ iMe ⁇ OH; and
  • R* is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
  • is CRi
  • W 3 is CR 3 ;
  • W* is CR ;
  • Rj is alkoxy
  • R3 is amino or aminoalkyl
  • R2 and R4 are each hydrogen
  • Y is selected from- ⁇ -, -IMHCH2-, -NHCH 2 CH 2 -, and -NHCH 2 CH 2 CH 2 -, with the nitrogen attached to the B ring;
  • R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, -C(0)NH 2 , -C ⁇ CHiOH ⁇ , -C(0)C(0)OMe, -CF 3 , -CH2CH2OH, 3 ⁇ 4CH 2 amino, and -CH ⁇ H ⁇ CMehOH; and
  • Re is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
  • Ri is alkoxy
  • R3 is amino or aminoalkyl
  • Y is selected from-NH-, -NHCH 2 -, -NHCH 2 CH 2 -, and -NHCH 2 CH 2 CH 2 -, with the nitrogen attached to the B ring;
  • R 5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
  • Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0) e, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF 3 , -C(0)-tBu, -C(0)NHiPr, -C(0)N e2, -C(0)NHEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF 3 , -CH 2 CH 2 OH, ⁇ 2 CH 2 amino, and -CHaCHiCCMe ⁇ H and
  • R $ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
  • the compound is selected from:
  • Another aspect of the invention provides a method for inhibition of BET protein function by binding to bromodomains, and their use in the treatment and prevention of diseases and conditions in a mammal (e.g., a human) comprising administering a therapeutically effective amount of a compound of Formula I or Formula la.
  • BET inhibitor compounds of Formula I or Formula la may be used as therapeutics for inflammatory disorders in which IL-6 and/or IL-17 have been implicated in disease.
  • the following autoimmune diseases are amenable to therapeutic use of BET inhibition by administration of a compound of Formula I or Formula la or a
  • Devic's Disease U. Linhares et al., "The Ex Vivo Production of IL-6 and IL-21 by CD4(+) T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients," J Clin Immunol (2012)), Encephalitis (D.
  • Leukocytoclastic vasculitis Min, C.K., et al., "Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines, " Eur J Haematol 76(3):265-8 (2006)), Lichen planus (N. Rhodus et al.,
  • the invention includes compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof; pharmaceutical compositions comprising one or more of those compounds; and methods of using those compounds or compositions for treating these diseases.
  • Acute and chronic (non-autoimmune) inflammatory diseases characterized by increased expression of pro-inflammatory cytokines, including IL-6, MCP-1, and IL-17, would also be amenable to therapeutic BET inhibition.
  • pro-inflammatory cytokines including IL-6, MCP-1, and IL-17.
  • These include, but are not limited to, sinusitis (D. Bradley and S. Kountakis, "Role of mterleukins and transforming growth factor- beta in chronic rhinosinusitis and nasal polyposis, " Laryngoscope 115(4):684-6 (2005)), pneumonitis (Besnard, A.G., et al., "Inflammasome-IL-l -Thl 7 response in allergic lung inflammation” J Mol Cell Biol 4(1):3-10 (2012)), osteomyelitis (T.
  • COPD chronic obstructive pulmonary disease
  • osteoarthritis L. Chen et al., "IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis, " Osteoarthritis Cartilage 19(6):711-8 (2011)), acute gout (W. Urano et al., "The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis," J Rheumatol 29(9): 1950-3 (2002)), acute lung injury (S. Traves and L. Donnelly, “Thl 7 cells in airway diseases,” Curr Mol Med 8(5):416-26 (2008)), acute renal failure (E.
  • the invention includes compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof; pharmaceutical
  • compositions comprising one or more of those compounds; and methods of using those compounds or compositions for treating these diseases.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used for treating rheumatoid arthritis (RA) and multiple sclerosis (MS).
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • Both RA and MS are characterized by a dysregulation of the IL-6 and IL-17 inflammatory pathways (A. imura and T.
  • BET inhibitor compounds of Formula I or Formula la may be used for treating sepsis and associated afflictions. BET inhibition has been shown to inhibit development of sepsis, in part, by inhibiting IL-6 expression, in preclinical models in both published (E. Nicodeme et al., Nature 468(7327):1119-23 (2010)) and proprietary data.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancer.
  • Cancers that have an overexpression, translocation, amplification, or rearrangement c-myc or other myc family oncoproteins (M YCN, L-myc) are particularly sensitive to BET inhibition. J. Delmore et al., Cell 146(6):904-17 (2010); J. Mertz et al., Proc Natl AcadSci USA 108(40): 16669-74 (2011).
  • cancers include, but are not limited to, B-acute lymphocytic leukemia, Burkitt's lymphoma, Diffuse large cell lymphoma, Multiple myeloma, Primary plasma cell leukemia, Atypical carcinoid lung cancer, Bladder cancer, Breast cancer, Cervix cancer, Colon cancer, Gastric cancer, Glioblastoma, Hepatocellular carcinoma, Large cell neuroendocrine carcinoma, Medulloblastoma, Melanoma, nodular, Melanoma, superficial spreading, Neuroblastoma, esophageal squamous cell carcinoma, Osteosarcoma, Ovarian cancer, Prostate cancer, Renal clear cell carcinoma, Retinoblastoma, Rhabdomyosarcoma, and Small cell lung carcinoma. M. Vita and M. Henriksson, Semin Cancer Biol 16(4):318- 30 (2006).
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers that result from an aberrant regulation (overexpression, translocation, etc) of BET proteins.
  • BET proteins include, but are not limited to, NUT midline carcinoma (Brd3 or Brd4 translocation to nutlin 1 gene) (C. French Cancer Genet Cytogenet 203(l):16-20 (2010)), B-cell lymphoma (Brd2 overexpression) (R.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers that rely on pTEFb (Cdk9/cyclin T) and BET proteins to regulate oncogenes.
  • cancers include, but are not limited to, chronic lymphocytic leukemia and multiple myeloma (W.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers in which BET-responsive genes, such as CDK6, Bcl2, TYR03, MYB, and hTERT are up- regulated.
  • BET-responsive genes such as CDK6, Bcl2, TYR03, MYB, and hTERT are up- regulated.
  • cancers include, but are not limited to, pancreatic cancer, breast cancer, colon cancer, glioblastoma, adenoid cystic carcinoma, T-cell prolymphocytic leukemia, malignant glioma, bladder cancer, medulloblastoma, thyroid cancer, melanoma, multiple myeloma, Barret's adenocarcinoma, hepatoma, prostate cancer, pro-myelocytic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, small cell lung cancer, and renal carcinoma.
  • pancreatic cancer breast cancer, colon cancer, glioblastoma, adenoid cystic carcinoma, T-cell prolymphocytic leukemia, malignant glioma, bladder cancer, medulloblastoma, thyroid cancer, melanoma, multiple myeloma, Barret's adenocarcinoma,
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers for which exist published and, for some, proprietary, in vivo and/or in vitro data showing a direct effect of BET inhibition on cell proliferation.
  • NMC NUT-midline carcinoma
  • AML acute myeloid leukemia
  • B-ALL acute B lymphoblastic leukemia
  • Burkitt's Lymphoma B-cell Lymphoma
  • Melanoma mixed lineage leukemia, multiple myeloma, pro-myelocytic leukemia (PML), and non-Hodgkin's lymphoma.
  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia," Nature 478(7370):524-8 (2011); M.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be combined with other therapies, chemotherapeutic agents, or anti-proliferative agents to treat human cancer and other proliferative disorders.
  • the list of therapeutic agents which can be combined with BET inhibitors in cancer treatment includes, but is not limited to, ABT-737, Azacititdine (Vidaza), AZD1 152 (Barasertib), AZD2281 (Olaparib), AZD6244 (Selumetinib), BEZ235, Bleomycin Sulfate, Bortezoraib (Velcade), Busulfan (Myleran), Camptothecin, Cisplatin,
  • Cyclophosphamide (Clafen), CYT387, Cytarabine (Ara-C), dacarbazine, DAPT (GSI-IX), Decitabine, Dexamethasone, Doxorubicin (Adriamycin), Etoposide, Everolimus (RAD001), Flavopiridol (Alvocidib), Ganetespib (STA-9090), Gefitinib (Iressa), Idarubicin, Ifosfamide (Mitoxana), IFNa2a (Roferon A), Melphalan (Alkeran), Methazolastone (temozolomide), Metformin, Mitoxantrone (Novantrone), Paclitaxel, Phenformin, PKC412 (Midostaurin), PLX4032 (Vemurafenib), Pomalidomide (CC-4047), Prelnisone (Deltasone), Rapamycin, Revlimid
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat benign proliferative and fibrotic disorders, including benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, juvenile polyposis syndrome, idiopathic
  • Formula I or Formula Ia,stereoisomers, tautoraers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cardiovascular diseases that are generally associated with including dyslipidemia, atherosclerosis, hypercholesterolemia, and metabolic syndrome (A. Belkina and G. Denis, Nat Rev Cancer 12(7):465-77 (2012); G. Denis Discov Med 10(55):489-99 (2010)).
  • BET inhibitor compounds of Formula I or Formula la may be used to treat non-cardiovascular disease characterized by deficits in ApoA-1 , including Alzheimer's disease. D. Elliott et al., Clin Lipidol 51(4):555-573 (2010).
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used in patients with insulin resistance and type ⁇ diabetes.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used as therapeutics for cancers that are associated with viruses including Epstein-Barr Virus (EBV), hepatitis virus (HBV, HCV), Kaposi's sarcoma associated virus (KSHV), human papilloma virus (HPV), Merkel cell polyoma virus, and human cytomegalovirus (CMV).
  • EBV Epstein-Barr Virus
  • HBV hepatitis virus
  • KSHV Kaposi's sarcoma associated virus
  • HPV human papilloma virus
  • Merkel cell polyoma virus and human cytomegalovirus
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat diseases including, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington disease, bipolar disorder, schizophrenia, Rubinstein-Taybi syndrome, and epilepsy.
  • diseases including, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington disease, bipolar disorder, schizophrenia, Rubinstein-Taybi syndrome, and epilepsy.
  • BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used as reversible, male contraceptive agents.
  • testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3'-UTR truncation in round spermatids
  • compositions of the present disclosure comprise at least one compound of Formula I or Formula la, or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof formulated together with one or more pharmaceutically acceptable carriers.
  • These formulations include those suitable for oral, rectal, topical, buccal and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration. The most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.
  • Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of a compound of the present disclosure as powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association at least one compound of the present disclosure as the active compound and a carrier or excipient (which may constitute one or more accessory ingredients).
  • the carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient.
  • the carrier may be a solid or a liquid, or both, and may be formulated with at least one compound described herein as the active compound in a unit-dose formulation, for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound.
  • a unit-dose formulation for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound.
  • Other pharmacologically active substances may also be present including other compounds.
  • the formulations of the present disclosure may be prepared by any of the well- known techniques of pharmacy consisting essentially of admixing the components.
  • conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Liquid pharmacologically administrable compositions can, for example, be prepared by, for example, dissolving or dispersing, at least one active compound of the present disclosure as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • suitable formulations may be prepared by uniformly and intimately admixing the at least one active compound of the present disclosure with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product
  • a tablet may be prepared by compressing or molding a powder or granules of at least one compound of the present disclosure, which may be optionally combined with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, at least one compound of the present disclosure in a f ee-flowing form, such as a powder or granules, which may be optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s).
  • Molded tablets may be made by molding, in a suitable machine, where the powdered form of at least one compound of the present disclosure is moistened with an inert liquid diluent.
  • Formulations suitable for buccal (sub-lingual) administration include lozenges comprising at least one compound of the present disclosure in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the at least one compound in an inert base such as gelatin and glycerin or sucrose and acacia.
  • Formulations of the present disclosure suitable for parenteral administration comprise sterile aqueous preparations of at least one compound of Formula I or Formula la or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof, which are approximately isotonic with the blood of the intended recipient. These preparations are administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing at least one compound described herein with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the present disclosure may contain from about 0.1 to about 5% w/w of the active compound.
  • Formulations suitable for rectal administration are presented as unit-dose suppositories. These may be prepared by admixing at least one compound as described herein with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
  • Formulations suitable for topical application to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers and excipients which may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof.
  • the active compound i.e., at least one compound of Formula 1 or Formula la or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof
  • the amount of active compound administered may be dependent on the subject being treated, the subject's weight, the manner of administration and the judgment of the prescribing physician.
  • a dosing schedule may involve the daily or semi- daily administration of the encapsulated compound at a perceived dosage of about 1 g to about 1000 mg.
  • intermittent administration such as on a monthly or yearly basis, of a dose of the encapsulated compound may be employed.
  • Encapsulation facilitates access to the site of action and allows the administration of the active ingredients simultaneously, in theory producing a synergistic effect
  • physicians will readily determine optimum dosages and will be able to readily modify adudinistration to achieve such dosages.
  • a therapeutically effective amount of a compound or composition disclosed herein can be measured by the therapeutic effectiveness of the compound.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used. In one embodiment, the
  • Preliminary doses as, for example, determined according to animal tests, and the scaling of dosages for human administration is performed according to art-accepted practices.
  • Toxicity and therapeutic efficacy can be determined by standard
  • compositions that exhibit large therapeutic indices are preferable.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • a therapeutically effective amount may vary with the subject's age, condition, and gender, as well as the severity of the medical condition in the subject
  • the dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
  • a compound of Formula I or Formula la or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof is administered in combination with another therapeutic agent.
  • the other therapeutic agent can provide additive or synergistic value relative to the adniinistration of a compound of the present disclosure alone.
  • the therapeutic agent can be, for example, a statin; a PPAR agonist, e.g., a
  • thiazolidinedione or fibrate a niacin, a RVX, FXR or LXR agonist; a bile-acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a cholesteryl ester transfer protein (CETP), an ion-exchange resin; an antioxidant; an inhibitor of AcylCoA cholesterol acyltransferase (ACAT inhibitor); a tyrophostine; a sulfonylurea-based drug; a biguanide; an alpha-glucosidase inhibitor; an apolipoprotein E regulator; a HMG-CoA reductase inhibitor, a microsomal triglyceride transfer protein; an LDL-lowing drug; an HDL- raising drug; an HDL enhancer, a regulator of the apolipoprotein A-IV and/or apolipoprotein genes; or any cardiovascular drug.
  • ACAT inhibitor AcylCoA cholesterol
  • a compound of Formula I or Formula la or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof is administered in combination with one or more anti-inflammatory agents.
  • Anti-inflammatory agents can include immunosuppressants, TNF inhibitors, corticosteroids, non-steroidal anti- ird ammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDS), and the like.
  • NSAIDs non-steroidal anti- ird ammatory drugs
  • DARDS disease-modifying anti-rheumatic drugs
  • anti-inflammatory agents include, for example, prednisone;
  • methylprenisolone Medrol®
  • triamcinolone methotrexate
  • Trexall® hydroxychloroquine
  • Paquenil® sulfasalzine
  • Leflunomide Arava®
  • etanercept Enbrel®
  • infliximab Remicade®
  • adalimumab Humira®
  • P0C1 3 (1.02 g, 6.66 mmol) was addded to a solution of 2-formyl-5- methoxybenzoic acid (1.0 g, 5.55 mmol) in anhydrous pyridine (20 mL) at 0 °C and stired for 30 rain. After that time 1 -methyl piperazine (0.556 g, 5.55 mmol) was added. The reaction was allowed to warm to rt and stir for 16 h. After that time the reaction was concentrated under reduced pressure, diluted with water and made basic with aqueous a 2 C03. The mixture was extracted with ethyl acetate (3 * 200 mL).
  • Example 18 2-(3-((l-bopropylpiperidijtt-4-yl)amino)pyridiii-2-yl)-5,7- dJmethoxyquinazoliii-4(31 -one
  • Lithium bis(trimethylsilyl)amide (1 M in THF, 3.2 mL, 3.2 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5,7-dime1hoxyquinazolin-4(3H)-one (0.322 g, 1.07 mmol) and 1 sopropylpiperidm-4-amine (0.676 mL, 4.28 mmol) in anhydrous THF (10 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimemylsUyl)anu ⁇ ie (1M in THF, 3.2 mL, 3.2 mmol) was added.
  • dimemoxyquinazolin-4(3H)-one (0.776 g, 80%) as an off-white solid: mp 227-228 °C; ⁇
  • Trifluoroacetic acid (5.0 mL) was added dropwise to a suspension of /er/- butyl 4-(2-((2-(5,7-dimemoxy-4-oxo-3,4-d ⁇
  • dimemoxyquinazob ' n-4(3H)-one (0.061 g, 27%) as a light yellow solid: mp 192-193 °C; ⁇
  • Example 36 2 ⁇ (l-IsobutyryIpiperidiji-4-yl)amino)pyridin-2-yI)-5,7- dimethoxyquinazolin-4 3i )-one
  • reaction was stirred at -78 °C for an additional 15 min, then allowed to warm to rt and stirred for 16 h.
  • the reaction mixture was cooled to 0 °C and aqueous NaOH solution (8 M, 60 mL) was added, followed by hydrogen peroxide (30 wt%, 40 mL).
  • the mixture was stirred at rt for 2 h, then cooled to 0 °C and saturated aqueous sodium thiosulfate solution was added carefully until clear solution was obtained (about 40 mL).
  • the resulting mixture was neutralized to pH 7 using 1 HC1 and extracted with ethyl acetate (2 x 200 mL). The combined organics were washed with water then brine, dried
  • Acetic anhydride (0.0248 g) was added at 0 °C to a solution of 5,7- dimemoxy-2-(4-meAoxy-2-fcipe ⁇ (0,100 g, 0.24 mmol) and triemylarnine (0.243 g, 2.4 mmol) in dichloromethane (25 mL). The reactrion was allowed to warm to rt and then stirred for 30 min. After that time the reaction was
  • Lithium bis(trimethylsi)yl)amide (1 M in THF, 6.0 mL, 6.0 m ol) was added to a stirred suspension of 2-(3-iluoro-5-methoxypyridin-2-yl)-5,7- d3 ⁇ 4iemoxyquinazo -4(3/- ⁇ ne (0.331 g, 1.0 mmol) and 1 -methylpiperidin-4-amine (0.343 g, 3.0 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 5 h.
  • Lithium bis(trimethylsilyl)amide (1 M in THF, 3.5 mL, 3.5 mrao ) was added to a stirred suspension of 2- ⁇ 3-fluoropyridijn-2-yl)-5,7-diraethoxyqiiinazolin-4(3H)-one (0.352 g, 1.17 mmol) and 4-amino- ⁇ ,N ⁇ imethylpiperidine-l-carix>x (0.500 g, 2.92 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 6 h.
  • Lithium bis(trimeraylsUyl)amide (1 M in THF, 4.0 mL, 4.0 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5 - ⁇ iimethoxyquina-Mljn ⁇ Si- ⁇ ne (0.350 g, 1.16 mmol) and 1 -methylpiperidine-4-amine (0.400 g, 3.5 mmol) in anhydrous THF (15 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h.
  • Trifluoroacetic anhydride (0.032 g, O.lSmmol was added to a solution of 5,7- iimeAoxy-2-(3 ⁇ iperidin ⁇ (0.070 g, 0.18 mmol) and triethylamine (0.182 g, 1.8 mmol) in THF (15 mL) at 0°C. The resulting mixture was allowed to warm to rt and stirred for 30 min. After that time the mixture was
  • Example 50 2 ⁇ 3 (l-IsopiOpylpiperidm ⁇ yI)ammo)-5 (l ⁇ op o yl iperidm ⁇ yl)aniino)ethoxy)pyridta-2-yl)-5,7-dimethoxyqum
  • ButyUithium (1.6 M in hexanes, 82 mL, 130 mntol) was added dropwise to a suspension of 3 -bromo-6-chloro-5-fl uoropyridine (25.0 g, 119 mmol) in anhydrous toluene (280 mL) cooled to -78 °C. After the addition was complete the reaction was stirred for 10 min. After that time, trimethyl borate (14.82 g, 1 3 mmol) was added dropwise while maintaining the temperature at -78 °C. After the addition was complete, the reaction was allowed to warm to rt and stirring was continued for 17 h.
  • Triethylamine trihydrofluoride (4.33 g, 26.9 mmol) was added in one portion to a suspension of 2-[5-(2-(te ⁇ butyldimemy ⁇
  • Example 51 2 ⁇ 4 ⁇ (2-(5,7-Dimethoxy ⁇ oxo-3,4-dihydr «quina3 ⁇ 4olin-2-yl)pyridin-3- yl)amino)piperidiA-l- l)- ,A ⁇ Hlimethyl ⁇ 2 ⁇ xoacetamide
  • N,N'-dicyclohexylcarbcKiiiiiiide (0.081 g, 0.39 mmol) was added at room temperature to a solution of 2-(dimethylamino 2-oxoacetic acid (0.046 g, 0.39 mmol) in DMF (15 mL), followed by 1 -hydroxy- 1 H-benzo ⁇ riazole (0.053 g, 0.39 mmol). The reaction was stirred for 1 h and then 5,7 ⁇ limeraoxy-2 ⁇ 3 ⁇ piperidm ⁇ y
  • Example 52 4 ⁇ (2 ⁇ 5,7-dimethoxy-4M)xo-3,4 ⁇ ihydn)quma2olin-2-yl)pyridin-3- y ⁇ amino ⁇ A'-etfaylpiperidiiie-l-car oxaniide
  • Ethyl isocyanate (0.016 g, 0.18 mmol) was added to an ice-cold solution of 5,7-dimetoox -2 ⁇ 3 ⁇ ipOTdin ⁇ ylamm ⁇ (0.070 g, 0.18 mmol) and triethylamine (0.182 g, 1.8 mmol) in THF (IS mL). The reaction was allowed to warm to rt and stirred for 30 min.
  • Hie product was purified by flash column chromatography (silica gel, 97:3 chloroform/methanol) followed by recrystalization from chloroform hexanes to give cis-A- ((2 ⁇ 5,7 ⁇ iimemoxy- )xo-3,4-dmydroquinazo
  • Example 54 4-((2 ⁇ 5,7-Dimethoxy-4 ⁇ xo-3 ⁇ Wmydroqumazolin-2-yI)pyridin-3- yl)amino)piperidine-l-carboxamide
  • Trimethylsilyl isocyanate (1.0 mL) was added to a solution of 5,7- dimemoxy-2 ⁇ 3 ⁇ iperidm ⁇ ylarnino)pyridm-2-yl ⁇ (0.050 g, 0.13 mmol) and triethyl amine (1.0 mL) in THF (15 mL) cooled to 0 °C. The reaction was allowed to warm to rt and stirred 16 h.
  • iV,iV-Dicyclohexylcarbodiiraide (0.113 g, 0.55 mmol) and 1 -hydroxy- 1H- benzotriazole (0.074 g, 0.55 mmol) were added to a solution of 2-hydroxypropanoic acid (0.058 g, 0.55 mmol; 85% in water) in DMF (15 mL) at rt.
  • the reaction was stirred for 1 h and then 5,7-dimethoxy-2-(3- ⁇ ipeTidm-4-ylanimo)pyridm ⁇ (0,070 g, 0.18 mmol) was added.
  • Tris(dibenzylideneacetone)dipalladium (0.092 g, 0.10 mmol) was added to a de-gassed solution of 3-bromo-2-(l,3-dioxolan-2-yl)pyridine (1.15 g, 5.00 mmol), 1- isopropylpiperidin-4-amine (1.03 mL, 6.50 mmol), sodium-tert-butoxide (0.865 g, 9.00 mmol) and 22'-bis(diphenylphosphmo>-l,r-bmaphuiyl (0.187 g, 0.30 mmol) in toluene (10 mL). The misture was de-gassed again and heated at 110 °C with stirring for 3 h under nitrogen. After that time the mixture was cooled to rt, filtered through celite, and
  • the aldehyde was dissolved in N ⁇ -dimethylacetamimde (20 mL) and 2-amino-4,6-difluorobenzamide (0.64 g, 3.70 mmol) was added followed by NaHS0 3 (58.5 wt%, 1.01 g, 5.55 mmol) and p- toluenesulfonic acid monohydrate (0.14 g, .74 mmol).
  • the reaction was heated at 130 °C with stirring for 16 h. After that time the mixture was cooled to rt, concentrated under reduced pressure and diluted with water (100 mL). The resulting precipitate was collected by filtration, washed with water and dried.
  • the product was purified by flash column
  • Example 63 ctf ⁇ ((2 ⁇ 5,7-Dimethoxy ⁇ xo-3,4-dihydi ⁇ uinazolin-2-yl)pyridin-3- yl)amino)--V-i8opropylcycloliexane-l-carb xamide
  • Example 65 7-ammo-2- ⁇ 3- ⁇ (l-Isopropylpiperidin ⁇ yl)amino)pyridin-2-yI)-5- methoiyquinazolin-4(3H)- one
  • reaction mixture was heated to 80 °C with stirring for 14 h. After that time the reaction was cooled to rt, diluted with chloroform (100 mL), washed with sat. NaHCC (20 mL), water (4 x 20 mL), dried (MgS0 4 ) and concentrated under reduced pressure.
  • the product was purified by flash column chromatography (silica gel, 90:10 chioroform/methanol) followed by trituration (diethyl ether) to give 2- ⁇ 3-(l-isopropylpiperidto ⁇ ylaiiun ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Description

Novel Quinazolinones as Bromodomain Inhibitors
[0001] This application claims priority from U.S. Provisional Patent Application No. 61/860,403, filed July 31, 2013, which is hereby incorporated by reference in its entirety.
[0002] The invention provides novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions associated with bromodomain and extra terminal domain (BET) proteins.
[0003] Post-translational modifications (PTMs) of histones are involved in regulation of gene expression and chromatin organization in eukaryotic cells. Histone acetylation at specific lysine residues is a PTM that is regulated by histone acetylases (HATs) and deacetylases (HDACs). A. Peserico and C. Simone, "Physical and functional HAT/HDAC interplay regulates protein acetylation balance," J Biomed Biotechnol 2011 :371832 (2011). Small molecule inhibitors of HDACs and HATs are being investigated as cancer therapy. I. Hoshino and H. Matsubara, "Recent advances in histone deacetylase targeted cancer therapy " Surg Today 40(9):809-15 (2010); S. Vernarecci et al., 'Tuning acetylated chromatin with HAT inhibitors: a novel tool for therapy" Epigenetics 5(2):105-11 (2010); .
Bandyopadhyay et al., "Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization," Cell Cycle 8(17):2779-88 (2009); M. Arif et al., "Protein lysine acetylation in cellular function and its role in cancer manifestation, " Biochim BiophysActa 1799(10-12):702-16 (2010). Histone acetylation controls gene expression by recruiting protein complexes that bind directly to acetylated lysine via bromodomains. R. Sanchez and M. Zhou, "The role of human bromodomains in chroniatin biology and gene transcription, " Curr Opin Drug Discov Devel 12(5):659-65 (2009). One such family, the bromodomain and extra terminal domain (BET) proteins, comprises Brd2, Brd3, Brd4, and BrdT, each of which contains two bromodomains in tandem that can independently bind to acetylated lysines, as reviewed in S. Wu and C. Chiang, "The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation," J Biol Chem 282(18): 13141-5 (2007).
[0004] Interfering with BET protein interactions via bromodomain inhibition results in modulation of transcriptional programs that are often associated with diseases
characterized by dysregulation of cell cycle control, inflammatory cytokine expression, viral transcription, hematopoietic differentiation, insulin transcription, and adipogenesis. A.
Belkina and G. Denis, "BET domain co-regulators in obesity, inflammation and cancer, " Nat Rev Cancer 12(7):465-77 (2012). BET inhibitors are believed to be useful in the treatment of diseases or conditions related to systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis, and the prevention and treatment of viral infections. R. Prinjha et al., "Place your BETs: the therapeutic potential of bromodomains, " Trends Pharmacol Sci 33(3): 146-53 (2012).
[0005] Autoimmune diseases, which are often chronic and debilitating, are a result of a dysregulated immune response, which leads the body to attack its own cells, tissues, and organs. Pro-inflammatory cytokines including IL-Ιβ, TNF-α, L-6, MCP-1, and IL-17 are overexpressed in autoimmune disease. IL-17 expression defines the T cell subset known as Thl 7 cells, which are differentiated, in part, by EL-6, and drive many of the pathogenic consequences of autoimmune disease. Thus, the IL-6 Thl7 axis represents an important, potentially draggable target in autoimmune disease therapy. A. Kimura and T. Kishimoto, "EL-6: regulator of Treg/Thl7 balance, " Eur J Immunol 40(7):1830-5 (2010). BET inhibitors are expected to have anti-inflammatory and immunomodulatory properties. A. Belkina and G. Denis, Nat Rev Cancer 12(7):465-77 (2012); R. Prinjha et al., Trends Pharmacol Sci 33(3): 146-53 (2012). BET inhibitors have been shown to have a broad spectrum of antiinflammatory effects in vitro including the ability to decrease expression of pro-inflammatory cytokines such as IL-Ιβ, MCP-1, TNF-α, and I L-6 in activated immune cells. O. Mirguet et al., "From ApoAl upregulation to BET family bromodomain inhibition: discovery of 1- BET151," BioorgMed Chem Lett 22(8):2963-7 (2012); E. Nicodeme et al., "Suppression of inflammation by a synthetic histone niimic," Nature 468(7327):1119-23 (2010); J. Seal et al., "Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)," Bioorg Med Chem Lett 22(8):2968-72 (2012). The mechanism for these anti-inflammatory effects may involve BET inhibitor disruption of Brd4 co-activation of NF-KB-regulated pro-inflammatory cytokines and or displacement of BET proteins from cytokine promoters, including EL-6. E. Nicodeme et al., Nature
468(7327):! 119-23 (2010); G. Zhang et al., "Down-regulation of NF-kappaB Transcriptional Activity in HTVassociated Kidney Disease by BRD4 Inhibition," J Biol Chem,
287(34):8840-51 (2012); M. Zhou et al., "Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29," J Virol 83(2): 1036-44 (2009). In addition, because Brd4 is involved in T-cell lineage differentiation, BET inhibitors may be useful in inflammatory disorders characterized by specific programs of T cell differentiation. W. Zhang et al., "Bromodomain-Containing-
2 Protein 4 (BREW) Regulates RNA Polymerase 11 Serine 2 Phosphorylation in Human CD4+ T Ce\\s,n J Biol Chem (2012).
[0006] The anti-inflammatory and immunomodulatory effects of BET inhibition have also been confirmed in vivo. A BET inhibitor prevented endotoxin- or bacterial sepsis- induced death and cecal ligation puncture-induced death in mice, suggesting utility for BET inhibitors in sepsis and acute inflammatory disorders. E. Nicodeme et al., Nature
468(7327): 111 -23 (2010). A BET inhibitor has been shown to ameliorate inflammation and kidney injury in HIV-1 transgenic mice, an animal model for HIV-associated nephropathy, in part through inhibition of Brd4 interaction with NF-kappaB. G. Zhang, et al., J Biol Chem 287(34):8840-51 (2012). The utility of BET inhibition in autoimmune disease was demonstrated in a mouse model of multiple sclerosis, where BET inhibition resulted in abrogation of clinical signs of disease, in part, through inhibition of IL-6 and IL-17. R. Jahagjrdar et al., "An Orally Bioavailable Small Molecule RVX-297 Significantly Decreases Disease in a Mouse Model of Multiple Sclerosis," World Congress of Inflammation Paris, France (2011). These results were supported in a similar mouse model where it was shown that treatment with a BET inhibitor inhibited T cell differentiation into pro-autoimmune Thl and Thl 7 subsets in vitro, and further abrogated disease induction by pro-mflammatory Thl cells. H. Bandukwala et al., "Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors," Proc Natl Acad Sci USA
109(36): 14532-7 (2012).
[0007] BET inhibitors may be useful in the treatment of a variety of chronic autoimmune inflammatory conditions. Thus, one aspect of the invention provides compounds, compositions, and methods for treating autoimmune and/or inflammatory diseases by administering one or more compounds of the invention or pharmaceutical compositions comprising one or more of those compounds. Examples of autoimmune and inflammatory diseases, disorders, and syndromes that may be treated using the compounds and methods of the invention include but are not limited to, inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis (G. Zhang et al., J Biol Chem 287(34):8840-51 (2012)), osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, psoriasis, allergy, Crohn's disease, irritable bowel syndrome, ulcerative colitis (R, Prinjha et al., Trends Pharmacol Sci 33(3): 146-53 (2012)), Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease
3 (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis (H. Bandukwala et al., Proc Natl Acad Sci USA 109(36): 14532-7 (2012)), scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, Type I diabetes (A. Be!kina and G. Denis, Nat Rev Cancer 12(7):465-77 (2012)), septic shock (G. Zhang et al J Biol Chem 287(34):8840-51 (2012)), systemic lupus erythematosus (SLE) (R. Prinjha et al, Trends Pharmacol Sci 33(3):146-53 (2012)), rheumatoid arthritis (G. Denis "Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation," Discov Med 10(55):489-99 (2010)), psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Guillain-Barre syndrome, Behcet's disease, uveitis, dry eye disease, scleroderma, mycosis fungoides, and Graves' disease.
[0008] BET inhibitors may be useful in the treatment of a wide variety of acute inflammatory conditions. Thus, one aspect of the invention provides compounds, compositions, and methods for treating inflammatory conditions including but not limited to, acute gout, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement, such as glomerulonephritis, vasculitis, including giant cell arteritis, Wegener's granulomatosis, polyarteritis nodosa, Behcet's disease, Kawasaki disease, and Takayasu's arteritis.
[0009] BET inhibitors may be useful in the prevention and treatment of diseases or conditions that involve inflammatory responses to infections with bacteria, viruses, fungi, parasites, and their toxins, such as, but not limited to sepsis, sepsis syndrome, septic shock (E. Nicodeme et al., Nature 468(7327):1119-23 (2010)), systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, adult respiratory distress syndrome (ARDS), acute renal failure, fulminant hepatitis, burns, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria, and SIRS associated with viral infections, such as influenza, herpes zoster, herpes simplex, and coronavirus. A. Belkina and G. Denis, Nat Rev Cancer
12(7):465-77 (2012). Thus, one aspect of the invention provides compounds, compositions, and methods for treating these inflammatory responses to infections with bacteria, viruses, fungi, parasites, and their toxins described herein.
4 [00010] Cancer is a group of diseases caused by dysregulated cell proliferation.
Therapeutic approaches aim to decrease the numbers of cancer cells by inhibiting cell replication or by inducing cancer cell differentiation or death, but there is still significant unmet medical need for more efficacious therapeutic agents. Cancer cells accumulate genetic and epigenetic changes that alter cell growth and metabolism, promoting cell proliferation and increasing resistance to programmed cell death, or apoptosis. Some of these changes include inactivation of tumor suppressor genes, activation of oncogenes, and modifications of the regulation of chromatin structure, including deregulation of histone PTMs. J. Watson "Giring 'incurable' cancer," Cancer Discov l(6):477-80 (2011); R. Morin et al., "Frequent mutation of histone-modifying genes h non-Hodgkin lymphoma" Nature 476(7360):298- 303 (2011).
[00011] One aspect of the invention provides compounds, compositions, and methods for treating human cancer, including, but not limited to, cancers that result from aberrant translocation or overexpression of BET proteins (e.g., NUT midline carcinoma (NMC) (C. French "NUT midline carcinoma," Cancer Genet Cytogenet 203(l):16-20 (2010) and B- cell lymphoma (R. Green wald et al., "E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia," Blood 103(4): 1475-84 (2004)). NMC tumor cell growth is driven by a translocation of the Brd4 or Brd3 gene to the nutlin 1 gene. P. Filippakopoulos et al., "Selective inhibition of BET bromodomains," Na/wre 468(7327): 1067-73 (2010). BET inhibition has demonstrated potent antitumor activity in murine xenograft models of NMC, a rare but lethal form of cancer. The present disclosure provides a method for treating human cancers, including, but not limited to, cancers dependent on a member of the myc family of oncoproteins including c-myc, MYCN, and L-myc. M. Vita and M. Henriksson, "The Myc oncoprotein as a therapeutic target for human cancer," Semin Cancer Biol 16(4):318-30 (2006). These cancers include Burkitt's lymphoma, acute myelogenous leukemia, multiple myeloma, and aggressive human medulloblastoma. M. Vita and M. Henriksson, Semin Cancer Biol 16(4):318-30 (2006). Cancers in which c-myc is overexpressed may be particularly susceptible to BET protein inhibition; it has been shown that treatment of tumors that have activation of c-myc with a BET inhibitor resulted in tumor regression through inactivation of c-myc transcription. M. Dawson et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature, 2011. 478(7370): p. 529-33; J. Delmore et al., "BET bromodomain inhibition as a therapeutic strategy to target c- Myc," Cell 146(6):904-17 (2010); J. Mertz et al., 'Targeting MYC dependence in cancer by inhibiting BET bromodomains," Proc Nail Acad Sci USA 108(40): 16669-74 (2011); C. Ott
5 et al., "BET bromodomain inhibition targets both c-Myc and IL7R in highrisk acute lymphoblastic leukemia," Blood 120(14):2843-52 (2012); J. Zuber et al., "RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia," Nature 478(7370):524-8 (2011).
[00012] Embodiments of the invention include methods for treating human cancers that rely on BET proteins and pTEFb (Cdk9/CyclinT) to regulate oncogenes (S. Wang, and P. Fischer, "Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol Sci 29(6):302-13 (2008)), and cancers that can be treated by inducing apoptosis or senescence by inhibiting Bcl2, cyclin-dependent kinase 6 (CDK6) (M. Dawson et al., Nature 478 (7370):529-33 (2011)), or human telomerase reverse transcriptase (hTERT). J. Delmore et al., Cell 146(6):904-17 (2010); M. Ruden and N. Puri, "Novel anticancer therapeutics targeting telomerase," Cancer Treat Rev (2012).
[00013] BET inhibitors may be useful in the treatment of cancers including, but not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryob 1 astic leukemia, acute monocytic leukemia, acute myeloid leukemia (M. Dawson et al., Nature 478(7370):529-33 (2011); J. Mertz, et al., Proc Natl Acad Sci USA 108(40): 16669-74 (2011); J. Zuber et al., Nature
478(7370):524-8 (2011)), adenocarcinoma, adenoid cystic carcinoma, adenoma,
adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angi oimmunob I astic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell acute lymphoblastic leukemia(C. Ott et al., Blood 120(14):2843-52 (2012)), B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma (R. Greenwald et al., Blood 103(4): 1475-84 (2004)), basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitfs lymphoma (J. Mertz et al., Proc Natl Acad Sci USA 108(40): 16669- 74 (2011)), breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small
6 round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associ a ted T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma,
gastrointestinal cancer, germ ceil tumor, gestational choriocarcinoma, giant cell
fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor,
gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia,
hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological
malignancy, hepatoblastoma, hepatospienic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia (Mertz, J.A., et al., Proc Natl Acad Sci USA 108(40): 16669-74 (2011)), chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer,
medulloblastoma, melanoma (M. Segura et al., "BRD4 is a novel therapeutic target in melanoma," Cancer Research 72(8):Supplement 1 (2012)), meningioma, Merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mixed lineage leukemia (M. Dawson et al., Nature 478(7370):529-33 (2011)), mucinous tumor, multiple myeloma(J. Delmore et al,, Cell 146(6):904-17 (2010)), muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, NUT- midline carcinoma (P. Filippakopoulos et al., Nature 468(7327): 1067-73 (2010)), ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath
meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma,
pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyerabryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor. Thus, one aspect of the inventions provides compounds, compositions, and methods for treating such cancers.
[00014] BET inhibitors may be useful in the treatment of benign proliferative and fibrotic disorders, including benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, juvenile polyposis syndrome, idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma, and cardiac fibrosis. X. Tang et al., "Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis," Am J Pathology in press (2013). Thus, one aspect of the invention provides compounds, compositions, and methods for treating such benign proliferative and fibrotic disorders.
[00015] Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in the United States. V. Roger et al., "Heart disease and stroke statistics-2012 update: a report from the American Heart Association," Circulation 125(l):e2-e220 (2012). Atherosclerosis, an underlying cause of CVD, is a multifactorial disease characterized by dyslipidemia and inflammation. BET inhibitors are expected to be efficacious in
atherosclerosis and associated conditions because of aforementioned anti -inflammatory effects as well as ability to increase transcription of ApoA-I, the major constituent of HDL. O. Mirguet et al., Bioorg Med Chem Lett 22(8):2963-7 (2012); C. Chung et al,, "Discovery and characterization of small molecule inhibitors of the BET family bromodomains," J Med Chem 54(11 ):3827-38 (2011 ). Accordingly, one aspect of the invention provides
8 compounds, compositions, and methods for treating cardiovascular disease, including but not limited to atherosclerosis.
[00016] Up-regulation of ApoA-I is considered to be a useful strategy in treatment of atherosclerosis and CVD. E. Degoma and D. Rader, "Novel HDL-directed
phannacotherapeutic strategies," Nat Rev Cardiol 8(5):266-77 (2011) BET inhibitors have been shown to increase ApoA-I transcription and protein expression. O. Mirguet et al., Bioorg Med Chem Lett 22(8):2963-7 (2012); C. Chung et al., J Med Chem 54(11):3827-38
(20 1) . It has also been shown that BET inhibitors bind directly to BET proteins and inhibit their binding to acetylated bistones at the ApoA-1 promoter, suggesting the presence of a BET protein repression complex on the ApoA-1 promoter, which can be functionally disrupted by BET inhibitors. It follows that, BET inhibitors may be useful in the treatment of disorders of lipid metabolism via the regulation of ApoA-I and HDL such as
hypercholesterolemia, dysUpidemia, atherosclerosis (E. Degoma and D. Rader, Nat Rev Cardiol 8(5):266-77 (2011)), and Alzheimer's disease and other neurological disorders.
D. Elliott et al., "Apolipoproteins in the brain: implications for neurological and psychiatric disorders," Clin Lipidol 51(4):555-573 (2010). Thus, one aspect of the invention provides compounds, compositions, and methods for treating cardiovascular disorders by upregulation of ApoA-1.
[00017] BET inhibitors may be useful in the prevention and treatment of conditions associated with ischemia-reperfusion injury such as, but not limited to, myocardial infarction, stroke, acute coronary syndromes (R. Prinjha et al. Trends Pharmacol Sci 33(3): 146-53
(2012) ), renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardio -pulmonary bypass procedures, hypertension, pulmonary, renal, hepatic, gastrointestinal, or peripheral limb embolism. Accordingly, one aspect of the invention provides compounds, compositions, and methods for prevention and treatment of conditions described herein that are associated with ischemia-reperfusion injury.
[00018] Obesity-associated inflammation is a hallmark of type II diabetes, insulin resistance, and other metabolic disorders. A. Belkina and G.Denis, Nat Rev Cancer
12(7):465-77 (2012); G. Denis Discov Med 10(55):489-99 (2010). Consistent with the ability of BET inhibitors to inhibit inflammation, gene disruption of Brd2 in mice ablates inflammation and protects animals from obesity-induced insulin resistance. F. Wang et al., "Brd2 disruption in mice causes severe obesity without Type 2 diabetes," Biochem J
425(l):71-83 (2010). It has been shown that Brd2 interacts with PPARy and opposes its transcriptional function. Knockdown of Brd2 in vitro promotes transcription of PPARy- regulated networks, including those controlling adipogenesis. G. Denis et al., "An emerging role for bromodomain-containing proteins in chromatin regulation and transcriptional control of adipogenesis," FEBS Lett 584(15):3260-8 (2010). In addition Brd2 is highly expressed in pancreatic β-cells and regulates proliferation and insulin transcription. F. Wang et al., Biochem J425(l):71-83 (2010). Taken together, the combined effects of BET inhibitors on inflammation and metabolism decrease insulin resistance and may be useful in the treatment of pre-diabetic and type Π diabetic individuals as well as patients with other metabolic complications. A. Bel na and G.Denis No/ /fev Ca icer 12(7):465-77 (2012). Accordingly, one aspect of the invention provides compounds, compositions, and methods for treatment and prevention of metabolic disorders, including but not limited to obesity-associated inflammation, type II diabetes, and insulin resistance.
[00019] Host-encoded BET proteins have been shown to be important for transcriptional activation and repression of viral promoters. Brd4 interacts with the E2 protein of human papilloma virus (HPV) to enable E2 mediated transcription of E2- target genes. D. Gagnon et al., "Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4," J Virol 83(9):4127-39 (2009). Similarly, Brd2, Brd3, and Brd4 all bind to latent nuclear antigen 1 (LANA1), encoded by Kaposi's sarcoma-associated herpes virus (KSHV), promoting LANAl- dependent proliferation of KSHV-infected cells. J. You et al., "Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes," J Virol 80(18):8909-19 (2006). A BET inhibitor has been shown to inhibit the Brd4-mediated recruitment of the transcription elongation complex pTEFb to the Epstein-Barr virus (EBV) viral C promoter, suggesting therapeutic value for EBV-associated malignancies. R. Palermo et al,, "RNA polymerase Π stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus," PLoSPathog 7(10):el002334 (2011). Also, a BET inhibitor reactivated HTV in models of latent T cell infection and latent monocyte infection, potentially allowing for viral eradication by complementary anti-retroviral therapy. J. Zhu et al., "Reactivation of Latent fflV-1 by Inhibition of BRD4," Cell Rep (2012); C. Banerjee et al., "BET bromodomain inhibition as a novel strategy for reactivation of HTV-1," J Leukoc Biol (2012); K.
Bartholomeeusen et al., "BET bromodomain inhibition activates transcription via a transient release of P-TEFb from 7SK snR P," J Biol Chem (2012); Z. Li et al., "The BET bromodomain inhibitor JQ1 activates HTV latency through antagonizing Brd4 inhibition of Tat-transactivation," Nucleic Acids Res (2012). [00020] BET inhibitors may be useful in the prevention and treatment of episome- based DNA viruses including, but not limited to, human papillomavirus, herpes virus, Epstein-Barr virus, human immunodeficiency virus (A. Belkina and G. Denis, Nat Rev Cancer 12(7):465-77 (2012)), adenovirus, poxvirus, hepatitis B virus, and hepatitis C virus. Thus, the invention also provides compounds, compositions, and methods for treatment and prevention of episome-based DNA virus infections described herein.
[00021] Some central nervous system (CNS) diseases are characterized by disorders in epigenetic processes. Brd2 haplo-insufFiciency has been linked to neuronal deficits and epilepsy. L. Velisek et al., "GABAergic neuron deficit as an idiopathic generalized epilepsy mechanism: the role of BRD2 haploinsufficiency in juvenile myoclonic epilepsy," PLoS One 6(8): e23656 (2011) SNPs in various bromodomain-containing proteins have also been linked to mental disorders including schizophrenia and bipolar disorders. R. Prinjha et al., Trends Pharmacol Sci 33(3):146-53 (2012). In addition, the ability of BET inhibitors to increase ApoA-I transcription may make BET inhibitors useful in Alzheimer's disease therapy considering the suggested relationship between increased ApoA-I and Alzheimer's disease and other neurological disorders. D. Elliott et al., Clin Ltpidol 51(4):555-573 (2010). Accordingly, one aspect of the invention provides compounds, compositions, and methods for treating such CNS diseases and disorders.
[00022] BRDT is the testis-specific member of the BET protein family which is essential for chromatin remodeling during spermatogenesis. J. Gaucher et al.,
"Bromodomam-dependent stage-specific male genome programming by Brdt," EMBO J 31(19):3809-20 (2012); E. Shang et al., "The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation,'' Development 134(19):3507-15 (2007). Genetic depletion of BRDT or inhibition of BRDT interaction with acetylated histones by a BET inhibitor resulted in a contraceptive effect in mice, which was reversible when small molecule BET inhibitors were used. M. Matzuk et al., "Small-Molecule Inhibition of BRDT for Male Contraception,'' Cell 150(4): 673-684 (2012); B. Berkovits et al., "The testis-specific double bromodomain- containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3'-UTR truncation in round spermatids," Nucleic Acids Res 40(15):7162-75 (2012). These data suggest potential utility of BET inhibitors as a novel and efficacious approach to male contraception. Thus, another aspect of the invention provides compounds, compositions, and methods for male contraception. [00023] Monocyte chemotactic protein- 1 (MCP-1, CCL2) plays an important role in cardiovascular disease. J. Niu and P. Kolattukudy, "Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications," Clin Sci (Lond) 117(3):95-109 (2009). MCP-1, by its chemotactic activity, regulates recruitment of monocytes from the arterial lumen to the subendothelial space, where they develop into macrophage foam cells, and initiate the formation of fatty streaks which can develop into atherosclerotic plaque. J. Dawson et al., 'Targeting monocyte chemoattractant protein- 1 signalling in disease," Expert Opin Ther Targets 7(l):35-48 (2003). The critical role of MCP-1 (and its cognate receptor CCR2) in the development of atherosclerosis has been examined in various transgenic and knockout mouse models on a hyperlipidemic background. L. Boring et al., "Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis," Nature 394(6696): 894-7 (1998); J. Gosling et al., "MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B," J Clin Invest
103(6):773-8 (1999); L. Gu et al., "Absence of monocyte chemoattractant protein -1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice, " Mol Cell 2(2):275-81 (1998); R. Aiello et al., "Monocyte chemoattractant protein- 1 accelerates atherosclerosis in apolipoprotein E-deficient mice," Arterioscler Thromb Vase Biol 19(6): 1518-25 ( 1999). These reports demonstrate that abrogation of MCP-1 signaling results in decreased macrophage infiltration to the arterial wall and decreased atherosclerotic lesion development
[00024] The association between MCP-1 and cardiovascular disease in humans is well-established. J. Niu and P. Kolattukudy, Clin Sci (Lond) 117(3):95- 109 (2009). MCP-1 and its receptor are overexpressed by endothelial cells, smooth muscle cells, and infiltrating monocytes macrophages in human atherosclerotic plaque. N. Nelken et al., "Monocyte chemoattractant protein- 1 in human atheromatous plaques," J Clin Invest 88(4): 1121-7 (1991). Moreover, elevated circulating levels of MCP-1 are positively correlated with most cardiovascular risk factors, measures of coronary atherosclerosis burden, and the incidence of coronary heart disease (CHD). R. Deoet al., "Association among plasma levels of monocyte chemoattractant protein- 1, traditional cardiovascular risk factors, and subclinical
atherosclerosis," J Am Coll Cardiol 44(9): 1812-8 (2004). CHD patients with among the highest levels of MCP-1 are those with acute coronary syndrome (ACS). J. de Lemos et al., "Association between plasma levels of monocyte chemoattractant protein- 1 and long-term clinical outcomes in patients with acute coronary syndromes," Circulation 107(S):690-5 (2003). In addition to playing a role in the underlying inflammation associated with CHD, MCP-1 has been shown to be involved in plaque rupture, ischemic/reperfusion injury, restenosis, and heart transplant rejection. J. Niu and P. Kolattukudy, Clin Sci (Lond)
1 17(3):95-109 (2009).
[00025] MCP- also promotes tissue inflammation associated with autoimmune diseases including rheumatoid arthritis (RA) and multiple sclerosis (MS). MCP-1 plays a role in the infiltration of macrophages and lymphocytes into the joint in RA, and is overexpressed in the synovial fluid of RA patients. A. Koch et al., "Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis," J Clin Invest 90(3):772-9 (1992).
Blockade of MCP-1 and MCP-1 signaling in animal models of RA have also shown the importance of MCP-1 to macrophage accumulation and proinflammatory cytokine expression associated with RA. C. Brodmerkel et al., "Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344," J Immunol 175(8):5370-8 (2005); H. Bruhl et al., "Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T∞U ' J Immunol 172(2):890-8 (2004); J. Gong et al., "An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model," J Exp Med 186(l):131-7 (1997); 65. J. Gong et al., "Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy," Rheumatology (Oxford 43(1): 39-42 (2004).
[00026] Overexpression of MCP-1, in the brain, cerebrospinal fluid (CSF), and blood, has also been associated with chronic and acute MS in humans. D. Mahad and R. Ransohoff, "The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)," Semin Immunol 15(1 ):23-32 (2003). MCP-1 is overexpressed by a variety of cell types in the brain during disease progression and contributes to the infiltration of macrophages and lymphocytes which mediate the tissue damage associated with MS. Genetic depletion of MCP-1 or CCR2 in the experimental autoimmune
encephalomyelitis (EAE) mouse model, a model resembling human MS, results in resistance to disease, primarily because of decreased macrophage infiltration to the CNS. B. Fife et al., "CC chemokine receptor 2 is critical for induction of experimental autoimmune
encephalomyelitis, "J Exp Med 192(6): 899-905 (2000); D. Huang et al., "Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis," J Exp Med 193(6):7l 3-26 (2001).
[00027] Preclinical data have suggested that small- and large-molecule inhibitors of MCP-1 and CCR2 have potential as therapeutic agents in inflammatory and autoimmune indications. Thus, one aspect of the invention provides compounds, compositions, and methods for treating cardiovascular, inflammatory, and autoimmune conditions associated with MCP-1 and CCR2.
[00028] Accordingly, the invention provides compounds that are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising one or more of those compounds, and use of these compounds or compositions in the treatment and prevention of diseases and conditions, including, but not limited to, cancer, autoimmune, and cardiovascular diseases.
[00029] The first aspect of the invention includes compounds of Formula I and methods of administering a therapeutically effective amount of those compounds to a mammal (e.g., a human) in need thereof:
Figure imgf000015_0001
Formula I
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof,
wherein:
Wi is selected from N and CRi;
W2 is selected from N and CR2;
W3 is selected from N and CR3;
W4 is selected from N and CR ;
X is selected from N and CH;
Y is selected from -S(O)-, -C(0>, -NH-, -NHCH2-, -NHCH2CH2-, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(C]-C3), halogen, hydroxyl, or amino;
R], R2, R3, and R4 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen; two adjacent substituents selected from Ri, R2, R3, and R* may be connected in a 5- or 6-membered ring to form a bicyclic carbocycle or bicyclic heterocycle;
Rs is selected from amino, S- and 6- membered carbocycies and heterocycles;
R$ is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl; and
R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
[00030] Another aspect of the invention includes compounds of Formula la and methods of administering a therapeutically effective amount of those compounds to a mammal (e.g., a human) in need thereof:
Figure imgf000016_0001
Formula la
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof,
wherein:
X is selected from N and CH;
Y is selected from -S(0)-, -C(0 , -NH-, -IMHCH2-, -NHCH2CH2-, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(Cj-C3), halogen, hydroxyl, or amino;
Ri and R3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen
R5 is selected from amino, aminoalkyl, 5- and 6- membered carbocycies and heterocycles optionally substituted with halogen, amino, amide, alky Ci-Ce), or alkox fCj- Q) for example, the structures Ra
Figure imgf000017_0001
H o
Figure imgf000017_0002
Figure imgf000017_0003
where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, - C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2CH2amino, and - CH2C¾C(Me)2OH;
R« is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl; and
R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
[00031] In another aspect of the invention, a pharmaceutical composition comprising a compound of Formula I or Formula la, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients is provided
[00032] In yet another aspect of the invention there is provided a compound of Formula I or Formula la, or a pharmaceutically acceptable salt thereof for use in therapy, in particular in the treatment of diseases or conditions for which a broraodomain inhibitor is indicated.
[00033]In yet another aspect of the invention there is provided a compound of Formula I or Formula la, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
DEFINITIONS
[00034] As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. The following abbreviations and terms have the indicated meanings throughout [00035] As used herein, "cardiovascular disease" refers to diseases, disorders and conditions of the heart and circulatory system that are mediated by BET inhibition.
Exemplary cardiovascular diseases, including cholesterol- or lipid-related disorders, include, but are not limited to, acute coronary syndrome, angina, arteriosclerosis, atherosclerosis, carotid atherosclerosis, cerebrovascular disease, cerebral infarction, congestive heart failure, congenital heart disease, coronary heart disease, coronary artery disease, coronary plaque stabilization, dyslipidemias, dyslipoproteinemias, endothelium dysfunctions, familial hypercholesterolemia, familial combined hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hyperbetalipoproteinemi a, hypercholesterolemia, hypertension, hyperlipidemia, intermittent claudication, ischemia, ischemia reperfusion injury, ischemic heart diseases, cardiac ischemia, metabolic syndrome, multi-infarct dementia, myocardial infarction, obesity, peripheral vascular disease, reperfusion injury, restenosis, renal artery atherosclerosis, rheumatic heart disease, stroke, thrombotic disorder, transitory ischemic attacks, and lipoprotein abnormalities associated with Alzheimer's disease, obesity, diabetes mellitus, syndrome X, impotence, multiple sclerosis, Parkinson's disease, and inflammatory diseases.
[00036] As used herein, "inflammatory diseases" refers to diseases, disorders, and conditions that are mediated by BET inhibition. Exemplary inflammatory diseases, include, but are not limited to, arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post
transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, diabetic nephropathy, diabetic vasculopathy, ocular inflammation, uveitis, rhinitis, ischemia- reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina, and small artery disease.
[00037] As used herein, "cancer" refers to diseases, disorders, and conditions that are mediated by BET inhibition. Exemplary cancers, include, but are not limited to, chronic lymphocytic leukemia and multiple myeloma, follicular lymphoma, diffuse large B cell lymphoma with germinal center phenotype, Burkitt's lymphoma, Hodgkin's lymphoma, follicular lymphomas and activated, anaplastic large cell lymphoma, neuroblastoma and primary neuroectodermal tumor, rhabdomyosarcoma, prostate cancer, breast cancer, NMC (NUT-midline carcinoma), acute myeloid leukemia (AML), acute B lymphoblastic leukemia (B-ALL), Burkitt's Lymphoma, B-cell lymphoma, melanoma, mixed lineage leukemia, multiple myeloma, pro-myelocytic leukemia (PML), non-Hodgkin's lymphoma, neuroblastoma, medul I ob 1 astoma, lung carcinoma (NSCLC, SCLC), and colon carcinoma.
[00038] "Subject" refers to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful for both human therapy and veterinary applications. In one embodiment, the subject is a human.
[00039] As used herein, "treatment" or "treating'' refers to an amelioration of a disease or disorder, or at least one discernible symptom thereof. In another embodiment, "treatment" or "treating" refers to an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient In yet another embodiment, "treatment" or "treating" refers to inhibiting the progression of a disease or disorder, either physically, e.g., stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both. In yet another embodiment, "treatment" or "treating" refers to delaying the onset of a disease or disorder. For example, treating a cholesterol disorder may comprise decreasing blood cholesterol levels.
[00040] As used herein, "prevention" or "preventing" refers to a reduction of the risk of acquiring a given disease or disorder.
[00041] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom.
[00042] By "optional" or "optionally'' is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which is does not For example, "optionally substituted aryl" encompasses both "aryl" and "substituted aryl" as defined below. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and or inherently unstable.
[00043] As used herein, the term "hydrate" refers to a crystal form with either a stoichiometric or non-stoichiometric amount of water is incorporated into the crystal structure.
[00044] The term "alkenyl" as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C2-Cg)a]kenyl. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, and 4-(2-methyl-3-butene)- pentenyL
[00045] The term "alkoxy" as used herein refers to an alkyl group attached to an oxygen (-O-alkyl-). "Alkoxy" groups also include an alkenyl group attached to an oxygen ("alkenyloxy") or an alkynyl group attached to an oxygen ("alkynyloxy") groups. Exemplary alkoxy groups include, but are not limited to, groups with an alkyl, alkenyl or alkynyl group of 1-8 carbon atoms, referred to herein as (Ci-Cg)alkoxy. Exemplary alkoxy groups include, but are not limited to methoxy and ethoxy.
[00046] The term "alkyl" as used herein refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-8 carbon atoms, referred to herein as (C).Cg)alkyL Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl- 1 -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-l-butyl, 2- methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl- 1 -pentyl, 3-methyl-l-pentyi, 4-methyl-l- pentyl, 2-methyl-2-pentyl, 3 -methy 1-2-pentyl , 4-methyl-2-pentyl, 2,2-dimethyl- 1 -butyl, 3,3- dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.
[00047] The term "alkynyl" as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-8 carbon atoms, referred to herein as (C2.Cg)alkynyl. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl- 1 -butyny 1 , 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl.
[00048] The term "amide" as used herein refers to the form -N a OXRb)- or
-C(0)NRbRc, wherein R^, R¾ and Rc are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen. The amide can be attached to another group through the carbon, the nitrogen, R¾, or RQ. The amide also may be cyclic, for example R0 and Rc, may be joined to form a 3- to 8-membered ring, such as 5- or 6-membered ring. The term "amide" encompasses groups such as sulfonamide, urea, ureido, carbamate, carbamic acid, and cyclic versions thereof. The term "amide" also encompasses an amide group attached to a carboxy group, e.g., -amide-COOH or salts such as -amide-COONa, an amino group attached to a carboxy group (e.g., -amino- COOH or salts such as -amino-COONa).
[00049] The term "amine" or "amino" as used herein refers to the form -NR^Rg or
-N(Rd)Re-, where Rj and Rg are independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, carbamate, cycloalkyl, haloalkyl, heteroaryl, heterocycle, and hydrogen. The amino can be attached to the parent molecular group through the nitrogen. The amino also may be cyclic, for example any two of and Re may be joined together or with the N to form a 3- to 12-membered ring (e.g., morpholino or piperidinyl). The term amino also includes the corresponding quaternary ammonium salt of any amino group. Exemplary amino groups include alkylamino groups, wherein at least one of R<j or is an alkyl group. In some embodiments Rd and Re each may be optionally substituted with hydroxyl, halogen, alkoxy, ester, or amino.
[00050] The term "aryl" as used herein refers to a mono-, bi-, or other
multi-carbocyclic, aromatic ring system. The aryl group can optionally be fused to one or more rings selected from aryls, cycloalkyls, and heterocyclyls. The aryl groups of this present disclosure can be substituted with groups selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone. Exemplary aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. Exemplary aryl groups also include, but are not limited to a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as n(C6)aryl."
[00051] The term "arylalkyl" as used herein refers to an alkyl group having at least one aryl substituent (e.g., -aryl-alkyl-). Exemplary arylalkyl groups include, but are not limited to, arylalkyls having a monocyclic aromatic ring system, wherein the ring comprises 6 carbon atoms, referred to herein as B( )arylalkyl.''
[00052] The term "carbamate'' as used herein refers to the form -RgOC(0)N(R¾)-,
-RgOC(0)N(Rh)Rj-, or -OC(0)NR Ri, wherein Rg< R¾ and Rj are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen. Exemplary carbamates include, but are not limited to, arylcarbamates or heteroaryl carbamates (e.g., wherein at least one of Rg} Rn and Rj are independently selected from aryl or heteroaryl, such as pyridine, pyridazine, pyrimidine, and pyrazine).
[00053] The term "carbocycle" as used herein refers to an aryl or cycloalkyl group.
[00054] The term "carboxy" as used herein refers to -COOH or its corresponding carboxylate salts (e.g., -COONa). The term carboxy also includes "carboxycarbonyl,'' e.g. a carboxy group attached to a carbonyl group, e.g., -C(0)-COOH or salts, such as -C(O)- COONa.
[00055] The term "cyano" as used herein refers to -CN.
[00056] The term "cycloalkoxy" as used herein refers to a cycloalkyl group attached to an oxygen.
[00057] The term "cycloalkyl" as used herein refers to a saturated or unsaturated cyclic, bicyclic, or bridged bicyclic hydrocarbon group of 3-12 carbons, or 3-8 carbons, referred to herein as "(C3-Cg)cycloalkyl," derived from a cycloalkane. Exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclohexenes, cyclopentanes, and cyclopentenes. Cycloalkyl groups may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Cycloalkyl groups can be fused to other cycloalkyl saturated or unsaturated, aryl, or heterocyclyl groups.
[00058] The term "dicarboxylic acid" as used herein refers to a group containing at least two carboxylic acid groups such as saturated and unsaturated hydrocarbon dicarboxylic acids and salts thereof. Exemplary dicarboxylic acids include alkyl dicarboxylic acids.
Dicarboxylic acids may be substituted with alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Dicarboxylic acids include, but are not limited to succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, maleic acid, phthalic acid, aspartic acid, glutamic acid, malonic acid, fumaric acid, (+V(-)-malic acid, (+)/(-) tartaric acid, isophthalic acid, and terephthalic acid. Dicarboxylic acids further include carboxylic acid derivatives thereof, such as anhydrides, imides, hydrazides (for example, succinic anhydride and succinimide).
[00059] The term "ester" refers to the structure -C(0)0-, -C(0)0-Rj_, -RkC(0)0-Rj_, or -RkCiC O-, where O is not bound to hydrogen, and Rj and Rfc can independently be selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, cycloalkyl, ether, haloalkyl, heteroaryl, and heterocyclyl. Rfc can be a hydrogen atom, but Rj cannot be a hydrogen atom. The ester may be cyclic, for example the carbon atom and Rj, the oxygen atom and Rfc or Rj and Rfc may be joined to form a 3- to 12-membered ring.
Exemplary esters include, but are not limited to, alkyl esters wherein at least one of Rj or Rk is alkyl, such as -0-C(0)-alkyl, -C(0>0-alkyl-, and -alkyl-C(0)-0-alkyl-. Exemplary esters also include aryl or heteoraryl esters, e.g. wherein at least one of Rj or Rk is a heteroaryl group such as pyridine, pyridazine, pyrimidine and pyrazine, such as a nicotinate ester.
Exemplary esters also include reverse esters having the structure -RjfC(0)0-, where the oxygen is bound to the parent molecule. Exemplary reverse esters include succinate, D- argininate, L-argininate, L-lysinate and D-lysinate. Esters also include carboxyiic acid anhydrides and acid halides.
[00060] The terms "halo" or "halogen" as used herein refer to F, CI, Br, or 1.
[00061] The term "haloalkyl" as used herein refers to an alkyl group substituted with one or more halogen atoms. "Haloalkyls" also encompass alkenyl or alkynyl groups substituted with one or more halogen atoms.
[00062] The term "heteroaryl" as used herein refers to a mono-, bi-, or multi-cyclic, aromatic ring system containing one or more heteroatoms, for example 1-3 heteroatoms, such as nitrogen, oxygen, and sulfur. Heteroaryls can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxy., ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Heteroaryls can also be fused to non-aromatic rings. Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (l,2,4)-triazolyl, pyrazinyl, pyrimidilyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl.
Exemplary heteroaryl groups include, but are not limited to, a monocyclic aromatic ring, wherein the ring comprises 2-5 carbon atoms and 1-3 heteroatoms, referred to herein as "(C2- C5)heteroaryl "
[00063] The terms "heterocycle," "heterocyclyl," or heterocyclic" as used herein refer to a saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered ring containing one, two, or three heteroatoms independently selected from nitrogen, oxygen, and sulfur. Heterocycles can be aromatic (heteroaryls) or non-aromatic. Heterocycles can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone. Heterocycles also include bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings
22 independently selected from aryls, cycloalkyls, and heterocycles. Exemplary heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyi, indolyl, isoquino!yl, isotbiazolidinyl, isotbiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyL piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl, pyrrolyL quinolinyl, quinoxaloyl, tetrahydrofuryl,
tetrahydroisoquinolyl, tetrahydropyranyl, te rahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, tbienyl, tbiomorpholinyl, thiopyranyl, and triazolyl.
[00064] The terms "hydroxy" and "hydroxy?' as used herein refer to -OH.
[00065] The term "hydroxyalkyl" as used herein refers to a hydroxy attached to an alkyl group.
[00066] The term "hydroxyary as used herein refers to a hydroxy attached to an aryl group.
[00067] The term "ketone" as used herein refers to the structure -C(0)-Rn (such as acetyl, -C(0)CH3) or -Rn.C(0 R0_. The ketone can be attached to another group through Rn or RQ. Rj, or RQ can be alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl, or or RQ can be joined to form a 3- to 12-membered ring.
[00068] The term "monoester" as used herein refers to an analogue of a dicarboxylic acid wherein one of the carboxylic acids is functionalized as an ester and the other carboxylic acid is a free carboxylic acid or salt of a carboxylic acid. Examples of monoesters include, but are not limited to, to monoesters of succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid, oxalic and maleic acid.
[00069] The term "phenyl" as used herein refers to a 6-membered carbocyclic aromatic ring. The phenyl group can also be fused to a cyclohexane or cyclopentane ring. Phenyl can be substituted with one or more substituents including alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylaJkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone.
[00070] The term "thioalkyl" as used herein refers to an alkyl group attached to a sulfur (-S-alkyl-).
23 100071] "Alkyl," "alkenyl," "alkynyl", "alkoxy", "amino" and "amide" groups can be optionally substituted with or interrupted by or branched with at least one group selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carbonyl, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxy!, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, thioketone, ureido and N. The substituents may be branched to form a substituted or unsubstituted heterocycle or cycloalkyl.
[00072] As used herein, a suitable substitution on an optionally substituted substituent refers to a group that does not nullify the synthetic or pharmaceutical utility of the
compounds of the present disclosure or the intermediates useful for preparing them.
Examples of suitable substitutions include, but are not limited to: -g alkyl, alkenyl or alkynyl; Ci-6 aryl, C2-5 heteroaryl; C37 cycloalkyl; C alkoxy; Ce aryloxy; -CN; -OH; oxo; halo, carboxy; amino, such as -NH(C alkyl), -N(Ci-g alkyl)2, -NH((C6)aryl), or
-N((C$)aryl)2; formyl; ketones, such as -CO(Ci-8 alkyl), -CO((C6 aryl) esters, such as
-CC>2(Ci-8 alkyl) and -CC¾ (C aryl). One of skill in art can readily choose a suitable substitution based on the stability and pharmacological and synthetic activity of the compound of the present disclosure.
[00073] The term "pharmaceutically acceptable carrier" as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
[00074] The term "pharmaceutically acceptable composition" as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
[00075] The term "pharmaceutically acceptable prodrugs" as used herein represents those prodrugs of the compounds of the present disclosure that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present disclosure. A discussion is provided in Higuchi et al., "Prodrugs as Novel Delivery Systems ? ACS Symposium Series, Vol. 14, and in Roche,
24 E.B., ed. Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
[00076] The term "pharmaceutically acceptable salt(s)" refers to salts of acidic or basic groups that may be present in compounds used in the present compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to sulfate, citrate, matate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicorinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate and pamoate (i.e., l,l'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
Compounds included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds included in the present compositions, that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
[00077] The compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term "stereoisomers" when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols "R" or "S," depending on the configuration of substituents around the stereogenic carbon atom. The present disclosure encompasses various stereoisomers of these compounds and mixtures thereof. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated "(±)" in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
[00078] Individual stereoisomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain
asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary,
25 separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct separation of the mixture of optica] enantiomers on chiral chromatographic columns. Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
Stereoisomers can also be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
[00079] Geometric isomers can also exist in the compounds of the present disclosure. The present disclosure encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the "Z" or "E" configuration wherein the terms "Z" and "E" are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the E and Z isomers.
[00080] Substituents around a carbon-carbon double bond alternatively can be referred to as "cis" or "trans," where "cis" represents substituents on the same side of the double bond and "trans" represents substituents on opposite sides of the double bond. The arrangements of substituents around a carbocyclic ring are designated as "cis" or "trans.'' The term "cis" represents substituents on the same side of the plane of the ring and the term "trans" represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated "cis/trans."
[00081] The compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the present disclosure, even though only one tautomeric structure is depicted.
26 EXEMPLARY EMBODIMENTS OF THE INVENTION
[00082] In certain aspects, the invention is directed to a compound according to Formula I:
Figure imgf000028_0001
Formula I
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:
Wi is selected from N and CRj;
W2 is selected from N and CR2;
W3 is selected from N and CR3;
W4 is selected from N and CR ;
X is selected from N and CH;
Y is selected from -S(0)-, -C(0>, -NH-, -NHCH2-, -NHC¾CH2-, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(Ct-C3), halogen, hydroxy I, or amino;
R], Ra, R3, and R4 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino (such as, e.g., aminoalkyl), aryloxy, aryl, hydroxyl, and halogen;
two adjacent substituents selected from Ri, R2, R3, and R4 may be connected in a 5- or 6-membered ring to form a bicyclic carbocycle or bicyclic heterocycle;
Rs is selected from amino and 5- and 6- membered carbocycles and heterocycles;
Re is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl; and
R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
[00083] Another aspect of the invention is directed to a compound according to Formula la:
27
Figure imgf000029_0001
Formula la
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:
X is selected from N and CH;
Y is selected from -S(0)-, -C(0 , -NH-, -NHCH2-, -NHCH2CH2-, and - HCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(Ci-C3), halogen, hydroxyl, or amino;
R] and R3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen;
Rs is selected from amino, aminoalkyl, S- and 6- membered carbocycles and heterocycles optionally substituted with halogen, amino, amide, alkyl(Ci-C6), or alkoxy(Ci- C¾) for example, the structures
Ra
Figure imgf000029_0002
where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, - C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2CH2amino, and - CH^CCMe^OH;
Re is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl; and
28 R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
[00084] In some embodiments of a compound of Formula I, each of Ri , R2, R3, and R , if present, are independently selected from hydrogen, alkyl, alkoxy, amino, and halogen.
[00085] In some embodiments of a compound of Formula la, each of Ri and R3 are independently selected from hydrogen, alkyl, alkoxy, amino, and halogen.
[00086] In some embodiments of a compound of Formula I, each of Ri , R2, R3, and R4, if present, are independently selected from hydrogen, alkyl, and alkoxy, each of which may be optionally substituted with hydroxyl, amino, or halogen.
[00087] In some embodiments of a compound of Formula la, each of Ri and R3 are independently selected from hydrogen, alkyl, and alkoxy, each of which may be optionally substituted with hydroxyl, amino, or halogen.
[00088] In some embodiments of a compound of Formula I, each of Ri, R2, R3, and R , if present, is independently selected from aryl and aryloxy, each of which may be optionally substituted with halogen, alkoxy, or amino.
[00089] In some embodiments of a compound of Formula la, each of Rj and R3 are independently selected from aryl and aryloxy, each of which may be optionally substituted with halogen, alkoxy, or amino.
[00090] In certain embodiments of a compound of Formula I, Wi is CRi, W3 is CR3, and Rj and R3 are each independently an alkoxy group, for example mefhoxy, ethoxy, isopropoxy, and propoxy.
[00091] In certain embodiments of a compound of Formula la, Ri and R3 are each independently an alkoxy group, for example methoxy, ethoxy, isopropoxy, and propoxy.
[00092] In other embodiments of a compound of Formula I, Wt is CRi, W2 is CR2, W3 is CR3, W is CR4, and Rj and R3 are each alkoxy and R2 and R4 are each hydrogen.
[00093] In other embodiments of a compound of Formula I, i is CRi, W2 is CR2, W3 is N, W is CR4, and Ri and R3 are each alkoxy and R2 is hydrogen.
[00094] In other embodiments of a compound of Formula I, Wi is CRj, W2 is CR2, W3 is CR3, W is CR4, and Ri and R3 are each methoxy and R2 and R4 are each hydrogen.
[00095] In other embodiments of a compound of Formula la, R] and R3 are each methoxy.
[00096] In other embodiments of a compound of Formula I, Wj is CRj, W2 is CR2, W3 is CR3, W4 is CR4, Ri is methoxy, R3 is amino or aminoalkyl, and R2 and R are each hydrogen.
2 [00097] In other embodiments of a compound of Formula la, Ri is methoxy and R is amino or aminoalkyl.
[00098] In some embodiments of a compound of Formula I or Formula la, R5 is aminoalkyl.
[00099] In some embodiments of a compound of Formula I or Formula la, Y is selected f om -NH-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with F, Me, OMe, and CL
[000100] In certain embodiments of a compound of Formula I or Formula la, Y is -
NH-.
[000101] In certain embodiments of a compound of Formula I or Formula la, X is N.
[000102] In certain embodiments of a compound of Formula I or Formula la, X is CH.
[000103] In some embodiments of a compound of Formula I or Formula la, R5 is selected from amino, aminoalkyl, and 5- and 6- membered carbocyc!es and heterocycles optionally substituted with halogen, amino, urea, ester, carbamate, amide, alkyl(C|-C6);
alkoxyCCi-Ce),∞d aryl.
[000104] In some embodiments of a compound of Formula I or Formula la, Rj is selected from -NHRa and 5- and 6-membered carbocycles and heterocycles optionally substituted with halogen, amino, urea, ester, carbamate, amide, alkyl(CrC«), alkoxy(Cj-C6), or aryl, for example, the structures
I h
Figure imgf000031_0001
a , where Ra is selected from hydrogen, alkyl, alkenyl, aryl, -C(0)Alkyl(Ci-C ), -C(0)Amino, -C(0)Oalkyl(C,-C4), and benzyl.
[000105] In some embodiments of a compound of Formula I or Formula la, R5 is selected from -NHRa and 5- and 6-membered carbocycles and heterocycles optionally substituted with halogen, amino, amide, alkyl(C]-C6), or alkoxy(C|-C6) for example, the structures
Figure imgf000032_0001
where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, - C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -C¾CH2OH, -CH2CH2amino, and - CH2CH2C(Me)2OH.
{000106] In some embodiments of a compound of Formula I or Formula la, R$ is selected from hydrogen, alkyl, alkoxy, aminoalkyl, and thioalkyl, each of which may be optionally substituted with halogen, amino, hydroxyl, or alkoxy.
[000107] In some embodiments of a compound of Formula I or Formula la, R$ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
[000108] In some embodiments of a compound of Formula I or Formula la, R« is selected from hydrogen, methyl, and methoxy.
[000109] In a selected embodiment of a compound of Formula I or Formula la, ¾ is selected from groups represented by Formula Π:
Figure imgf000032_0002
wherein:
D and E are independently selected from O, N, and S;
¾ is selected from hydrogen and alkyl, and Rg is present only if D is N;
R9 and Rio are independently selected from hydrogen, alkyl, and cycloalkyl, and only one of R9 and Rio is present if E is O or S;
R9 and Rio may be connected to form a carbocycle or a heterocycle containing one or more heteroatoms; and n is selected from 1, 2, and 3.
[000110] In some embodiments of a compound of Formula I or Formula la, D is O and E is N;
n is 1; and
R-9 and Rio are independently selected from hydrogen, alkyl, and carbocycle.
[000111] In certain embodiments of a compound of Formula I or Formula la, Re is
selected from:
Figure imgf000033_0001
, and V
[000112] In some embodiments of a compound of Formula I or Formula la, R7 is selected from hydrogen, methoxy, ethoxy, propoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, and -OCF3.
[000113] In some embodiments of a compound of Formula I,
W, is CR!;
W2 is CR2;
W3 is CR3;
Wij is CRt;
Ri and R3 are each alkoxy;
R2 and R4 are each hydrogen;
Y is selected from-NH-, -MHCH2-, - HCH2CH2-, and - HCH2CH2CH2-, with the nitrogen attached to the B ring;
R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
32
Figure imgf000034_0001
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C<0)NHEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2CH2amino, and -CH2CH2C(Me)20H; and
R$ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
[000114] In some embodiments of a compound of Formula la,
R] and R3 are each alkoxy;
Y is selected from-NH-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring;
R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
Figure imgf000034_0002
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0) e, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2CH2amino, and -CH^H^iMe^OH; and
R* is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
[000115] In some embodiments of a compound of Formula I,
W| is CRi;
33 W2 is C¾;
W3 is CR3;
W* is CR ;
Rj is alkoxy;
R3 is amino or aminoalkyl;
R2 and R4 are each hydrogen;
Y is selected from-ΝΗ-, -IMHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring;
R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
Figure imgf000035_0001
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, -C(0)NH2, -C^CHiOH^, -C(0)C(0)OMe, -CF3, -CH2CH2OH, ¾CH2amino, and -CH^H^CMehOH; and
Re is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
[000116] In some embodiments of a compound of Formula la,
Ri is alkoxy;
R3 is amino or aminoalkyl;
Y is selected from-NH-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring;
R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
34
Figure imgf000036_0001
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0) e, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)N e2, -C(0)NHEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, ^2CH2amino, and -CHaCHiCCMe^H and
R$ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
[000117] In some embodiments, the compound is selected from:
5,7-I¾me&oxy-2^4-methoxy-2^(l-me^
4(3H)-one;
5,7-Dimemoxy-2^4-memoxy-2^4-memylpiperazane-l -carbonyl)phenyl) quinazolin- 4(3H)-one;
2-{2-((l-isopropylpiperidin-4-yl)amino)-4-methoxyphenyl)-5 -dim
4(3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-((l-me^ylpynOli
4(3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-(methyl(l-m
quinazolm-^/ -one;
5,7-Dimeraoxy-2^4Hnemoxy-2^((lHro^
quinazolin-4(3H)-one;
5,7-Dimethoxy-2-(4-memoxy-2^((l-memylpyrrolio^
quinazolin-4(3H)-one;
2-(2^(2^sopropylannno)emyl)ani^
4(3H>one;
5,7-dimethoxy-2-(4-Met oxy-2-((teti^ydro-2H-pyran-4-yl)amm
phenyl)quinazolin-4(3H)-one;
2^2^( sopropylpipericun^-yl)anim^
35 5 -Dimeihoxy-2^4-methoxy-2^(2^pyrrolidiii-l-yl)eA
4(3H)-one;
5J-Dimethoxy-2^4-methoxy-2^(2^
4(3H one;
5 -Dimethox -2^4Hmethoxy-2^(3-mo
4(3H)-one;
5^-0^βώο^-2^4Η∞β&ο^-2^(2-Μθφ^
4(3H one;
5 -Dimethoxy-2^4-methoxy-^^
4(3H one;
2^2^((l-Isopropylpyrj lid^
dime hoxyquinazolin-4(3H)-one;
2^2^((14sopropy lpyrrolidin-2-y^^
dimethoxyquinazoUn^3 ^ne;
2^3^(l-IiK)propylpiperidin^yl)aiiuno)pyridm
4(3H one;
2-(2-((l-IsobutyrylpipericUn-4-yl)^
dimethoxyquinatzolin-4(3H)-one;
2-(2^(3-{Isopropylamiiio)propy
dimethoxyquina2»lin-4(3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-((3-(methylpiperazin-l-yl)propyl)amino)- phenylquinazolin-4(3 H)-one;
2^2^(2^4-Isopropylpipera.rin-^
dimethoxyquinazolin^3/ )-one;
5 -Dimethoxy-2-[4-methoxy-2^1-methylpiperidin^
4(3H one;
5J-Dimethoxy-2^4-methoxy-2^(2^iperazin- 4{3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-((2-(4-methylpiperazin- 1 -yl)ethyl)amino)phenyl)- qiiinazolin-4(3H)-one;
2-(2-((l-Isopropylpiperidin^yl)^^
4(3 /)-one;
2^3-((l-I-K)propylpiperidin^-yl)a^
36 5 J-IMmethoxy-2^4-methoxy-2-[3-(piperazin- 1 -yl)propylamino]phenyl)quina2»lin- 4(3H)-one;
2^2-((4,4-DimethyIcyclohexyl)am^
4(3H)-one;
2^3^(l-Isopropylpiperidin^yl)am ^
diraethoxyquinazolin^3H)-one;
2-(2-((/r.^-4-(2-Hydroxypropan-2-yl)cyclohexyl)amino)-4-niethoxyp
dimethoxyqiiinazoliQ-4(3H)-one;
2^3^(1 -Isobutyrylpiperidw^^
dimethoxyqiiinazolin^37i)- )ne;
2^4-Chloro-2-((l-isopropylpiperi^
4(3H)-one;
2^4 ;hJoro-2^(1 sobiit iy^^
4(3#)-one;
2^2^(1-Beiizylpiperidin^yl)am^
4(3H)-one;
2^(l-Isobutyrylpiperidin^yl
one;
2^3^(1 -Acetylpiperidin^yl)ai^
one;
N-(cls-4-((2-(5 ,7-Dimethoxy-4-oxo-3 , -dihydroquinazo lin-2-yl)-5-niethoxypyridin-3 - yl)amiiio)cyclohexyl)isobutyramide;
2-(2^(l-Acetylpiperidin^-yl)amm^
4(3H)-one;
5 -Dimethoxy-2^5-methoxy-3-((l rc
yl)qiiiiiazolin^(3 -one;
5 -Dimethoxy-2^3^((l-methylp^
yl)qiiinazolin-4(3H)-one;
4^(2-(5 -Dimethox ^oxo-3,4^ihydra^
dimethylpiperidine-1 -carboxamide;
2-(3^(3^sopropylan ino)propyl)aniino)pyridin-2-yl)-5 ^i
4(3H one;
5J-Dimethoxy-2^3^(l-methylpiperidin^
one;
37 cis-4-((2-(5,7~Dimethoxy-4-oxo-3,4-dihycLroqm^ yl)amino)-N-isopropylcyclohexane- 1 -carboxamide;
5 -Dimethoxy-2-(3-((l-(2,2 -trifluoro^
yl)quinazolin-4(J//)-one;
4^(2-(5J-Dimemoxy-4-oxo-3^ lihyd^
isopropylpiperidine-l^arboxamide;
5 -Dime oxy-2-(3-((l-pivaloylpi^
one;
5,7-Dimethoxy-2-(3-((2-mo holinoeth l^
2-(3-((l-Isopropylpiperidm-4-yl^
yl)ainmo)ethoxy)pyridm
2-(4-((2-(5 -Dimethoxy-4-oxo-3 < ^
yl)amino)piperidin- 1 -yl)-N, N-diraethyl-2-oxoacetamide;
4-((2-(5 -diinemoxy-4-oxo-3^^i^
ethylpiperidine-l-carboxamide;
cw-4^(2-(5,7-Dimethoxy-4-oxo-3,4-<iihydroquinazolin-2-yl)py^ N^ limethylcyclohexane- 1 -carboxamide;
4-((2-(5,7-Dimethoxy-4-oxo-3}4-dihydroquina2Olin-2-yl)pyri yl)amino)piperidine- 1 -carboxamide;
Methyl-2-(4-((2-(5,7-dimel3ioxy-4-oxo-3^^
y l)amino)piperidin- 1 -yl)-2-oxoacetate;
_V-(2-((2-(5 -Dimeraoxy-4-oxo-3i4-dmyd
yl)amino)ethyl)isob ityramide;
.V-(3-((2-(5J-Dimethoxy-4-ox^
yl)amino)propyl)isobutyramide;
2-(3-((l-l_sopropylpiperidin-4-yl)a^
d]pyi½iidin-4(5H)-one;
2-(3-((l-(2-Hydroxy-2-meihylpropyl)piperidin-4-yl)amino)pyri dimethoxyquinazolin-4(3H)-one;
2-(3-((l-(2-hydroxypropanoyl)piperidm-4-y))ammo)pyri dimethoxyquinazolin-4(5H)-one;
2-(3-((l-Isopropylpiperidin-4-yl)amm^
methoxybenzyl)ammo)quinaz»lm-4(3H)-<)n
38 2-[5-(2-Hydroxyemoxy)-3-(l-isopropylpiperidm^
dimethoxyquinazolin^3 /)-one;
c&-4-((2-(5,7-Dimemoxy-4-oxo-3,4^^
isopropylcyclohexane- 1 -carboxamide;
2-[5-(2-Hydroxyetooxy)-3-(l-isobutyroyl^^^
dimet oxyqiiinazolin^3H)-one;
7-amino-2-(3-(( 1 -Isopropylpiperidin-4-yl)ani o
4(3H)-one;
2-{3-(l-Isopropylpiperid -4-ylamino^
5 <limethoxyqiiinazolin^3J¾0<)ne;
2-{5-[2-(Isopropyiariimo)emoxy]-3-(l^^
5,7-dime oxyquinazolm-4(^
2-(3-((l-(l -Hydroxy-2-methylpropan-2-yl)piperidin-4-yl)amino)pyriclin-2-yl)-5,7- dimewoxyquinazolin-4(3 Q-one; and
7-(Emylamino)-2-(3-((l-isopropy^^
methoxyquinazolin-4(3H)-one;
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof.
[000118] Another aspect of the invention provides a method for inhibition of BET protein function by binding to bromodomains, and their use in the treatment and prevention of diseases and conditions in a mammal (e.g., a human) comprising administering a therapeutically effective amount of a compound of Formula I or Formula la.
[000119] In one embodiment, because of potent effects of BET inhibitors in vitro on IL-6 and 1L-17 transcription, BET inhibitor compounds of Formula I or Formula la may be used as therapeutics for inflammatory disorders in which IL-6 and/or IL-17 have been implicated in disease. The following autoimmune diseases are amenable to therapeutic use of BET inhibition by administration of a compound of Formula I or Formula la or a
stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof because of a prominent role of IL-6 and/or IL-17: Acute Disseminated Encephalomyelitis (T. Ishizu et al., "CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis, " J
Neuroimmunol 175(1-2): 52-8 (2006)), Agammaglobulinemia (M. Gonzalez-Serrano, et al.," Increased Pro-inflammatory Cytokine Production After Lipopolysaccharide Stimulation in Patients with X-linked Agammaglobulinemia," J Clin Immunol 32(5):967-74 (2012)), Allergic Disease (L. McKinley et al., "TH17 cells mediate steroid-resistant airway
39 inflammation and airway hyperresponsiveness in mice," J Immunol 181(6):4089-97 (2008)), Ankylosing spondylitis (A. Taylan et al., "Evaluation of the T helper 17 axis in ankylosing spondylitis," Rheumatol Int 32(8):2511-5 (2012)), Anti-GBM Anti-TBM nephritis (Y. Ito et al., "Pathogenic significance of interleukin-6 in a patient with antiglomerular basement membrane antibody-induced glomerulonephritis with multinucleated giant cells," Am J Kidney Dis 26(l):72-9 (1995)), Anti-phospholipid syndrome (P. Soltesz et al.,
"Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction," Rheumatology (Oxford) 47(11 ): 1628-34 (2008)), Autoimmune aplastic anemia (Y. Gu et al., "Interie*ikin (BL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia," Br J Haematol 142(1): 109-14 (2008)), Autoimmune hepatitis (L. Zhao et al., "Interleukin-17 contributes to the
pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression," PLoS One 6(4):el 8909 (2011)), Autoimmune inner ear disease (B. Gloddek et al.,
"Pharmacological influence on inner ear endothelial cells in relation to the pathogenesis of sensorineural hearing loss," Adv Otorhinolaryngol 59:75-83 (2002)), Autoimmune myocarditis (T. Yamashita et al., "IL-6-mediated Thl7 differentiation through RORgammat is essential for the initiation of experimental autoimmune myocarditis," Cardiovasc Res 91(4):640-8 (2011)), Autoimmune pancreatitis (J. Ni et al.," Involvement of mterleukin-17A in Pancreatic Damage in Rat Experimental Acute Necrotizing Pancreatitis," Inflammation (2012)), Autoimmune retinopathy (S. Hohki et al., "Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Thl7 responses," Exp Eye Res 91(2): 162-70 (2010)), Autoimmune thrombocytopenic purpura (D. Ma et al., "Profile of Thl7 cytokines (IL-17, TGF-beta, EL-6) and Thl cytokine (IFN- gamma) in patients with immune thrombocytopenic purpura," Ann Hematol 87(11):899-904 (2008)), Behcet's Disease (T. Yoshimura et al., "Involvement of Thl 7 cells and the effect of anti-EL-6 therapy in autoimmune uveitis," Rheumatology (Oxford) 48(4):347-54 (2009)), Bullous pemphigoid (L. D'Auria et al., "Cytokines and bullous pemphigoid," Eur Cytokine Netw 10(2):123-34 (1999)), Castleman's Disease (H. El-Osta and R. Kurzrock, "Castleman's disease: from basic mechanisms to molecular therapeutics," Oncologist 16(4):497-511 (2011)), Celiac Disease (A. Lahdenpera et al., "Up-regulation of small intestinal interleukin- 17 immunity in untreated coeliac disease but not in potential coeliac disease or in type 1 diabetes," Clin Exp Immunol 167(2):226-34 (2012)), Churg-Strauss syndrome (A. Fujioka et al., "The analysis of mRNA expression of cytokines from skin lesions in Churg-Strauss syndrome," J Dermatol 25(3):171-7 (1998)), Crohn's Disease (V. Holtta et al., "IL-23/IL-17 immunity as a hallmark of Crohn's disease," Inflamm Bowel Dis 14(9): 1175-84 (2008)), Cogan's syndrome (M. Shibuya et al., "Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis," Mod Rheumatol (2012)), Dry eye syndrome (C. De Paiva et al., "IL-17 disrupts corneal barrier following desiccating stress," Mucosal Immunol 2(3):243-53 (2009)), Essential mixed cryoglobulinemia (A. Antonelli et al., "Serum levels of proinflammatory cytokines interleukin-lbeta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobdmemia," Arthritis Rheum 60(12):3841-7 (2009)),
Dermatomyositis (G. Chevrel et al., "Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis," J
Neuroimmunol 137(1 -2):125-33 (2003)), Devic's Disease (U. Linhares et al., "The Ex Vivo Production of IL-6 and IL-21 by CD4(+) T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients," J Clin Immunol (2012)), Encephalitis (D.
Kyburz and M. Corr, "Thl7 cells generated in the absence of TGF-beta induce experimental allergic encephalitis upon adoptive transfer," Expert Rev Clin Immunol 7(3):283-5 (2011)), Eosinophlic esophagitis (P. Dias and G. Banerjee, "The Role ofThl7/IL-17 on Eosinophilic Inflammation," JAutoimmun (2012)), Eosinophilic fasciitis (P. Dias and G. Banerjee, J Autoimmun (2012)), Erythema nodosum (1. Kahawita and D. Lockwood, "Towards understanding the pathology of erythema nodosum leprosum," Trans R Soc Trop Med Hyg 102(4):329-37 (2008)), Giant cell arteritis (J. Deng et al., "Thl7 and Thl T-cell responses in giant cell arteritis," Circulation 121(7):906-15 (2010)), Glomerulonephritis (J. Ooi et al., "Review: T helper 17 cells: their role in glomerulonephritis," Nephrology (Carlton)
15(5):513-21 (2010)), Goodpasture's syndrome (Y. Ito et al., "Pathogenic significance of interleukin-6 in a patient with antiglomerular basement membrane antibody-induced glomerulonephritis with multinucleated giant cells," Am J Kidney Dis 26(l):72-9 (1995)), Granulomatosis with Polyangiitis (Wegener's) (H. Nakahama et al., "Distinct responses of interleukin-6 and other laboratory parameters to treatment in a patient with Wegener's granulomatosis," Intern Med 32(2):189-92 (1993)), Graves' Disease (S. Kim et al.,
"Increased serum interleukin-17 in Graves' ophthalmopathy," Graefes Arch Clin Exp
Ophthalmol 250(10): 1521 -6 (2012)), GuiHain-Barre syndrome (M. Lu and J. Zhu, "The role of cytokines in Guillain-Barre syndrome," J Neurol 258(4):533-48 (2011)), Hashimoto's thyroiditis (N. Figueroa-Vega et al., "Increased circulating pro-inflammatory cytokines and Thl 7 lymphocytes in Hashimoto's thyroiditis," J Clin Endocrinol Metab 95(2):953-62 (2009)), Hemolytic anemia (L. Xu et al., "Critical role of Thl 7 cells in development of autoimmune hemolytic anemia," Exp Hematol (2012)), Henoch-Schonlein purpura( H, Jen et al., "Increased serum inter leukin- 17 and peripheral Thl7 cells in children with acute Henoch- Schonlein purpura," Pediatr Allergy Immunol 22(8):862-8 (2011)), IgA nephropathy (F. Lin et al., "Imbalance of regulatory T cells to Thl 7 cells in IgA nephropathy," Scand J Clin Lab Invest 72(3):221-9 (2012)), Inclusion body myositis (P. Baron et al., "Production of 1L-6 by human myoblasts stimulated with Abeta: relevance in the pathogenesis of IBM," Neurology 57(9):1561-5 (2001)), Type I diabetes (A. Belkina and G. Denis, Nat Rev Cancer 12(7):465- 77 (2012)), Interstitial cystitis (L. Lamale et al., "Interleukin-6, histamine, and
methylhistamine as diagnostic markers for interstitial cystitis," Urology 68(4):702-6 (2006)), Kawasaki's Disease (S. Jia et al., "The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease," Clin Exp Immunol 162(l):131-7 (2010)),
Leukocytoclastic vasculitis (Min, C.K., et al., "Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines, " Eur J Haematol 76(3):265-8 (2006)), Lichen planus (N. Rhodus et al.,
"Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone," Oral Dis 12(2):112-6 (2006)), Lupus (SLE) (M. Mok et al., "The relation of mterleukin 17 (IL-17) and IL-23 to Thl Th2 cytokines and disease activity in systemic lupus erythematosus," J Rheumatol 37(10):2046-52 (2010)), Microscopic polyangitis (A. Muller Kobold et al., "In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis," Clin Exp Rheumatol 17(4):433-40 (1999)), Multiple sclerosis (F. Jadidi-Niaragh and A. Mirshafiey, "Thl 7 cell, the new player of neuroinflammatory process in multiple sclerosis," Scand J Immunol 74(1): 1-13 (2011)), Myasthenia gravis (R. Aricha et al., "Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis," J Autoimmun 36(2):135-41 (2011)), myositis (G. Chevrel et al., "mterleukin- 17 increases the effects of EL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis," J Neuroimmunol 137(l-2):125-33 (2003)), Optic neuritis (S. Icoz et al.,
"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients," IntJNeurosci 120(l):71-5 (2010)), Pemphigus (E. Lopez-Robles et al., "TNFaJpha and IL-6 are mediators in the blistering process of pemphigus," Int J Dermatol 40(3): 185-8 (2001 )), POEMS syndrome (K. Kallen et al., "New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?" Expert Opin Investig Drugs
8(9): 1327-49 (1999)), Polyarteritis nodosa (T. Kawakami et al., "Serum levels of mterleukin- 6 in patients with cutaneous polyarteritis nodosa," Acta Derm Venereol 92(3):322-3 (2012)), Primary biliary cirrhosis (K. Harada et al., "Periductal mterleukin-17 production in
42 association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis," Clin Exp Immunol 157(2):261-70 (2009)), Psoriasis (S. Fujishima et al., "Involvement of IL-17F via the induction of IL-6 in psoriasis," Arch Dermatol Res 302(7):499-505 (2010)), Psoriatic arthritis (S. Raychaudhuri et al., IL-17 receptor and its functional significance in psoriatic arthritis," Mol Cell Biochem 359(1 -2):419-29 (2012)), Pyoderma gangrenosum (T. Kawakami et al., "Reduction of mterleukin-6, interleukin-8, and anti-phosphatidylserine-pro thrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis," Am J Gastroenterol 104(9):2363-4 (2009)), Relapsing polychondritis (M. Kawai et al., "Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis," Rheumatology (Oxford) 48(3):318-9 (2009)), Rheumatoid arthritis (Z. Ash and P. Emery, "The role of tocilizumab in the management of rheumatoid arthritis," Expert Opin Biol Ther, 12(9):1277-89 (2012)), Sarcoidosis (F. Belli et al., "Cytokines assay in peripheral blood and bronchoalveolar lavage in the diagnosis and staging of pulmonary granulomatous diseases," Int J Immunopathol Pharmacol 13(2):61-67 (2000)), Scleroderma (T. Radstake et al., "The pronounced Thl7 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes," PLoS One, 4(6): e5903 (2009)), Sjogren's syndrome (G. Katsifis et al., "Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome
immunopathogenesis, " Am J Pathol 175(3): 1167-77 (2009)), Takayasu's arteritis (Y. Sun et al., "MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis, " Int J Cardiol 156(2):236-8 (2012)), Transverse myelitis (J. Graber et al., " terleukin-17 in transverse myelitis and multiple sclerosis," J Neuroimmunol 196(1 -2): 124-32 (2008)), Ulcerative colitis (J. Mudter and M. Neurath, "11-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance," Inflamm Bowel Dis 13(8): 1016-23 (2007)), Uveitis (H. Haruta et al., "Blockade of mterleukin-6 signaling suppresses not only thl7 but also interphotoreceptor retinoid binding protein-specific Thl by promoting regulatory T cells in experimental autoimmune uveoretinitis," Invest Ophthalmol Vis Sci 52(6):3264-71 (2011)), and Vitiligo (D. Bassiouny and O. Shaker, "Role of interleukin-17 in the
pathogenesis of vitiligo," Clin Exp Dermatol 36(3):292-7 115. (2011)). Thus, the invention includes compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof; pharmaceutical compositions comprising one or more of those compounds; and methods of using those compounds or compositions for treating these diseases.
43 [000120] Acute and chronic (non-autoimmune) inflammatory diseases characterized by increased expression of pro-inflammatory cytokines, including IL-6, MCP-1, and IL-17, would also be amenable to therapeutic BET inhibition. These include, but are not limited to, sinusitis (D. Bradley and S. Kountakis, "Role of mterleukins and transforming growth factor- beta in chronic rhinosinusitis and nasal polyposis, " Laryngoscope 115(4):684-6 (2005)), pneumonitis (Besnard, A.G., et al., "Inflammasome-IL-l -Thl 7 response in allergic lung inflammation" J Mol Cell Biol 4(1):3-10 (2012)), osteomyelitis (T. Yoshii et al., "Local levels of interleukin-lbeta, -4, -6 and tumor necrosis factor alpha in an experimental model of murine osteomyelitis due to staphylococcus aureus," Cytokine 19(2):59-65 2002), gastritis (T. Bayraktaroglu et al., "Serum levels of tumor necrosis factor-alpha, interleukin-6 and interleukin-8 are not increased in dyspeptic patients with Helicobacter pylori-associated gastritis," Mediators Inflamm 13(l):25-8 (2004)), enteritis (K. Mitsuyama et al., "STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMPl/Yit mice," Gut 55(9):1263-9. (2006)), gingivitis (R. Johnson et al., "Interleukin-11 and DL-17 and the pathogenesis of periodontal disease ," J Periodontal 75(l):37-43 (2004)), appendicitis (S. Latifi et al., "Persistent elevation of serum interleukin-6 in intraabdominal sepsis identifies those with prolonged length of stay," JPediatr Surg 39(10): 1548-52 (2004)), irritable bowel syndrome (M. Ortiz-Lucas et al., "Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines," Rev Esp Enferm Dig 102(12):711-7 (2010)), tissue graft rejection (L. Kappel et al., "IL-17 contributes to CD4-mediated graft-versus-host disease ," Blood
113(4):945-52 (2009)), chronic obstructive pulmonary disease (COPD) (S. Traves and L. Donnelly, "Thl 7 cells in airway diseases," Curr Mol Med 8(5):416-26 (2008)), septic shock (toxic shock syndrome, SIRS, bacterial sepsis, etc) (E. Nicodeme et al., Nature
468(7327):1119-23 (2010)), osteoarthritis (L. Chen et al., "IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis, " Osteoarthritis Cartilage 19(6):711-8 (2011)), acute gout (W. Urano et al., "The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis," J Rheumatol 29(9): 1950-3 (2002)), acute lung injury (S. Traves and L. Donnelly, "Thl 7 cells in airway diseases," Curr Mol Med 8(5):416-26 (2008)), acute renal failure (E. Simmons et al., "Plasma cytokine levels predict mortality in patients with acute renal failure," Kidney Int 65(4): 1357-65 (2004)), burns (P. Paquet and G. Pierard, "Interleukin-6 and the skin," Int Arch Allergy Immunol 109(4):308-17 (1996)), Herxheimer reaction (G. Kaplanski et al., "Jarisch-Herxheimer reaction complicating the treatment of chronic Q fever
endocarditis: elevated TNFalpha and IL-6 serum levels," J Infect 37(l):83-4 (1998)), and
44 SIRS associated with viral infections (A. Belkinaand G. Denis, Nat Rev Cancer 12(7):465-77 (2012)). Thus, the invention includes compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof; pharmaceutical
compositions comprising one or more of those compounds; and methods of using those compounds or compositions for treating these diseases.
[000121] In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used for treating rheumatoid arthritis (RA) and multiple sclerosis (MS). Strong proprietary data exist for the utility of BET inhibitors in preclinical models of RA and MS. R. Jahagirdar et al., "An Orally Bioavailable Small Molecule RVX-297 Significantly Decreases Disease in a Mouse Model of Multiple Sclerosis," World Congress of Inflammation, Paris, France (2011). Both RA and MS are characterized by a dysregulation of the IL-6 and IL-17 inflammatory pathways (A. imura and T. Kishimoto, "IL-6: regulator of Treg/Thl7 balance, " Eur J Immunol 40(7): 1830-5 (2010)) and thus would be especially sensitive to BET inhibition. In another embodiment, BET inhibitor compounds of Formula I or Formula la may be used for treating sepsis and associated afflictions. BET inhibition has been shown to inhibit development of sepsis, in part, by inhibiting IL-6 expression, in preclinical models in both published (E. Nicodeme et al., Nature 468(7327):1119-23 (2010)) and proprietary data.
[000122] In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancer. Cancers that have an overexpression, translocation, amplification, or rearrangement c-myc or other myc family oncoproteins (M YCN, L-myc) are particularly sensitive to BET inhibition. J. Delmore et al., Cell 146(6):904-17 (2010); J. Mertz et al., Proc Natl AcadSci USA 108(40): 16669-74 (2011). These cancers include, but are not limited to, B-acute lymphocytic leukemia, Burkitt's lymphoma, Diffuse large cell lymphoma, Multiple myeloma, Primary plasma cell leukemia, Atypical carcinoid lung cancer, Bladder cancer, Breast cancer, Cervix cancer, Colon cancer, Gastric cancer, Glioblastoma, Hepatocellular carcinoma, Large cell neuroendocrine carcinoma, Medulloblastoma, Melanoma, nodular, Melanoma, superficial spreading, Neuroblastoma, esophageal squamous cell carcinoma, Osteosarcoma, Ovarian cancer, Prostate cancer, Renal clear cell carcinoma, Retinoblastoma, Rhabdomyosarcoma, and Small cell lung carcinoma. M. Vita and M. Henriksson, Semin Cancer Biol 16(4):318- 30 (2006).
45 [000123] In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers that result from an aberrant regulation (overexpression, translocation, etc) of BET proteins. These include, but are not limited to, NUT midline carcinoma (Brd3 or Brd4 translocation to nutlin 1 gene) (C. French Cancer Genet Cytogenet 203(l):16-20 (2010)), B-cell lymphoma (Brd2 overexpression) (R. Greenwald et al., Blood 103(4): 1475-84 (2004)), non-small cell lung cancer (BrdT overexpression) (C Grunwald et al., "Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer," Int J Cancer 118(10):2522-8 (2006)), esophageal cancer and head and neck squamous cell carcinoma (BrdT
overexpression) (M. Scanian et a)., "Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9," Cancer Lett 150(2):55-64 (2000)), and colon cancer (Brd4) (R. Rodriguez et al., "Aberrant epigenetic regulation of bromodomain BRIM in human colon cancer," J Mol Med (Berl) 90(5):587-95 (2012)).
[000124] In one embodiment, because BET inhibitors decrease Brd-dependent recruitment of pTEFb to genes involved in cell proliferation, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers that rely on pTEFb (Cdk9/cyclin T) and BET proteins to regulate oncogenes. These cancers include, but are not limited to, chronic lymphocytic leukemia and multiple myeloma (W. Tong et al., "Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma,'' J Clin Oncol 28(18):3015-22 (2010)), follicular lymphoma, diffuse large B cell lymphoma with germinal center phenotype, Burkitt's lymphoma, Hodgkin's lymphoma, follicular lymphomas and activated, anaplastic large cell lymphoma (C. Bellan et al., "CDK9/CYCLIN Tl expression during normal lymphoid differentiation and malignant transformation," J Pathol 203(4):946-52 (2004)), neuroblastoma and primary
neuroectodermal tumor (G. De Falco et al., "Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and FNET tumors," Cancer Biol Ther 4(3):277-81 (2005)), rhabdomyosarcoma (C. Simone and A. Giordano, "Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells," Cell Death Differ 14(l):192-5 (2007)), prostate cancer (D. Lee et al., "Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the
46 efficiency of transcriptional elongation," J Biol Chem 276(13):9978-84 (2001)), and breast cancer (K. Bartholomeeusen et al., "BET bromodomain inhibition activates transcription via a transient release of P-TEFb from 7SK snR P," J Biol Chem (2012)).
[000125] In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers in which BET-responsive genes, such as CDK6, Bcl2, TYR03, MYB, and hTERT are up- regulated. M. Dawson et al., Nature 478(7370):529-33 (2011); J. Delmore et al., Cell 146(6):904-17 (2010). These cancers include, but are not limited to, pancreatic cancer, breast cancer, colon cancer, glioblastoma, adenoid cystic carcinoma, T-cell prolymphocytic leukemia, malignant glioma, bladder cancer, medulloblastoma, thyroid cancer, melanoma, multiple myeloma, Barret's adenocarcinoma, hepatoma, prostate cancer, pro-myelocytic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, small cell lung cancer, and renal carcinoma. M. Ruden and N. Puri, "Novel anticancer therapeutics targeting telomerase," Cancer Treat Rev (2012); P. Kelly and A. Strasser, "The role of Bel -2 and its pro-survival relatives in tumourigenesis and cancer therapy" Cell Death Differ 18(9):1414-24 (2011); T. Uchida et al., "Antitumor effect of bcl-2 anti sense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice," Mol Urol 5(2):71-8 (2001).
[000126] Published and proprietary data have shown direct effects of BET inhibition on cell proliferation in various cancers. In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cancers for which exist published and, for some, proprietary, in vivo and/or in vitro data showing a direct effect of BET inhibition on cell proliferation. These cancers include NMC (NUT-midline carcinoma), acute myeloid leukemia (AML), acute B lymphoblastic leukemia (B-ALL), Burkitt's Lymphoma, B-cell Lymphoma, , Melanoma, mixed lineage leukemia, multiple myeloma, pro-myelocytic leukemia (PML), and non-Hodgkin's lymphoma. P. Filippakopoulos et al., Nature 468(7327): 1067-73 (2010); M. Dawson et al., Nature 478(7370):529-33 (2011); Zuber, J., et al., "RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia," Nature 478(7370):524-8 (2011); M.
Segura,et al, Cancer Research. 72(8):Supplement 1 (2012). The compounds of the invention have a demonstrated BET inhibition effect on cell proliferation in vitro for the following
47 cancers: Neuroblastoma, Medulloblastoma, lung carcinoma (NSCLC, SCLC), and colon carcinoma.
[000127] In one embodiment, because of potential synergy or additive effects between BET inhibitors and other cancer therapy, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be combined with other therapies, chemotherapeutic agents, or anti-proliferative agents to treat human cancer and other proliferative disorders. The list of therapeutic agents which can be combined with BET inhibitors in cancer treatment includes, but is not limited to, ABT-737, Azacititdine (Vidaza), AZD1 152 (Barasertib), AZD2281 (Olaparib), AZD6244 (Selumetinib), BEZ235, Bleomycin Sulfate, Bortezoraib (Velcade), Busulfan (Myleran), Camptothecin, Cisplatin,
Cyclophosphamide (Clafen), CYT387, Cytarabine (Ara-C), Dacarbazine, DAPT (GSI-IX), Decitabine, Dexamethasone, Doxorubicin (Adriamycin), Etoposide, Everolimus (RAD001), Flavopiridol (Alvocidib), Ganetespib (STA-9090), Gefitinib (Iressa), Idarubicin, Ifosfamide (Mitoxana), IFNa2a (Roferon A), Melphalan (Alkeran), Methazolastone (temozolomide), Metformin, Mitoxantrone (Novantrone), Paclitaxel, Phenformin, PKC412 (Midostaurin), PLX4032 (Vemurafenib), Pomalidomide (CC-4047), Prelnisone (Deltasone), Rapamycin, Revlimid (Lenalidomide), Ruxolitinib (INCB018424), Sorafenib (Nexavar), SU11248 (Sunitinib), SU11274, Vinblastine, Vincristine (Oncovin), Vinorelbine (Navelbine), Vorinostat (SAHA), and WP1130 (Degrasyn).
[000128] In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat benign proliferative and fibrotic disorders, including benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, juvenile polyposis syndrome, idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma, and cardiac fibrosis. X. Tanget al., Am J Pathology in press (2013).
[000129] In one embodiment, because of their ability to up-regu!ate ApoA-1 transcription and protein expression (O. Mirguet et al., Bioorg Med Chem Lett 22(8):2963-7 (2012); C. Chung et al., J Med Chem 54(11):3827-38 (2011)), BET inhibitor compounds of
48 Formula I or Formula Ia,stereoisomers, tautoraers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat cardiovascular diseases that are generally associated with including dyslipidemia, atherosclerosis, hypercholesterolemia, and metabolic syndrome (A. Belkina and G. Denis, Nat Rev Cancer 12(7):465-77 (2012); G. Denis Discov Med 10(55):489-99 (2010)). In another embodiment, BET inhibitor compounds of Formula I or Formula la may be used to treat non-cardiovascular disease characterized by deficits in ApoA-1 , including Alzheimer's disease. D. Elliott et al., Clin Lipidol 51(4):555-573 (2010).
[000130] In one embodiment, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used in patients with insulin resistance and type Π diabetes. A. Belkina and G. Denis, Nat Rev Cancer 12(7):465- 77 (2012); G. Denis Discov Med 10(55):489-99 (2010); F. Wang et al., Biochem J
425(l):71-83 (2010); G. Denis et al, FEBSLett 584(15):3260-8 (2010). The antiinflammatory effects of BET inhibition would have additional value in decreasing inflammation associated with diabetes and metabolic disease. . Alexandraki et al.,
"Inflammatory process in type 2 diabetes: The role of cytokines," Ann N YAcadSci 1084:89- 117 (2006).
[000131] In one embodiment, because of their ability to down-regulate viral promoters, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used as therapeutics for cancers that are associated with viruses including Epstein-Barr Virus (EBV), hepatitis virus (HBV, HCV), Kaposi's sarcoma associated virus (KSHV), human papilloma virus (HPV), Merkel cell polyoma virus, and human cytomegalovirus (CMV). D. Gagnon et al., J Virol 83(9):4127-39 (2009); J. You et al., J Virol 80(18):8909-19 (2006); R. Palermo et al., WRNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus," PLoSPathog 7(10):el 002334 (2011); E. Poreba et al., "Epigenetic mechanisms in virus-induced tumorigenesis," Clin Epigenetics 2(2):233-47. 2011. In another embodiment, because of their ability to reactivate HIV-1 in models of latent T cell infection and latent monocyte infection, BET inhibitors could be used in combination with anti -retroviral therapeutics for treating HIV. J. Zhu, et al., Cell Rep (2012); C. Banerjee et al., J Leukoc Biol (2012); K. Bartholomeeusen et al., J Biol Chem (2012); Z. Li et al., Nucleic Acids Res (2012.)
49 [000132] In one embodiment, because of the role of epigenetic processes and bromodomain-containing proteins in neurological disorders, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used to treat diseases including, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington disease, bipolar disorder, schizophrenia, Rubinstein-Taybi syndrome, and epilepsy. R. Prinjha et al., Trends Pharmacol Scl 33(3): 146-53 (2012); S. Muller et al., "Bromodomains as therapeutic targets,'' Expert Rev Mol Med 13:e29 (2011).
[000133] In one embodiment, because of the effect of BRDT depletion or inhibition on spermatid development, BET inhibitor compounds of Formula I or Formula la, stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates thereof, or compositions comprising one or more of those compounds may be used as reversible, male contraceptive agents. M. Maizuk et al., "Small-Molecule Inhibition of BRDT for Male Contraception," Cell 150(4): p. 673-684 (2012); B. Berkovits et al., "The testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3'-UTR truncation in round spermatids," Nucleic Acids Res 40(15):7162-75 (2012).
Pharmaceutical Compositions
[000134] Pharmaceutical compositions of the present disclosure comprise at least one compound of Formula I or Formula la, or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof formulated together with one or more pharmaceutically acceptable carriers. These formulations include those suitable for oral, rectal, topical, buccal and parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) administration. The most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.
[000135] Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of a compound of the present disclosure as powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As indicated, such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association at least one compound of the present disclosure as the active compound and a carrier or excipient (which may constitute one or more accessory ingredients). The carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient. The carrier may be a solid or a liquid, or both, and may be formulated with at least one compound described herein as the active compound in a unit-dose formulation, for example, a tablet, which may contain from about 0.05% to about 95% by weight of the at least one active compound. Other pharmacologically active substances may also be present including other compounds. The formulations of the present disclosure may be prepared by any of the well- known techniques of pharmacy consisting essentially of admixing the components.
[000136] For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmacologically administrable compositions can, for example, be prepared by, for example, dissolving or dispersing, at least one active compound of the present disclosure as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. In general, suitable formulations may be prepared by uniformly and intimately admixing the at least one active compound of the present disclosure with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product For example, a tablet may be prepared by compressing or molding a powder or granules of at least one compound of the present disclosure, which may be optionally combined with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, at least one compound of the present disclosure in a f ee-flowing form, such as a powder or granules, which may be optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, where the powdered form of at least one compound of the present disclosure is moistened with an inert liquid diluent.
[000137] Formulations suitable for buccal (sub-lingual) administration include lozenges comprising at least one compound of the present disclosure in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the at least one compound in an inert base such as gelatin and glycerin or sucrose and acacia.
[000138] Formulations of the present disclosure suitable for parenteral administration comprise sterile aqueous preparations of at least one compound of Formula I or Formula la or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof, which are approximately isotonic with the blood of the intended recipient. These preparations are administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing at least one compound described herein with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the present disclosure may contain from about 0.1 to about 5% w/w of the active compound.
[000139] Formulations suitable for rectal administration are presented as unit-dose suppositories. These may be prepared by admixing at least one compound as described herein with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
(000140) Formulations suitable for topical application to the skin may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers and excipients which may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof. The active compound (i.e., at least one compound of Formula 1 or Formula la or tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof) is generally present at a concentration of from about 0.1% to about 15% w/w of the composition, for example, from about 0.5 to about 2%.
[000141] The amount of active compound administered may be dependent on the subject being treated, the subject's weight, the manner of administration and the judgment of the prescribing physician. For example, a dosing schedule may involve the daily or semi- daily administration of the encapsulated compound at a perceived dosage of about 1 g to about 1000 mg. In another embodiment, intermittent administration, such as on a monthly or yearly basis, of a dose of the encapsulated compound may be employed. Encapsulation facilitates access to the site of action and allows the administration of the active ingredients simultaneously, in theory producing a synergistic effect In accordance with standard dosing regimens, physicians will readily determine optimum dosages and will be able to readily modify adiriinistration to achieve such dosages.
[000142] A therapeutically effective amount of a compound or composition disclosed herein can be measured by the therapeutic effectiveness of the compound. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used. In one embodiment, the
therapeutically effective amount of a disclosed compound is sufficient to establish a maximal
52 plasma concentration. Preliminary doses as, for example, determined according to animal tests, and the scaling of dosages for human administration is performed according to art-accepted practices.
[000143] Toxicity and therapeutic efficacy can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compositions that exhibit large therapeutic indices are preferable.
[000144] Data obtained from the cell culture assays or animal studies can be used in formulating a range of dosage for use in humans. Therapeutically effective dosages achieved in one animal model may be converted for use in another animal, including humans, using conversion factors known in the art (see, e.g., Freireich et al., Cancer Chemother. Reports 50(4):219-244 (1966) and Table 1 for Equivalent Surface Area Dosage Factors).
Table 1. Equivalent Surface Area Dosage Factors:
Figure imgf000054_0001
[000145] The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. Generally, a therapeutically effective amount may vary with the subject's age, condition, and gender, as well as the severity of the medical condition in the subject The dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
53 [000146] In one embodiment, a compound of Formula I or Formula la or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, is administered in combination with another therapeutic agent. The other therapeutic agent can provide additive or synergistic value relative to the adniinistration of a compound of the present disclosure alone. The therapeutic agent can be, for example, a statin; a PPAR agonist, e.g., a
thiazolidinedione or fibrate; a niacin, a RVX, FXR or LXR agonist; a bile-acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a cholesteryl ester transfer protein (CETP), an ion-exchange resin; an antioxidant; an inhibitor of AcylCoA cholesterol acyltransferase (ACAT inhibitor); a tyrophostine; a sulfonylurea-based drug; a biguanide; an alpha-glucosidase inhibitor; an apolipoprotein E regulator; a HMG-CoA reductase inhibitor, a microsomal triglyceride transfer protein; an LDL-lowing drug; an HDL- raising drug; an HDL enhancer, a regulator of the apolipoprotein A-IV and/or apolipoprotein genes; or any cardiovascular drug.
[000147] In another embodiment, a compound of Formula I or Formula la or a tautomer, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, is administered in combination with one or more anti-inflammatory agents. Anti-inflammatory agents can include immunosuppressants, TNF inhibitors, corticosteroids, non-steroidal anti- ird ammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDS), and the like. Exemplary anti-inflammatory agents include, for example, prednisone;
methylprenisolone (Medrol®), triamcinolone, methotrexate (Rheumatrex®, Trexall®), hydroxychloroquine (Plaquenil®), sulfasalzine (Azulfidine®), leflunomide (Arava®), etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), rituximab
(Rituxan®), abatacept (Orencia®), interleuki— 1, anakinra (Kineret™), ibuprofen, ketoprofen, fenoprofen, naproxen, aspirin, acetaminophen, indomethacin, sulindac, meloxicam, piroxicam, tenoxicam, lornoxicam, ketorolac, etodolac, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, diclofenac, oxaprozin, apazone, nimesulide, nabumetone, tenidap, etanercept, tolmetin, phenylbutazone, oxyphenbutazone, diflunisal, salsalate, olsalazine, or sulfasalazine.
54 EXAMPLES
Example 1: 5,7-Dimetho3^-2-(4-methoxy-2-((l-methy^^
quinazolin-4(3H)-one
Figure imgf000056_0001
[000148] To a solution of 2-fluoro-4-methoxybenzaldehyde (5.0 g, 25.3 mmol) and 2- amino-4,6-dimethoxybenzamide (3.9 g, 25.3 mmol) in N,N-diraethylacetamide (100 mL) was added NaHS03 (58.5 % SO2 content, 6,8 g, 38.1 mmol) followed by /7-toluenesulfonic acid monohydrate (0.97 g, 5.1 mmol). The resulting mixture was heated at 120 °C for 18 h. After that time the reaction was cooled to rt and poured onto ice. The precipitated solids were collected by filtration, washed with water and dried under vacuum to give 2-(2-fluoro-4- meraoxyphenyl)-5,7-<lime&oxyqm (4.8 g, 57%) as an off-white solid: Ή
NMR (400 MHz, DMSO-<¾) δ 11.89 (br s, lH), 7.71 (t, J= 8.6 Hz, 1H), 6.99 (dd, J = 12.9, 2.3 Hz, 1H), 6.92 (dd, J= 8.8, 2.5 Hz, 1H), 6.72 (d, J= 2.3 Hz, 1H), 6.55 (d, J = 2.3 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 6H); ESI MS m/z 331 (M + H]+.
[000149] To a suspension of 2-{2-fluoro-4-methoxyphenyl)-5,7-<iimeth^
4(3J?)-one (1.0 g, 3 mmol) and 1 -methylpiperidin-4-amine (0.38 g, 3.3 mmol) in THF (25mL) was added lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol). The reaction mixture was heated at reflux with stirring for 18 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with cold water (25 mL) and concentrated under reduced pressure. The precipitated solids were collected by filtration and dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol to 90:10
dichloromethane methanol) to give 5 ,7-dimethoxy-2-( -methoxy-2-(( 1 -methylpiperidin-4- yl)anu^o)phenyl)qumazolin-4(3H)-one (0.052 g, 4%) as an off-white solid: mp 252-253 °C, Ή NMR (400 MHz, DMSO-ife) δ 11.51 (br s, 1H), 9.50 (d, J= 7.4 Hz, 1H), 7.83 (d, J = 8.6 Hz, 1H), 6.58 (d,J= 1.95 Hz, 1H), 6.51 (d, J= 2.3 Hz, 1H), 6,16-6.26 (m, 2H), 3.89 (s, 3H),
55 3.85 (s, 3H), 3.79 (s, 3H), 3.4g-3.61 (m, lH), 2.55-2.66 (m, 2H), 2.24-2.37 (m, 2H), 2.20 (s, 3H), 1.93-2.02 (m, 2H), 1.52-1.66 (m, 2H); ESI MS mlz 425 [M + H]+.
Example 2: 5,7-Dimethoxy-2^4-methoxy^^
quinazolin-4(3//)-one
Figure imgf000057_0001
[000150] P0C13 (1.02 g, 6.66 mmol) was addded to a solution of 2-formyl-5- methoxybenzoic acid (1.0 g, 5.55 mmol) in anhydrous pyridine (20 mL) at 0 °C and stired for 30 rain. After that time 1 -methyl piperazine (0.556 g, 5.55 mmol) was added. The reaction was allowed to warm to rt and stir for 16 h. After that time the reaction was concentrated under reduced pressure, diluted with water and made basic with aqueous a2C03. The mixture was extracted with ethyl acetate (3 * 200 mL). The combined organic layers were washed with saturated NaHC03 solution, water, brine, dried over Na2SC>4 and concentrated to give 4-methoxy-2-(4-methylpiperazine- 1 -carbonyl) benzaldehyde as yellow solid (1.0 g,
68%): 1H NMR (400 MHz, CDC13) δ 9.86 (s, 1H), 7.82 (d, J - 8.6 Hz, 1 H), 6.95 (dd, J= 8.6, 1.95 Hz, 1H), 6.76 (d, J= 2.3 Hz, 1H), 3.66-3.87 (m, 5H), 3.11-3.18 (m, 2H), 2.46 (br s, 2H), 2.16-2.28 (m, 5H).
[000151] To a solution of 4-methoxy-2-(4-methylpiperazine- 1 - carbonyl)benzaldehyde (1.0 g, 3.81 mmol) and 2-ammo-4,6-dimethoxybenzamide (0.748 g, 3.81 mmol) in N,i¥<iimethyl acetamide (40 mL), were added NaHS03 (1.03 g, 5.72 mmol) and j toluenesulfonic acid monohydrate (0.871 g, 4.58 mmol). The reaction was heated at 120 °C for 16 h. After that time the mixture was cooled to rt, concentrated under reduced pressure, diluted with water (100 mL) and made basic with NajCOa. The water was removed by lyophilization and the residue was extracted with 3% methanol in dichloromethane (2 * 250 mL). The solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography (silica gel, 97:3 dichloromethane methanol) to give 5,7- dimemoxy-2-(4-memoxy-2^4-methylpiperazine-l -carbonyl)phenyl)qmnazolm-4(3H)- >ne as
56 light yellow solid (0.140 g, 8%): mp 215 °C dec.; !H NMR (400 MHz, CDC13) δ 9.84 (br s, IH), 7.91 (d, J= 8.6 Hz, 1H), 7.04 (d<LJ= 8.8, 2.5 Hz, 1H), 6.86 (d,J= 2.3 Hz, 1H), 6.72 (d, J= 2.3 Hz, IH), 6.45 (d, J= 1.95 Hz, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 3.88 (s, 3H), 3.80 (br s, 2H), 3.23 (br s, 2H), 2.43 (br s, 2H), 2.19 (s, 3H), 1.67 (br s, 2H); ESI MS m/z 439 [M + H]+.
Example 3: 2^2^(l-isopropylpiperidm^yl)amino)-4-methoxyphenyI)-5,7- dimethoxyquinazolin-4(3H)-one
Figure imgf000058_0001
[000152] To a suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7- dimethoxyquinazolin-4(3H)-one (0.660 g, 2 mmol) in anhydrous THF (20 mL) was added 1- isopropylpiperidin-4-amine (1.25 mL, 8 mmol) and lithium bis(trimethylsilyl)amide (1 M in THF, 10 mL, 10 mmol). The reaction was heated at reflux with stirring for 48 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was added and reflux with stirring was continued for an additional 6 h. After that time the reaction was cooled to rt, diluted with cold water (3 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 97:3
dichloromethane methanol then 97:3 dichloromethane/7 N ammonia in methanol) to give 2- (2-(( 1 -isopropylpiperidin-4-yl)amino)-4-me1lioxyphenyl)-5 ,7-dimeA
one (0.267 g, 30%) as an off-white solid: mp 248-250 °C; Ή NMR (400 MHz, DMSO-t¾) δ 11.49 (br s, IH), 9.49 (d, J= 7.4 Hz, 1H), 7.83 (d, J= 8.6 Hz, 1H), 6.53-6.64 (m, IH), 6.50 (s, IH), 6.10-6.29 (m, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.51 (br s, IH), 2.63-2.76 (m, 3H), 2.42 (t, J = 9.2 Hz, 2H), 1.97 (br s, 2H), 1.47-1.63 (m, 2H), 0.97 (d, J= 6.25 Hz, 6H); ESI MS m/z 453 [M + H]+.
57 Example 4: 5,7-Dimethoxy-2-(4-methoxy-2-((l-methylpyrrolidin-3- yl)ammo)phenyl)quinazoljn-4(3H)-one
Figure imgf000059_0001
[000153] To a suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7- dimethoxyquinazolin- (3H)-one (0.660 g, 2 mmol) in anhydrous THF (25 mL) was added 1- methylpyrrolidine-3-amine dihydrochloride (1.03 g, 6 mmol) and lithium
bis(trimethylsilyl)amide (1 M solution in THF, 18 mL, 18 mmol). The reaction was heated at reflux with stirring for 24 h. After that time the reaction was cooled to rt, diluted with cold water (5 mL) and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (30 mL), diluted with water (30 mL) and stirred for lh. The precipitated solid was collected by filtration, washed with water then hexanes and air dried. The product was triturated (1:1, ethyl acetate hexanes) to give 5 ,7-dimethoxy-2-{ -methoxy-2-( 1 - memylpynOlidm -yl)phenyl)cm^ (0.160 g, 20%) as an off-white solid: mp
214-215 °C; 1H NMR (400 MHz, DMSO-<fc) δ 9.85 (br s, lH), 7.88 (d, J= 9.0 Hz, 1H), 6.53 (d, J= 1.95 Hz, 1H), 6.49 (s, 1H), 6.20 (dd, J= 8.8, 2.15 Hz, lH), 6.11 (s, 1H), 4.05 (br s, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 2.69-2.82 (m, 2H), 2.55 (m, IH), 2.33-2.41 (m, 2H), 2.32 (s, 3H), 1.59-1.68 (m, 1 H); ESI MS m/z 411 [M + H]+.
58 Example 5: 5,7-Dimethoxy-2-<4-«methoxy-2-<methyl(l-methylpiperidin-4- yl)amino)phenyl) quinazolin-4(3H)-one
Figure imgf000060_0001
[000154] To a suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7- dimethoxyquinazolin-4(3/ )-one (0.660 g, 2 mmol) in anhydrous THF (20 mL) was added N, 1 -dimethylpiperidin-4-amine (0.50 g, 8 mmol) and lithium bis(trimemylsilyl)amide (1 M in THF, 6 mL, 6 mmol). The reaction was heated at reflux with stirring for 3 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was added and reflux with stirring was continued for an additional 16 h. After that time the reaction was cooled to rt, diluted with cold water (5 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 97:3
dicUoromethane methanol then 97:3 dichloromethane/ 7N ammonia in methanol) to give 5,7- dimemoxy-2-(4-memoxy-2^memyl(l-methylpiperidin-4-yl)^
one (0.362 g, 41%) as an off-white solid: mp 217-218 °C; 1H NMR (400 MHz, DMSO-tk) δ 13.45 (s, 1H), 8.27 (d, J= 9.0 Hz, lH), 6.97 (d, J= 2.3 Hz, 1H), 6.91 (dd, J= 9.0, 2.3 Hz, 1H), 6.72 (d, J= 1.95 Hz, 1H), 6.50 (d, J= 2.3 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 2.77-2.84 (m, 1H), 2.65-2.76 (m, 5H), 2.06 (s, 3H), 1.59-1.76 (m, 4H), 1.45-1.59 (m, 2H); ESI MS m/z 439 [M + H]+.
59 Example 6: 5,7-Diniethoxy-2-(4-methoxy-2-(((l-methylpiperidin-4- y])methyl)amino)phenyl) quinazolin-4(3/ )-one
Figure imgf000061_0001
[000155] Lithium bis(trimethy Isily l)amide (1 M in THF, 11.2 mL, 11.2 mmol) was slowly added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7- dimethoxyquinazolin-4(3H)-one (0.616 g, 1.86 mmol) and ( 1 -methylpiperidin-4- yl)methanamine (0.956 g, 7.46 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 24 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH CI (IS mL) and concentrated under reduced pressure. The residue was suspended in water (25 mL), men saturated aqueous NaHC03 solution was added to adjust pH to about 8.5. The resulting suspension was stirred at rt for 30 min and the precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/7N ammonia in methanol to 97:3 dichloromethane/7N ammonia in methanol) to give 5,7-dimethoxy-2-(4-methoxy-2-(((l-methylpiperidin-4- yl)memyl)arnino)phenyl)qumazolm-4(3H)-one (0.180 g, 22%) as a light yellow solid: mp 264-265 °C; 1H N R (400 MHz, DMSO-< ) 6 11.47 (br s, 1H), 9.63 (br s, 1H), 7.88 (d, J= 9,0 Hz, 1H), 6.60 (d, J= 1.95 Hz, 1H), 6.48 (d, J= 1.95 Hz, 1H), 6.13-6.24 (m, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.08-3.14 (m, 2H), 2.80-2.87 (m, 2H), 2.15 (s, 3H), 1.85- 1.95 (m, 2H), 1.74-1.81 (m, 2H), 1.65-1.73 (m, 1H), 1.43-1.54 (m, 2H); ESI MS m/z 439 [M + H]+. Example 7: 5,7-Dimethoxy-2-(4-inethoxy-2-(((l-iiiethylpyrrolidin-3- yI)methyl)amino)phenyl)-quinazolin-4<3A)-one
Figure imgf000062_0001
[000156] A 1 M solution of lithium hexamethyldisilazide in THF (10 mL, 10 mmol) was added in a single portion to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7- diraethoxyquinazolin-4(3H)-one (0.826 g, 2.5 mmol) and l-methyl-3- aminomethylpyrrolidine (0.571 g, 5 mmol) in anhydrous THF (20 mL). The reaction mixture was stirred and heated to reflux for 19 h. After cooling to rt, the reaction mixture was quenched with a saturated aqueous solution of NH4CI (15 mL) and concentrated under reduced pressure to a volume of 20 mL. A solution of saturated aqueous NaHCQj (350 mL) was added and the mixture was extracted with chloroform (4 χ 30 mL). The combined extracts were dried over MgS04, filtered and concentrated under reduced pressure to give a yellow solid. The product was purified by flash column chromatography (silica gel, 95:5 chloroform/methanol) followed by recrystallized from chloroform hexanes to give 5,7- dimethoxy-2-(4-methoxy-2-(((l-methylpyrrolidin-3-yl)m th
4(3H one (0.367 g, 35%) as a yellow solid: mp 233-235°C; 1H NMR (400 MHz, CDCI3) δ 9.65 (br s, 1H), 9.23 (br s, 1H), 7.56 (d, J= 9.2 Hz, 1H), 6.60 (d, J= 2.4 Hz, 1H), 6.41 (d, J= 2.4 Hz, 1H), 6.30 (dd, J= 9.2, 2.4 Hz, 1H), 6.21 (d, J= 2.4 Hz, 1H), 3.98 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H), 3.23-3,20 (m, 2H), 2.83-2.78 (m, 1H), 2.71-2.55 (m, 3H), 2.48-2.45 (m, 1H), 2.37 (s, 3H), 2.21-2.12 (m, 1H), 1.73-1.65 (m, 1H); ESI MS m/z 425 [M + H]+. Example 8: 2-(2-{(2-( opropylanaino)ethyl)amino)-4-methoxyphenyI)-5,7- dimethoxyquinazolin-4(3H)-one
Figure imgf000063_0001
[000157] To a suspension of 2-(2-fluoro-4-methoxyphenyl)-5 ,7 umemoxyquinazolin- {3H)-one (0.660 g, 2 mmol) in anhydrous THF (20 mL) was added N' -isopropylethane- 1 ,2- diamine(l mL, 8 mmol) and lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol). The reaction was heated at reflux with stirring for 16 h. After mat time a second portion of lithium bis(trimethylsily])amide (1 M in THF, 6 mL, 6 mmol) was added and reflux with stirring was continued for an additional 16 h. After that time the reaction was cooled to rt, diluted with sat. NH4CI solution (6 mL) and concentrated under reduced pressure. The residue was treated with water (50 mL) and the resulting precipitate was collected by filtration, washed with water, dried and triturated with ethyl acetate to give 2-(2-((2- (isopropylamino)emyl)am o)^m
g, 47%) as a yellow solid: mp 262-264 °C; 1H NMR (400 MHz, DMSO-dfc) δ 9.35 (t, J= 5.3 Hz, 1H), 7.83 (d, J= 9.0 Hz, 1H), 6.89 (s, lH), 6.44-6.55 (m, 1H), 6.20-6.37 (m, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.82 (s, 3H), 3.60 (br s, 2H), 3.23 (br s, 1H), 3.03-3.15 (m, 2H), 1.20 (d, J= 6.25 Hz, 6H); ESI MS m/z 413 [M + Hf.
62 Example 9: S^^Lmethox ^^Methox - ^tetrahydi^^-p ran^y^amino)- phenyl)qiiinazolin-4(3H)-one
Figure imgf000064_0001
[000158] To a suspension of 2-(2-fluoro-4-me hoxyphenyl)-5,7-dimethoxyquinazolin- 4(3H)-one (0.66 g, 2 mmol) and tetrahydro-2H-pyran-4-amine (0.3 g, 3 raraol) in THF (50 mL) was added lithium bis(trimethylsilyl)aniide (1 M in THF, 9 mL, 9 mmol). The reaction was heated at reflux with stirring for 18 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 9 mL, 9 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with cold water (25 mL) and concentrated under reduced pressure. The precipitated solids were collected by filtration and dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol to 90:10 dichloromethane methanol) to give 5,7- dimethoxy-2-(4-methoxy-2-((tetrahydro-2H-pyran-4-yl)am
(0.12 g, 14%) as solid: mp 286-287 °C; 1H MR (400 MHz, CDC13) δ 9.48 (br s, 1H), 9.36 (d, J= 7.0 Hz, lH), 7.56 (dd, J= 9.0, 2.7 Hz, 1H), 6,58 (d, J= 1.95 Hz, 1H), 6.42 (d, J= 2.3 Hz, lH), 6.31 (dd, J= 8.8, 2.5 Hz, 1H), 6.25 (d, J= 2.3 Hz, 1H), 4.05 (dt, J= 11.9, 4.0 Hz, 2H), 3.99 (s, 3H), 3.93 (s, 3H), 3.86 (s, 3H), 3.58 - 3.71 (m, 3H), 2.18 - 2.07 (m, 2H), 1.75 - 1.64 (m, 2H); ESI MS mlz 412 [M + H]+.
63 Example 10: 2-(2-((l-Isopropylp-p«ridm-4-yl)amino)phenyI^^
4(3H one
Figure imgf000065_0001
[000159] To a solution of 2-araino-4,6-dimethoxybenzamide (3.160 g, 16.1 mmol) and 2-fluorobenzaldehyde (2.0 g, 16.1 mmol) in N,N-dimethylacetamide (20 mL) was added sodium bisulfite (S8.5 % S(¾ content, 4.29 g, 24.2 mmol) followed by jc toluenosulfonic acid monohydrate (0.613 g, 3.2 mmol). The resulting mixture was heated at 120 °C for 17 h. After mat time the reaction was cooled to rt and concentrated under reduced pressure. The residue was diluted with water (100 mL) and saturated aqueous NaHCQj was added to adjust the pH to 8. The resulting suspension was stirred for 30 min at rt and the precipitated dark orange solid was collected by filtration, washed with water and air-dried. The product was triturated with ethyl acetate to give 2-(2-fluorophenyl)-5 Hiimethoxyquina^lin-4(3H)-one (2.40 g, 50%) as an off-white solid: 1H NMR (400 MHz, OMSO-ek) δ 12.09 (br s, 1H), 7.70-7.78 (m, IH), 7.54-7.65 (m, lH), 7.30-7.41 (m, 2H), 6.74 (d, = 2.3 Hz, 1H), 6.58 (d, J= 2.3 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H); ESI MS m/z 301 [M + H .
[000160] Lithium bis(triinethylsilyl)amide (1 M in THF, 12 mL, 12 mmol) was slowly added to a stirred suspension of 2-(2-fluorophenyl)-5,7-dimemoxyquinazohn
(0.600 g, 2 mmol) and 1 -isopropylpiperidin-4-amine (1.14 g, 8 mmol) in anhydrous THF (20 mL). The reaction was heated to reflux with stirring for 40 h. After that time the reaction mixture was cooled to rt, diluted with saturated aqueous. NH4CI (5 mL), and concentrated under reduced pressure. The residue was diluted with water (20 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichlorome thane/7N ammonia in methanol to 97:3 dichloromethane 7N ammonia in methanol) to give 2-(2-((l-isopropylpiperidm-4-yl)amino)phenyl)-5,7-
64 dimethoxyquinazolin-^SHJ-one (0.230 g, 27%) as a yellow solid: mp 267-269 °C; lH NMR (400 MHz, CDC13) δ 9.53 (br s, lH), 8.98 (d, J= 7.4 Hz, 1H), 7.57 (d, J= 8 Hz, 1H), 7.3 (m, 1H), 6.80 (d, J= 8.6 Hz, 1H), 6.70 (m, 1H), 6.64 (d, J= 2.3 Hz, 1H), 6.44 (d, J= 2.3 Hz, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.45-3.55 (m, 1H), 2.85-2.95 (m, 2H), 2.69-2.84 (m, 1H), 2.31-2.46 (m, 2H), 2.12-2.18 (m, 2H), 1.65-1.75 (m, 2H), 1.09 (d, J= 6.2 Hz, 6H); ESI MS m/z 423 [M + H]+.
Example 11: 5,7-Dimethoxy-2-(4-methoiy-2-((2-(pyrrolidin-l- yl)ethyl)amino)phenyl)quinazoljii-4(3£-)-one
Figure imgf000066_0001
[000161] Lithium bis(trime ylsttyl)amide (1 M in THF, 6 mL, 6 mraol) was slowly added to a stirred suspension of 2 2-fluoro^methoxyphenyl)-5 J
4(3i¾)-one (0.660 g, 2 mmol) and 2-(pynOlidin- 1 -yl)ethan- 1 -amine (1.01 mL, 8 mmol) in anhydrous THF (20 mL). The reaction was heated at reflux with stirring for 16 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was added and reflux with stirring was continued for an additional 16 h. After that time the reaction was cooled to it, diluted with sat. NH4CI solution (6 mL) and concentrated under reduced pressure. The residue was treated with water (50 mL) and the precipitated solids were collected by filtration and dried. The product was triturated with ethyl acetate to give 5,7 iimemoxy-2 4-memoxy-2^(2^yrroUdm
one (0.640 g, 75%) as a yellow solid: mp 226-228 °C; Ή NMR (400 MHz, CDC13) δ 9.10
(br s, lH), 7.51 (d, J= 8.6 Hz, 1H), 6.67 (d, J= 1.95 Hz, 1H), 6.40 (d, J= 1.95 Hz, 1H), 6.30 (dd, J= 8.8, 2.15 Hz, lH), 6.23 (d, J= 1.95 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.32-3.41 (m, 2H), 2.87 (t, J= 6.25 Hz, 2H), 2.63 (br s, 4H), 1.81 (br s, 4H); ESI MS m/z 425
[M + Hj+.
65 Example 12: 5,7-Dimethoxy-2-(4-methoxy-2- (2-(piperidin-l-yl)ethyl)aiiilno)- phenyl)quinazoliii-4(31 )-one
Figure imgf000067_0001
[000162] To a suspension of 2^2-fluoro-4-methoxyphenyi)-5,7^ra^
4(3H>one (0.50 g, 1.5 mmol) and 2-(piperidin- 1 -yl)ethan-l -amine (0.39 g, 3 mmol) in THF (50mL) was added lithium bis(trimethylsUyl)amide (1 M in THF, 4.5 mL, 4.5 mmol). The reaction mixture was heated at reflux with stirring for 18 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 4.5 mL, 4.5 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with cold water (25 mL) and concentrated under reduced pressure. The precipitated solids were collected by filtration and dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol to 90:10
dichloromethane methanol) to give 5,7-dixnethoxy-2-(4-rnethoxy-2-((2-(piperidin- 1 - yl)ethyl)ammo)phenyl)quinazolin-4(3H)-one (0.16 g, 24%) as an off-white solid: mp 231— 232 °C;Ή NMR (400 MHz, CDC13) δ 9.42 (br s, 1H), 8.87 (t, J= 4.5 Hz, lH), 7.50 (d, J= 9.0 Hz, 1H), 6.71 (d, J= 2.3 Hz, lH), 6.41 (d, J= 2.3 Hz, IH), 6.30 (dd, J= 8.6, 2.3 Hz, 1H), 6.23 (d, J= 2.7 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H), 3.28-3.39 (m, 2H), 2.71 (t, J = 6.4 Hz, 2H), 2.48 (br s, 4H), 1.58 (quin, J= 5.6 Hz, 4H), 1.37-1.48 (m, 2H); ESI MS mlz 439 [M + H]+.
66 Example 13: 5,7-Dimethoxy-2-(4-methoxy-2-((3-morpholijiopropyl)an ino)- phenyl)qiijnazolin- (3fi)-one
Figure imgf000068_0001
[000163] To a suspension of 2-(2-fluoro-4-methoxyphenyl)-5 -dimethoxyquinazolin- 4(3H)-one (0.50 g, 1.5 mmol) and 3-morpholinopropan- 1 -amine (0.39 g, 3 mmol) in THF (50mL) was added lithium bis(trimethylsilyl)amide (1 M in THF, 4.5 mL, 4.5 mmol). The reaction mixture was heated at reflux with stirring for 18 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 4.5 mL, 4.5 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with cold water (25 mL) and concentrated under reduced pressure. The precipitated solids were collected by filtration and dried The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/niethanol to 90:10
dichloromethane/m ethanol) to give 5 ,7-dimethoxy-2-(4-methoxy-2-((3 - morpholmopropyl)amino)phenyl)qu^ (0.16 g, 24%) as an off-white solid; mp 234-235 °C; Ή NMR (400 MHz, CDCfe) 6 8.99 (br s, 1H), 8.93-8.97 (m, 1H), 7.41 (d, J = 9.0 Hz, 1H), 6.61 (d, J= 2.3 Hz, 1H), 6.42 (d, J= 2.3 Hz, 1H), 6.30 (dd, J= 9.0, 2.3 Hz, 1H), 6.25 (d, J= 2.3 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.69-3.74 (m, 4H), 3.28-3.35 (m, 2H), 2.54 (t, J= 7.4 Hz, 2H), 2.44-2.50 (m, 4H), 1.91-1.98 (m, 2H); ESI MS w/z 455 [M + H]+.
67 Example 14: 5,7-Dimethoxy-2^4-methoxy-2^(2-moiT>holino€thy0ainino)phenyl)- quinazolin-4(3H)-one
Figure imgf000069_0001
[000164] Lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was slowly added to a stirred suspension of 2-(2-fluro-4-methoxyphenyl)-5,7-dimemoxyquinazolin- (4(3/- one (0.660 g, 2 mmol) and 2^moφholm^yl)emanan^ine (0.780 g, 6 mmol) in anhydrous THF (25 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1M in THF, 6 mL, 6 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that time the reaction was cooled to it, diluted with saturated aqueous NH4CI (5 mL) and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 mL), diluted with water (20 mL) and stirred for 1 h. The precipitated solid was collected by filtration, washed with water then hexanes and air dried. The product was purified by column chromatography (silica gel, 90:10 ethyl acdetate methanol) to give 5,7-dimethoxy-2-(4- meΛoxy((2-moφholmoethyl)amm^ (0.330 g, 38%) as a yellow solid: mp 239-240 °C; 1H NMR (400 MHz, CDCI3) 69.18 (br s, lH), 8.87 (br s, lH), 7.45 (d, J= 9.0 Hz, 1H), 6.72 (d, J= 2.3 Hz, 1H), 6.42 (d, J= 1.95 Hz, 1H), 6.31 (dd, J= 9.0, 2.3 Hz, 1H), 6.23 (d, J= 2.3 Hz, 1H), 3.99 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H), 3.69-3.76 (m, 4H), 3.30-3.38 (m, 2H), 2.76 (t, J= 62 Hz, 2H), 2.51-2.59 (m, 4H); ESI MS m/z 441 [M + H]+.
68 Example 15: 5,7-Dimethoxy-2-(4-methoxy-2-((3-(pyrrolidin-l- yl)propy amino)phenyI)quinazoIin- (3J7)- ne
Figure imgf000070_0001
[000165] Lithium bis(trime hylsily])amide (1 M in THF, 12 mL, 12 mmol) was slowly added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5 ,7-dimethoxyquinazolin- 4(3H)-one (0.661 g, 2 mmol) and 3 -(pyrrolidin- 1 -yl)propan- 1 -amine (1.030 g, 8 mmol) in anhydrous THF (20 mL). After the addition was complete the reaction was heated to reflux with stirring for 24 h. After that time, the reaction was cooled to rt, diluted with saturated aqueous solution of NH4CI (10 mL), and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 mL), diluted with water (20 mL) and stirred for 1 h. The precipitated solid was collected by filtration, washed with water then hexanes and air dried. The product was purified by column chromatography (silica gel, 99:1 dichloromethane 7N ammonia in methanol to 97:3 dichloromethane/7N ammonia in methanol) to give 5,7- dimethoxy-2-(4-me1hoxy-2-((3-(pyrrolid^
(0.220 g, 25%) as a yellow solid: 1H MR (400 MHz, CDCI3) δ 9.33 (br s, 1H), 9.04 (br s, 1H), 7.49 (d, J= 8.8 Hz, 1H), 6.62 (d, J= 2.3 Hz, 1H), 6.41 (d, 7= 2.3 Hz, 1H), 6.29 (dd, J= 8. 8, 2.3 Hz, 1H), 6.23 (d, J= 2.3 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H), 3.31 (t, J= 7.0 Hz, 2H), 2.62-2.68 (m, 2H), 2.48-2.56 (m, 4H), 1.99 (quin, J = 7.0 Hz, 2H), 1.75-1.80 (m, 4H); ESI MS m/z 439 [M + H]+.
69 Example 16: 2-(2-(((l Jsopropylpyrrolidin-3-yI)methyl)amuio)-4-methoxyphenyl)-5,7- dimethoxyquinazolin-4(3/-r)-one
Figure imgf000071_0001
[000166] Lithium bis(lrimeraylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was slowly added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5 ,7-dimethoxyquinazolin- (4(3H one (0.660 g, 2 mmol) and (1 -isopropylpyrrolidin-3-yl)methanamine (1.14 g, 8 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium
bis(trimethylsilyl)amide (1M in THF, 6 mL, 6 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that time the reaction was cooled to rt, diluted with saturated aqueous N¾CI (6 mL) and concentrated under reduced pressure. The residue was diluted with water (SO mL) and the precipitated solid was collected by filtration, washed with water and dried. The resulting solids were triturated with ethyl acetate, then with 90: 10 diethyl ether/methanol and dried under vacuum to give 2-(2-{((l -isopropylpyrrolidin-3- yl)merayl)ammo)^me&oxyphenyl)-5,7^ (0.347 g, 38%) as a pale orange solid: mp 228-230 °C; 1H N R (400 MHz, CDC13) δ 9.50 (br s, 1H), 9.21 (br s, 1H), 7.53 (d, J= 8.6 Hz, 1H), 6.59 (d, J = 1.95 Hz, 1H), 6.40 (d, J= 1.95 Hz, 1H), 6.30 (dd, J= 8.8, 2.5 Hz, 1H), 6.21 (d, J= 2.3 Hz, 1H), 3.98 (s, 3H), 3.90 (s, 3H), 3.86 (s, 3H), 3.16-3.25 (m, 2H), 3.01 (t,J= 8.8 Hz, 1H), 2.55-2.80 (m, 3H), 2.30-2.45 (m, 2H), 2.10-2.23 (m, 1H), 1.62-1.74 (m, 1H), 1.12 (d, J= 6.2 Hz, 6H); ESI MS m/z 453 [M + H]4. Example 17: 2^2^((l-IsopropylpyrroUd.n-2-y inethyl)amino)-4-methoxyphi dimethoxyquinazoIin~4(3H)-onc
Figure imgf000072_0001
[000167] Lithium bis(trimethylsilyl)amide (1 M in THF, 12 raL, 12 mmol) was slowly added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5 ,7-dimethoxyquinazolin- (4(3H)-one (0.660 g, 2 mmol) and (l-isopropylpyrrolidm-2-yl)methanamine (1.140 g, 8 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 24 h. After that time the reaction was cooled to it, diluted with saturated aqueous H4CI (10 mL) and concentrated under reduced pressure. The residue was diluted with water (20 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and dried. The product was purified by column chromatography (silica gel, 99:1 dichloromethane/7N ammonia in methanol to 97:3 dichloromethane/7N ammonia in methanol) to give 2-(2-(((l- isor^pylpyrrotolm-2-yl)m
one (0.240 g, 27%) as a yellow solid: mp 207-209 °C; 1H NMR (400 MHz, CDC13) δ 9.33
(br s, 1H), 9.20 (br s, 1H), 7.49 (d, J= 8.9 Hz, 1H), 6.67 (d, J= 2.3 Hz, 1H), 6.40 (d, J= 2.3 Hz, 1H), 6.29 (dd, ^=8.9, 2.3 Hz, 1H), 6.22 (d, J= 2.3 Hz, lH), 3.98 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H), 3.15-3.30 (m, 2H), 2.99-3.12 (m, 3H), 2.53-2.61 (m, lH), 1.68-1.97 (m, 4H), 1.16 (d, J= 6.6 Hz, 3H), 1.02 (d, J= 6.25 Hz, 3H); ESI MS m/z 453 [M + Hj+.
Example 18: 2-(3-((l-bopropylpiperidijtt-4-yl)amino)pyridiii-2-yl)-5,7- dJmethoxyquinazoliii-4(31 -one
Figure imgf000073_0001
[000168] Lithium bis(trimethylsilyl)amide (1 M in THF, 3.2 mL, 3.2 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5,7-dime1hoxyquinazolin-4(3H)-one (0.322 g, 1.07 mmol) and 1 sopropylpiperidm-4-amine (0.676 mL, 4.28 mmol) in anhydrous THF (10 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimemylsUyl)anu\ie (1M in THF, 3.2 mL, 3.2 mmol) was added. Heating to reflux with stirring was continued for 2 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (3 mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and the precipitated solid was collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 97:3 dichloromethane/methanol then 97:3 dichloromethane/7 N ammonia in methanol) to give 2-(3-((l-isopropylpiperidin-4- yl)ammo)pyrid -2-yi)-5,7-dm (0.145 g, 32%) as a yellow solid: mp 170-172 °C; Ή NMR (400 MHz, CDC13) δ 10.92 (br s, lH), 9.50 (d, J = 7.8 Hz, 1H), 7.89 (d, J= 4.3 Hz, lH), 7,23 (dd, J= 8.6, 4.3 Hz, 1H), 7.10 (d, J= 8.6 Hz, 1H), 6.65 (d, J= 2.3 Hz, 1H), 6.45 (d, J= 2.3 Hz, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.43-3.57 (m, 1H), 2.86- 2.98 (m, 2H), 2.78 (sept, 7= 6.5 Hz, 1H), 2.42 (t, J= 10.2 Hz, 2H), 2.09-2.21 (m, 2H), 1.61- 1.83 (m, 2H), 1,10 (d, J= 6.6 Hz, 6H); ESI MS m/z 424 [M + H]+.
72 Example 19: 2^2^(l-bobutyiylpiperidin^yi)amino)-4-niethoxyphenyl)-5,7- dimethoxyquraazolin-4(3H)-one
Figure imgf000074_0001
[000169] Lithium bis(trimethylsilyl)amide (1 M in THF, 12.0 mL, 12.0 mmol) was added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7-dimethoxyquinazolin- (4(3H)-one (0.660 g, 2.0 mmol) and 1 -( -aminopiperidin- 1 -y l)-2-methylpropan- 1 -one hydrochloride (1.240 g, 6.0 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1M in THF, 6.0 mL, 6.0 mmol) was added Hearing to reflux with stirring was continued for 16 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (S.O mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and extracted with CH2CI2 (2 x 30 mL). The combined organics were concentrated under reduced pressure and purified by flash column chromatography (silica gel, 90:10 ethyl acetete/methanol) followed by prep. HPCL to give 2-(2-((l-isobutyrylpiperidm-4-yl)amino)-4-methoxyphenyl
4(3 _ one (0.090 g, 9%) as a yellow solid: Ή NMR (400 MHz, CDC13) δ 9.35 (br s, 1H), 9.19 (br s, IH), 7.50 (d, J = 8.6 Hz, 1H), 6.54 (s, 1H), 6.42 (s, 1H), 6.32 (d, J= 8.6 Hz, 1H), 6.25 (br s, 1H), 427 (br s, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.70 (br s, IH), 3.23- 3.43 (m, 2H), 2.84 (sept, J = 62 Hz IH), 2.07-2.20 (m, 2H), 1.59-1.71 (m, 2H), 1.14 (d, J=6.2 Hz, 6H); ESI MS m/z 481 [M + H]+.
73 Example 20: 2-(2^(3^sopropylamino)propyI)amino)-4-metho3cyphenyI)-5,7- dimethoxyqninazolin-4(3J7)-one
Figure imgf000075_0001
[000170] Lithium bis(trimethylsilyl)amide (1 M in THF, 6 mL, 6 mmol) was added to a stirred suspension of 2~(2-fluoro-4-methoxyphenyl)-5,7-dim
(0.660 g, 2 mmol) and Λ^-isopropylpropane-l ,3-cUamine (1.35 mL, 8 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1M in THF, 6 mL, 6 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (6 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the precipitated solid was collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 97:3 dichloromethane/methanol then 97:3 dichloromethane 7 N ammonia in methanol) to give 2-(2-((3- (isopropylaim^o)propyl)ammo)^meth^
(0.171 g, 20%) as a yellow solid: mp 208-210 °C; 1H NMR (400 MHz, DMSO-4 δ 7.83 (d, J= 9.8 Hz, 1H), 6.61 (d, J= 2.3 Hz, 1H), 6.49 (d, J= 2.3 Hz, 1H), 6.16-6.24 (m, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.50 (br s, 2H), 3.26 (t, J= 6.6 Hz, 2H), 2.64-2.75 (m, 3H), 1.86-1.76 (m, 2H), 0.95 (d, J = 5.9 Hz, 6H); ESI MS m/z 427 [M + H]+.
74 Example 21: 5,7-Dimethoxy-2-<4-methoxy-2-((3-(methylpiperazin-l-yI)propyI)amino)- phenylquinazoIin-4(3/-one
Figure imgf000076_0001
[000171] Lithium bis(trimethylsilyl)amide (1 M in THF, 6.0 mL, 6.0 mmol) was added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5 J^iirnethoxyquinazolin- (4(3H)-one (0.660 g, 2.0 mmol) and 3-(4-methylpiperazin- 1 -yl)propan- 1 -amine (0.942 g, 6.0 mmol) in anhydrous THF (25 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium
bis(trimeihylsilyl)amide (1M in THF, 6.0 mL, 6.0 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH CI (5.0 mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and ethyl acetate (10 mL) and stirred for 1 h. The precipitated solids were collected by filtration, washed with water, then hexanes and air dried. The material was triturated with ethyl acetate (2 x 20 mL) and ether (2 χ 20 mL) to give 5,7- dimethoxy-2-(4-methoxy-2-((3-(rnethylpiperazin- 1 -yl)propy 1 )amino)phenyl quinazolin- AQH one (0.440 g, 47%) as a light yellow solid: mp 220-222 °C; 1H MR (400 MHz,
CDCI3) δ 9.00 (br s, IH), 7.51 (d, J= 8.8 Hz, 1H), 6.61 (d, J= 2.3 Hz, 1H), 6.41 (d, J= 1.9 Hz, 1H), 6.29 (dd, J= 8.8, 1.9 Hz, IH), 6.23 (d, J= 2.3 Hz, IH), 3.98 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H), 3.29 (t, J= 6.5 Hz, 2H), 2.37-2.66 (m, 1 IH), 2.29 (s, 3H), 1.90-2.00 (m, 2H); ESI MS w z 468 [M + H]+.
75 Example 22: 2^2^(2^4Jsopn>pylpiperazin-l-yl)ethyl)amino)-4-methoxyphenyl)-5,7- dimethoxyquinazoIin-4(3H)-one
Figure imgf000077_0001
[000172] Lithium bis(trimethylsilyl)amide (1 M in THF, 4 mL, 4 mmol) was added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5 ,7-^Umethoxyquinazolin-^3/i)-one (0.660 g, 2 mmol) and 2-(4-isopropylpiperazin- 1 -yl)ethan- 1 -amine (1.02 g, 6 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium bis(trimeuylsilyl)amide (1 M in THF, 4 mL, 4 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that time the reaction was cooled to it, diluted with saturated aqueous NH4CI (6 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the precipitated solid was collected by filtration, washed with water and dried. The solid was triturated with ethyl acetate followed by 90:10 diethyl ether/methanol and dried under vacuum to give 2^2^(2-(4-isopropylpiperazm^
dimemoxyquinazolin-4(3H)-one (0.776 g, 80%) as an off-white solid: mp 227-228 °C;Ή
NMR (400 MHz, DMS(W6) δ 11.44 (br s, 1H), 9.29 (t, J= 4.3 Hz, 1H), 7.80 (d, J= 9.8 Hz, lH), 6.72 (d, J= 2.3 Hz, 1H), 6.51 (d, J= 2.3 Hz, 1H), 6.15-6.26 (m, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.33 (br s, lH), 3.25 (q, J= 5.1 Hz, 2H), 2.64 (t, J= 5.7 Hz, 2H), 2.52- 2.60 (m, 1H), 2.43 (br s, 8H), 0.90 (d, J= 6.6 Hz, 6H); ESI MS m/z 482 [M + Hl+.
76 Example 23: 5,7-Dimethoxy-2-[4-methoxy-2-(l-niethylpip€ridiii-4- ylsaIfinyl)phenyl]quinazoliii-4(3i7)-one
Figure imgf000078_0001
[000173] A mixture of 2^2-fluoro-4-methoxyphenyl)-5,7^raethoxyquinazolin- 4(3H)-one (3.62 g, 11 mmol), l-me1hylpiperidine-4-thioi (1.51 g, 11.5 mmol), K2CO3 (3.04 g, 22 mmol) and anhydrous D SO (44 mL) was heated at 90 °C with stirring for 20 h. After that time the reaction was cooled to it, diluted with CHCI3 (150 mL) and washed with water (3 x 100 mL) and brine (100 mL), dried (MgSQ and concentrated under reduced pressure. The residue was triturated with diethyl ether (3 x 30 mL) and dried in vacuum to give 5,7- dime^oxy-2-[4-methoxy-2-(l-methylpipOT (4.59 g, 95%) as an off-white solid: 1H NMR (400 MHz, CDC13) δ 11.40 (br s, 1H), 7.82 (d, J= 8.8 Hz, 1H), 6.98 (d, J= 2.4 Hz, lH), 6.87 (dd, J= 8.8, 2.4 Hz, 1H), 6.78 (d, J= 2.4 Hz, lH), 6.46 (d, J= 2.4 Hz, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H), 2.99-2.93 (m, 1H), 2.70- 2.67 (m, 2H), 2.21 (s, 3H), 1.91-1.84 (m, 4H), 1.59-1.50 (m, 2H).
[000174] A solution of NaI04 (0.449 g, 2.1 mmol) in water (7 mL) was added dropwise to a stirred suspension of 5,7-dimethoxy-2-[4-rnethoxy-2-(l -methylpiperidin-4- yltWo)phenyl]quinazolin-4(3H one (0.883 g, 2 mmol) in methanol (20 mL). After the addition was complete the reaction was stirred for 18 h at rt. After that time the reaction was diluted with water (80 mL) and the precipitated solid collected by filtration, washed with water (4 * 30 mL) and dried. The product was purified by flash column chromatography (silica gel, 95:5 chloroform/ methanol) to give 5,7-dimethoxy-2-[4-methoxy-2-(l- memylpiperidm-4-ylsulfin^ (0.312 g, 34%) as a white solid: mp 263-265 °C; 1H NMR (400 MHz, CDCI3) δ 7.93 (d, J = 8.4 Hz, 1H), 7.74 (<LJ = 2.8 Hz, 1H), 7.13 (dd, J = 8,4, 2,8 Hz, lH), 6.65 (d, J= 2.4 Hz, 1H), 6.49 (d, J= 2.4 Hz, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 3.93 (s, 3H), 3.48-3.40 (m, 1H), 3.06-2.93 (m, 2H), 2.24 (s, 3H), 2.21- 1.87 (m, 5H), 1.36-1.33 (m, IH); ESI MS m z 458 [M + H]4.
77 Example 24: 5,7-Dimcthoxy-2^4-methoxy-2^(2^iperazin-l- yI)ethyl)amino)phenyI)qainazoliii-4<3i-rH)ne
Figure imgf000079_0001
[000175] Lithium bis(trimethylsilyl)amide (1 M in THF, 6.0 mL, 6.0 mmol) was added slowly to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7- dimethoxyquinazolin-(4(3H)-one (0.660 g, 2.0 mmol) and rerr-butyl 4-(2- aminoethyl)piperazine-l -carboxylate (0.916 g, 4.0 mmol) in anhydrous THF (25 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimewy yl)amide (1 M in THF, 4.0 mL, 4.0 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that rime the reaction was cooled to it, diluted with saturated aqueous NH4CI (5.0 mL) and concentrated under reduced pressure. The residue was diluted with water (40 mL) and stirred for 1 h. The precipitated solid was collected by filtration, washed with water and hexanes and air dried. The product was purified by flash column chromatography (silica gel, 99: 1 ethyl
acetate/methanol) to give rA-butyl 4~(2-((2~(5,7-dimethoxy-4-oxo-3,4-dihydro^
yl)-5 -melJioxyphenyl)arnino)ethyl)piperazine- 1 -carboxylate (0.440 g, 41%) as an off-white solid: 1HNMR (400 MHz, CDCI3) δ 9.06 (br s, 1H), 8.82 (br s, 1H), 7.43 (d, J= 9.0 Hz, 1H), 6.68 (d, J= 2.0 Hz, 1H), 6.42 (d, J- 2.0 Hz, 1H), 6.31 (dd, J= 8.8, 2.1 Hz, 1H), 6.22 (d, J= 2.3 Hz, 1H), 3.99 (s, 3H), 3.89 (s, 3H), 3.86 (s, 3H), 3.44 (br s, 4H), 3.34 (q,J= 5.5 Hz, 2H), 2.76 (t, J= 6.1 Hz, 2H), 2.49 (br s, 4H), 1.45 (s, 9H); ESI MS m/z 540 [M + H]+.
[000176] Trifluoroacetic acid (5.0 mL) was added dropwise to a suspension of /er/- butyl 4-(2-((2-(5,7-dimemoxy-4-oxo-3,4-d ^
memoxyphenyl)amino)ethyl)piperazine-l -carboxylate (0.420 g, 0.78 mmol) in CH2CI2 (20 mL). The reaction mixture was stirred at rt for 3 h. After that time the reaction was concentrated under reduced pressure and the residue diluted with ice-cold water (30 mL). The resulting mixture was made basic with solid NaHCCb and extracted with CH2CI2 (3 * 30
78 mL). The combined organics were dried and concentrated to give a solid residue that was triturated (3 20 mL, 50:50 hexanes/diethyl ether) to give 5,7-dimethoxy-2-(4-methoxy-2- ((2-^ipeimm-l-yl)erayl)amin^ (0.230 g, 67%) as an off-white solid: mp 210-212 °C; lH NMR (400 MHz, CDC13) δ 8.86-S.94 (m, 1H), 7.48 (d, J= 8.6 Hz, 1H), 6.72 (d, J= 2.3 Hz, 1H), 6.42 (d, J= 2.3 Hz, lH), 6.31 (dd, J - 8.8, 2.1 Hz, 1H), 6.22 (d, J= 2.3 Hz, 1H), 3.99 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H), 3.34 (q, ./= 5.9 Hz, 2H), 2.84-2.% (m, 4H), 2.75 (t, J= 6.3 Hz, 2H), 2.52 (br s, 4H); ESI MS m/z 440 [M + H]+.
Example 25: 5,7-Dimethoiy-2-(4-methoxy-2^(2^4-methylpipei¾zin-l- yl)ethyl)amino)phenyl)-qainazolin-4(3jH)-one
Figure imgf000080_0001
[000177] Lithium bis(trimethylsilyl)amide (1 M in THF, 4 mL, 4 mmol) was added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7-dimeth^
(0.660 g, 2 mmol)and 2-(4-methylpiperazin- 1 -yl)eihan- 1 -amine (0.86 g, 6 mmol) in anhydrous THF ( 20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1M in THF, 4 mL, 4 mmol) was added. Heating to reflux with stirring was continued for 16 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (6 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the precipitated solid was collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 96:4 dichloiOmethane/methanol then 96:4 dichloromethane/7 N ammonia in methanol) to give 5,7-dimethoxy-2-(4-methoxy-2-((2- (4-methylpiperazm-l-yl)e&yl)arri^ (0.310 g, 34%) as pale yellow solid: mp 230-231 °C; Ή NMR (400 MHz, DMSO-ifc) 8 11.46 (br s, 1H), 9.26 (t, J=
4.3 Hz, 1H), 7.79 (d, J= 9.4 Hz, 1H), 6.70 (d, J= 1.95 Hz, 1H), 6.51 (d, J= 1.95 Hz, 1H),
79 6.14-6.27 (m, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 3.80 (s, 3H), 3.26 (q, J= 5.1 Hz, 2H), 2.65 (t, J = 5,9 Hz, 2H), 2.47 (br s, 4H), 2.32 (br s, 4H), 2.11 (s, 3H); ESI MS m/z 454 [M + H]+.
Example 26: 2^2^(l-Isopropylpiperidin^yl)amino)-5-methoxyphenyl)-5,7- dimethoxyquinazolin-4(3H)-one
Figure imgf000081_0001
[000178] A mixture of 2-bromo-5-methoxybenzaldehyde (5.0 g, 23.3 mmol), propane- 1,3-diol (2.13 g, 28.0 mmol) and wjra-toluenosulfomc acid monohydrate (0.10 g, 0.53 mmol) in anhydrous toluene (110 mL) was heated to reflux for 24 h with azeotropic removal of water using a Dean-Stark apparatus. After that time the reaction was cooled to rt, washed with 5% aqueous Na2C03 solution (50 mL), dried over Na2S04 and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 95:5 hexanes/ethyl acetate to 80:20 hexanes ethyl acetate) to give 2-(2-bromo-5-methoxyphenyl>- 1,3-dioxane (5.8 g, 91%) as a thick viscous liquid: Ή NMR (400 MHz, CDC13) δ 7.40 (d, J= 8,6 Hz, 1H), 7.24 (d, J = 2.7 Hz, 1H), 6.77 (dd, J= 8.8, 2.9 Hz, 1 H), 5.72 (s, 1 H), 4.27 (dd, J = 11.3, 4.7 Hz, 2H), 4.03 (t, 7= 11.3 Hz, 2H), 3.81 (s, 3H), 2.18-2.32 (m, 1H), 1.44-1.48 (m,
1H).
[000179] A mixture of 2-(2-bromo-5-methoxyphenyl)-l,3-dioxane (5.1 g, 18.7 mmol), 1-isopropylpiperioUn^amine (3.45 g, 24.38 mmol), 2^'-bis(diphenylphosphino)-l, - binaphthyl (0.746 g, 1.2 mmol) and tris(dir^en2yUdeneacetone)dipalladium(0) (0.366 g, 0.4 mmol) in anhydrous toluene (50 mL) was purged with nitrogen for 15 min. Sodium- r/- butoxide (3.24 g, 33.7 mmol) was added and the mixture was purged with nitrogen for an additional 5 min. The reaction mixture was heated at 110 °C for 18 h, then cooled to rt, diluted with ethyl acetate (100 mL) and filtered. The reaction was concentrated under reduced pressure and the residue was purified by flash column chromatography (silica gel, 90:10 ethyl acetate/methanol) to give A'r-(2^1,3^ioxan-2-yl)-4-memoxyphenyl)-l-isopropylpiperidm-4^ amine (4.5 g, 73%) as a thick viscous liquid: 1H NMR (400 MHz, CDC13) δ 6.90 (d, J= 2.7 Hz, 1H), 6.79 (dd, J= 8.6, 2.7 Hz, lH), 6.66 (d, J= 8.6 Hz, 1H), 5.41 (s, 1 H), 4.54 (br s, lH), 4.25 (dd, J- 11.1, 4.9 Hz, 2H), 3.91-4.02 (m, 2H), 3.74 (s, 3H), 3.31 (br s, 1H), 2.83 (d, J= 11.3 Hz, 2H), 2.74 (dt, J = 12.9, 6.4 Hz, lH), 2.31 (t, J= 10.4 Hz, 2H), 2.13-2.26 (m, 1H), 2.09 (br s, 1H), 1.42-1.60 (m, 3H), 1.06 (d, J= 6.6 Hz, 6H); ESI MS m z 335 [M + Hf .
[000180] A solution of HCI (2.5 M, 15 mL, 37.5.0 mmol) was slowly added to a vigorously stirred solution of N-(2-(l ,3-dioxan-2-yl)-4-metfioxy^^
4-amine (1.5 g, 4.5 mmol) in methanol (15 mL) cooled to 0 °C . The resulting mixture was allowed to warm to rt and stirred for 2 h. The majority of methanol was removed under reduced pressure and the residue was diluted with water (30 mL). The pH of the aqueous phase was adjusted to approx. 10 using solid Na2C03. The mixture was extracted with ethyl acetate (2 x 50 mL). The combined organics were washed with brine, dried over Na2SC> , and concentrated under reduced pressure to give 2-(( 1 -i sopropylpiperidin-4 -yl)amino)-5- methoxybenzaldehyde as a thick viscous gum (0.820 g, 65%): 1H NMR (400 MHz, CDC13) δ 9.78 (s, 1H), 8.14 (d, J= 7.0 Hz, 1H), 7.06 (dd, J= 9.2, 2.9 Hz, IH), 7.0 (d, J= 3.1 Hz, 1H), 6.69 (d, J= 9.4 Hz, 1H), 3.79 (s, 3H), 3.44 (br s, 1H), 2.80-2.89 (m, 2H), 2.75 (br s, 1H), 2.35 (br s, 2H), 2.06 (br s, 2H), 1.62 (d, J= 9.4 Hz, 2H), 1.07 (d, J= 6.3 Hz, 6H); ESI MS m/2277 [M + Hl+.
[000181] A mixture of 2^(l-isopropylpiperidm^yl)amino)-5-memoxybenzaldehyde (0.8 g, 2.9 mmol), 2-amincH4,6-dimelhoxybenzamide (0.57 g, 2.9 mmol), sodium bisulfite (58.5 % SO content, 0.773 g, 4.5 mmol) and r -toluenosulfonic acid monohydrale (0228 g, 1.2 mmol) in N,N-dmemylacetamide (15 mL) was stirred and heated at 120°C for 20 h. After that time, the reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was diluted with water (20 mL) and the pH was adjusted to approx. 10 with aqueous Na2C<¼ solution. The mixture was extracted with CH2CI2 (3 * 40 mL) and the combined organics were concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 99:1 ethyl acetate/7N ammonia in methanol to 97:3 ethyl acetate/7-V ammonia in methanol) followed by prep. HPLC to give 2-(2-((l- isopropylpiperidm^yl)ainm^
(0.043 g, 3%) as a yellow solid: 1H NMR (400 MHz, DMSO-cfe) 6 8.53-8.63 (m, IH), 8.20 (br s, IH), 7.34 (br s, IH), 6.95 (d, J= 7.4 Hz, IH), 6.77 (d, J= 9.0 Hz, IH), 6.60 (s, IH), 6.53 (s, IH), 3.87 (s, 3H), 3.84 (s, 3H), 3.74 (s, 3H), 3.58-3.68 (m, IH), 3.44 (br s, IH), 2.73 (br s, 2H), 2.40 (br s, 2H), 1.93 (br s, 2H), 1.52 (br s, 2H), 0.95 (d, J = 5.5 Hz, 6H); ESI MS w¾ 453 [M + H]+. Example 27: 2-(3^(l-Isopropylpiperidin^yl)aniino)phenyl)-5,7HliinethoxyqumazoIin- 4(3H)-one
Figure imgf000083_0001
[000182] A mixture of 3 -broraobenzaldehyde (10.0 g, 54.1 mmol), propane- 1, 3 -diol (4.93 g, 64.9 mmol) and /wra-toluenosulfonic acid monohydrate (0.10 g, 0.53 mmol) in anhydrous toluene (100 raL) was heated to reflux for 24 h with azeotropic removal of water using a Dean-Stark apparatus. After that time the reaction was cooled to rt, washed with 5% aqueous Na2C03 solution (50 mL), dried over Na2S04 and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 95:5 hexanes/ethyl acetate to 90:10 hexanes/eth l acetate) to give 2-(3-bromophenyl)-l,3-dioxane (11.5 g, 87%) as a light brown oil: Ή NMR (400 MHz, CDC13) δ 7.62-7.70 (m, 1H), 7.46 (ddd, J= 8.1, 2.05, 12 Hz, 1H), 7.40 (d, J= 7.8 Hz, 1H), 7.15-7.27 (m, 1H), 5.46 (s, 1H), 4.24-4.29 (m, 2H), 3.98 (t of d, J= 12.11, 2.74 Hz, 2H), 2.11-2.33 (m, 1H), 1.39-1.51 (m,
1H).
[000183] A mixture of 2-(3-bromophenyl)-l,3-dioxane (5.0 g, 20.6 mmol), 1- isopropylpiperidm-4~amine (3) (4.39 g, 30.9 mmol), 2,2'-bis(diphenylphosphino)-l,r- binaphthyl (1.28 g, 2.06 mmol) and tris(diber^hdeneacetone)dipalladium(0) (0.94 g, 1.03 mmol) in anhydrous toluene (60 mL) was purged with nitrogen for 15 min. Sodium-terf- butoxide (3.95 g, 1.1 mmol) was added and the mixture was purged with nitrogen for an additional 5 min. The reaction mixture was heated at 110 °C for 4 h, then cooled to rt, diluted with ethyl acetate (100 mL) and filtered. The reaction was concentrated under reduced pressure and the residue was purified by flash column chromatography (silica gel, 98:2 dichloromethane methanol to 95:5 dichloromethane/methanol) to give JV-(3-(l,3-dioxan-2- yl)phenyl)-l-isopropylpiperidin-4-amine (4,43 g, 71%) as an off-white solid: 1H NMR (400 MHz, CDCI3) δ 7.12-7.16 (m, 1H), 6.76 (d, J= 7.4 Hz, 1H), 6.72 (d, J= 1.95 Hz, 1H), 6.56 (dd, J= 7.4, 1.95 Hz, 1H), 5.42 (s, 1H), 4.26 (dd, J= 11,1, 4.6 Hz, 2H), 3.96-4.05 (m, 2H), 3.52-3.54 (m, 1H), 3,24-3.37 (m, 1H), 2.82-2.85 (m, 2H), 2.65-2.79 (m, 1H), 2.13-2.34 (m,
82 3H), 2.03-2.08 (m, 2H), 1.33-1.52 (m, 3H), 1.05 (d, J= 6.6 Hz, 6H); ESI MS m/z 305 [M + H]+.
[000184] A solution of HC1 (2iV, 50 mL, 100 mmol) was added slowly to a vigorously stirred solution of N-(3-(l,3-dioxan-2-yl)phenyl)-l-isoprop^^ (4.43 g, 14.6 mmol) in methanol (50 mL) cooled to 0 °C. The resulting mixture was allowed to warm to rt and stirred for 17 h. The majority of methanol was removed under reduced pressure and the residue was diluted with water (30 mL). The pH of the aqueous phase was adjusted to approx. 10 using solid NazCOj. The mixture was extracted with ethyl acetate (2 x 150 mL). The combined organics were washed with brine, dried over NaaSO,*, and concentrated under reduced pressure. The product was triturated (50:50 diethyl ether hexanes) to give 3-((l- isopropylpiperidin-4-yl)amirio)benzaldehyde (0.90 g, 25%) as an off-white solid: 1H NMR (400 MHz, CDC13) δ 9.92 (s, 1H), 7.30-7.39 (m, 1H), 7.21 (d, J= 7.8 Hz, 1H), 7.05 (br s, 1H), 6.85-6.94 (m, 1H), 3.92-4.05 (m, 1H), 3.54-3.68 (m, 1H), 3.39-3.57 (m, 3H), 2.67- 2.94 (m, 2H), 2.32-2.49 (m, 1H), 2.13-2.33 (m, 3H), 1.46 (d, J= 6.6 Hz, 6H); ESI MS m/z 247 [M + H]+.
[000185] A mixture of 3^(l-isopropylpiperidin-4-yl)amino)benzaldehyde (0.450 g, 1.83 mmol), 2-ammo-4,6-dmiemoxybetLzamide (0.287 g, 1.46 mmol), sodium bisulfite (58.5 % SO2 content, 0.487 g, 2.74 mmol) and />arii-toluenosulfonic acid monohydrate (0.174 g, 0.91 mmol) in W,#-dime&ylacetamide (15 mL) was stirred and heated at 120 °C for 17 h. After mat time, the reaction mixture was cooled to rt and concentrated under reduced pressure. Water (50 mL) was added and the resulting suspension was stirred for 30 min at rt The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99: 1 ethyl acetate/ 7N ammonia in methanol to 97:3 ethyl acetate/7N ammonia in methanol) to give 2-(3-((l- isopropylpiperi<lin-4-yl)arm^ (0.310 g, 50%) as a white solid: mp 239-341 °C; JH NMR (400 MHz, DMSO-ifc) δ 11.89 (br s, 1H), 7.24- 7.36 (m, 2H), 7.09-7.23 (m, 1H), 6.76 (d, J= 7.8 Hz, 1H), 6.70 (d, J= 2.3 Hz, 1H), 6.53 (d, J = 2.3 Hz, lH), 5.70 (d, J= 8.2 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.26-3.37 (m, 1H), 2.65- 2.81 (m, 3H), 2.20-2.29 (m, 2H), 1,75-1.94 (m, 2H), 1.28-1.41 (m, 2H), 0.98 (d, J= 6.6 Hz, 6H); ESI MS /z 423 [M + H]+.
83 Example 28: 5,7-Dimethoi.y-2-(4-methoxy-2-[3-(piperaziii-l- yl)propylamino]phenyl)qainazolin-4(31 - )ne
Figure imgf000085_0001
[000186] Lithium bis(trimemykilyl)amide (1 M in THF, 10,3 mL, 10.3 mmol) was added to a stirred suspension of 2-(2-fluoro-4-raethoxyphenyl 5 ,7-dimethoxyquinazolin- 4(3H)-one (0.679 g, 2.06 mmol) and l-/err-butoxycarbonyl^3-aniinopropyl)piperazine (0.957 g, 3.93 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 24 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (IS mL) and concentrated under reduced pressure. Saturated aqueous NaHC03 (SO mL) was added and the mixture was extracted with chloroform (4 x 30 mL). The combined organic layers were dried (MgSO^) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 98:2 chloroform methanol) followed by recrystalization from chloroform/hexanes to give 5,7-dimethoxy-2-(4-methoxy-2-[3-{l-te^butoxycarbonylpiperazin-4- yl)propylamino]phenyl)quinazolm^3 -<>ne (0.253 g, 22%) as a yellow solid: lH NMR (400 MHz, CDCI3) δ 9.50 (br s, 1H), 9.04 (br s, 1H), 7.54 (d, J= 8.8 Hz, 1H), 6.60 (d, J= 2.4 Hz, 1H), 6.41 (<L J = 2.4 Hz, lH), 6.30 (dd, J= 8.8, 2.4 Hz, 1H), 6.23 (d, J= 2.4 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.44-3.42 (m, 4H), 3.33-3.29 (m, 2H), 2.56-2.53 (m, 2H), 2.41 (br s, 4H), 1.98-1.93 (m, 2H), 1.46 (s, 9H).
[000187] A solution of 5,7Kiimethoxy-2-(4-methoxy-2-[3-(l-/er/- butoxycarbonylpiperazm^yl)propyla^ (0.253 g, 0.46 mmol) in chloroform (10 mL) was added dropwise to a solution of HC1 (1.0 g, 27.4 mmol) in methanol (18 mL) cooled to 0 °C. After the addition was complete, the reaction was allowed to warm to rt and stir for 1 h. After that time the reaciton was concentrated under reduced pressure and the residue was triturated with chloroform (4 30 mL). The product was then neutralized with saturated aqueous NaHC03 (20 mL) and extracted with chloroform (3 * 20 mL). The combined organic layers were dried (MgS04) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 90:10
84 chloroform/methanol) to give 5,7-diraethoxy-2-(4-methoxy-2-[3-(piperazin- 1 - yl)propylammo]phenyl)quinazol ^(^ (0.091 g, 44%) as a yellow solid: mp 225-228 °C; Ή NMR (400 MHz, CDC ) δ 7.52 (d, J= 9.2 Hz, 1H), 6.61 (d, J= 2.0 Hz, 1H), 6.41 (d, J = 2.4 Hz, 1H), 6.30 (dd, J= 9.2, 2.0 Hz, 1H), 6.23 (d, J= 2.0 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.86 (s, 3H), 3.31-3.28 (m, 2H), 2.91-2.88 (m, 4H), 2.55-2.46 (m, 6H), 1.99-1.92 (m, 2H); ESI MS m/z 454 [M + H]+.
Example 29: 2^2^(4,4-Dimethylcyclohexyl)amino)-4-methoxyphenyl)-5,7- dime(hoxyquinazolin-4(3A)-one
Figure imgf000086_0001
[000188] Lithium bis(trimethylsilyl)amide (1 M in THF, 6.0 mL, 6.0 mraol) was added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7-dimethoxyquinazolm^ 4(3#)-one (0.661 g, 2 mmol) and 4,4-dimethylcyclohexan- 1 -amine (0.509 g, 4 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 24 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (5 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by column chromatography (silica gel, 99:1 dichloromethane/methanol to 97:3
dichloromethane/methanol), followed by preparative HPLC to give 2-(2-((4,4- <limethylcyclohexyl)amino)-4-m (0.060 g,
7%) as a light yellow solid: Ή NMR (400 MHz, CDCI3) δ 9.23 (br s, 1H), 9.15 (br s, 1H), 7.45 (d, J= 9.0 Hz, 1H), 6.65 (d, J= 2.3 Hz, 1H), 6.41 (d, J= 2.3 Hz, 1H), 6.22-^.29 (m, 2H), 3.98 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H), 3.41-3.50 (m, 1H), 1.88-1.98 (m, 2H), 1.48- 1.67 (m, 4H), 1.29-1.39 (m, 2H), 0.99 (s, 3H), 0.98 (s, 3H); ESI MS m/z 438 [M + H]+.
85 Example 30: 2^3^(l-Isopropylpiperidin-4-yl)amino)-5-inethoxypyrid-n-2-yl)-5,7- dimethoxyqiiinazoUn-4(3/j ~<>ne
Figure imgf000087_0001
[000189] Lithium bis(trimethylsilyl)amide (1 M in THF, 1.0 mL, 1.0 mmol) was added to a stirred suspension of 2-(3-fluoro-5-methoxypyridin-2-yl)-5,7- dimethoxyquinazolin-4(3H)-one (0.166 g, 0.50 mmol) and 1 -isopropylpiperidin-4-araine (0.24 mL, 1.50 mmol) in anhydrous THF (5 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After mat time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 1.0 mL, 1.0 mmol) was added and reflux with stirring was continued for an additional 5 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (1 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 97:3 di chloromethane/methanol then 97:3 dichloromethane 7N ammonia in methanol) to give 2-(3-((l-isopropylpiperidin-4- yl)amino)-5-metiioxypyridin-2-yl)-5,7-dim (0.070 g, 31%) as a yellow solid: mp 207-208 °C; 1H NMR (400 MHz, CDC13) δ 10.71 (br s, 1H), 9.58 (d, J= 7.8 Hz, 1H), 7.63 (d, J= 2.3 Hz, 1H), 6.60 (d, J= 2.3 Hz, 1H), 6.49 (d, J= 2.3 Hz, lH), 6.42 (d, J= 2.3 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.90 (s, 3H), 3.40-3.52 (m, lH), 2.86-2.97 (m, 2H), 2.78 (sept, J = 6.6 Hz, 1H), 2.43 (t, J= 10.55 Hz, 2H), 2.10-2.20 (m, 2H), 1.68-1.83 (m, 2H), 1.10 (d, J= 6.6 Hz, 6H); ESI MS m/z 454 [M + HJ+.
86 Example 31: 2-{2-((i ,a ts-4-(2-Hydroxypropan-2-yl)€yclohexyl)amino)-4- metho yphenyl^S^^imethoxyqoinazolin^S ^ne
Figure imgf000088_0001
[000190] Lithium bis(trimethylsilyl)amide (1 M in THF, 7.2 mL, 7.2 mmol) was added to a stirred suspension of 2-(2-fluoro-4-methoxyphenyl)-5,7-dimethoxyquina2Olin- 4(3 i one (0.400 g, 1.20 mmol) and 2 frani^-ammocyclohexyl)propan-2-ol (0.476 g, 3.03 mmol) in anhydrous THF (15 mL). After the addition was complete, the reaction was heated to reflux with stirring for 21 h. After that time the reaction was cooled to rt, diluted with saturated aqueous H4CI (6 mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol to 97:3 dichloromethane/methanol) followed by recrystalization from chloroform hexanes to give 2-(2-((rram,-4-(2-hydroxypropan-2-yl)cyclohexyl)amino)-4-methoxyphenyi)-5,7- dimemoxyquiria2olm^3//)-one (0.115 g, 20%) as a light yellow solid: mp: 253 °C dec.; JH NMR (400 MHz, CDC13) δ 9.18 (br s, 1H), 9.14 (d, J= 7.0 Hz, 1H), 7.46 (d, J= 9.0 Hz, 1H), 6.58 (d, J= 2.3 Hz, 1H), 6.41 (d, J= 2.3 Hz, 1H), 6.22--6.30 (m, 2H), 3.98 (s, 3H), 3.93 (s, 3H), 3.85 (s, 3H), 3.25-3.33 (m, 1H), 2.29-2.37 (m, 2H), 1.93-1.99 (m, 2H), 1.24-1.46 (m, 6H), 123 (s, 6H); ESI MS m/z 468 [M + HJ+.
87 Example 32: 2^3^(l-¾obutyiylpiperidin^yl)amino)-5-methoxypyridiii-2-yl)-5,7- dimethoxyquinazolin-4(3H)-one
Figure imgf000089_0001
[000191] Lithium bis(trimethylsilyl)amide (1 M in THF, 2.4 mL, 2.4 mmol) was added to a stirred suspension of 2-(3-fiuoro-5-methoxypyridin-2-yl)-5,7- dimethoxyquinazolin-4(3 H)-one (0.155 g, 0.468 mmol) and 1^4-aminopiperidin-l-yl)-2- methy I propan- 1 -one hydrochloride (0.290 g, 1.40 mmol) in anhydrous THF (5 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 0.9 mL, 0.9 mmol) was added and reflux with stirring was continued for an additional 5 h. After that time the reaction was cooled to rt, diluted with saturated aqueous H4CI (1 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, dichloromethane to 98:2 dichJoromethane methanol) followed by trituration with diethyl ether to give 2-(3-((l-i-wbutyrylpiperidin~4-yl)am^
dimemoxyquinazob'n-4(3H)-one (0.061 g, 27%) as a light yellow solid: mp 192-193 °C; Ή
NMR (400 MHz, CDC13) δ 10.69 (s, 1H), 9.69 (d, J= 7.0 Hz, lH), 7.66 (d, J= 2.3 Hz, 1H), 6.54 (d, J= 2.3 Hz, lH), 6.50 (d, J= 2.3 Hz, 1H), 6.43 (d, J= 1.95 Hz, 1H), 4.23-4.34 (m, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.92 (s, 3H), 3.83-3.91 (m, 1H), 3.67-3.75 (m, lH), 3.32- 3.46 (m, 2H), 2.86 (sept, J= 6.6 Hz, lH), 2.06-2.21 (m, 2H), 1.59-1.79 (m, 2H), 1.16 (<LJ= 6.6 Hz, 6H); ESI MS m/z 482 [M + H]+.
88 Example 33: 2^4-Chlor<>-2-((l-isopropylpip€ridin-4-yI)amino)ph
dimethox qainazolin-4(31 -one
Figure imgf000090_0001
[000192] To a solution of 2-am o-4,6-dimeraoxybenza^ (3.30 g, 17.0 mmol) and 4-chloro-2-fluorobenzaldehyde (3.0 g, 18.9 mmol) in #A/-dimemylacetamide (50 mL) was added NaHS03 (58.S % SO2 content, 5.05 g, 28.4 mmol) and wa-toluenosulfonic acid monohydrate (0.72 g, 3.8 mmol). The resulting mixture was heated at 120 °C for 17 h. After that time the reaction was cooled to rt, concentrated under reduced pressure, and diluted with water (100 mL). The resulting suspension was stirred for 30 min at rt and the precipitated yellow solids were collected by filtration, washed with water and air-dried. The product was purified by trituration (90:10 diethyl ether/methanol, 100 mL) to give 2-(4-chloro-2- fluorophenyl)-5,7-dime&oxyqu^ (2.36 g, 43%) as an off-white solid: Ή
N R (400 MHz, DMSO-4 δ 12.15 (s, IH), 7.77-7.79 (m, 1H), 7.65 (dd, J= 10.2, 1.6 Hz, 1H), 7.45 (dd, J= 8.2, 1.6 Hz, 1H), 6.75 (d, J= 2.15 Hz, IH), 6.59 (d, J= 2.15 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H); ESI MS m/z 335 [M + H]+.
1000193] Lithium bis(trimeihylsilyl)ainide (1 M in THF, 12.0 mL, 12.0 mmol) was added to a stirred suspension of 2-(4-chloro-2-fluorophenyl>5,7-dm^^
one (0.650 g, 1.94 mmol) and l-isopropylpiperidin-4-amine (0.854 g, 6.0 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 6 h. After that time the reaction was cooled to rt, diluted with saturated aqueous N¾Cl (10 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/7N ammonia in methanol to 97:3 dichloromethane/7N ammonia in methanol) to give 2-(4-chloro-2-(( 1 - isopropylpiperidm-4-yl)ammo)phenyl)-5,7-$ (0.200 g, 22%) as a yellow solid: mp 265 °C dec.; 1H NMR (400 MHz, CDCI3) δ 9.99 (br s, IH), 9.23 (d, J=
89 7.4 Hz, lH), 7.59 (d, J- 8.6 Hz, 1H), 6.74 (d, J= 1.8 Hz, 1H), 6.66 (dd, J= 8.6, 1.8 Hz, 1H), 6.62 (d, J= 2.15 Hz, 1H), 6.45 (d, J= 2.15 Hz, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.41-3.47 (m, 1H), 2.86-2.94 (m, 2H), 2.72-2.81 (m, 1H), 2.35-2.46 (m, 2H), 2.11-2.19 (m, 2H), 1.61- 1.75 (m, 2H), 1.08 (d, J= 6.6 Hz, 6H); ESI MS w z 457 and 459 [M + Hj+.
Example 34: 2^4-CWon>-2^(l-isobutyrylpiperidin-^yl)amino)phenyl 5,7- dimethoxyquinazolin-4(3J I)- ne
Figure imgf000091_0001
[000194] Lithium bis(trimethylsi]yl)amide (1 M in THF, 16.0 mL, 16.0 mmol) was added to a stirred suspension of 2-(4-cMoro-2-fluoiOpheny1)-5,7-d ^^
one (0.660 g, 1.97 mmol) and 1 -(4-aminopiperidin-l -yl)-2-inethylpropan- 1 -one
hydrochloride (1.22 g, 5.92 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 6 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NHtCl (10 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/ methanol to 97:3 dichloromethane/ methanol) to give 2-(4-chloro-2- ((l-isobutyrylpiperidm-4-yl^^ (0.250 g,
26%) as a yellow solid: mp 281- 283 °C; 1H NMR (400 MHz, CDCI3) δ 10.70 (br s, 1H),
9.33 (d, J = 7.0 Hz, 1H), 7.75 (d, J= 8.2 Hz, 1H), 6.75 (d, J= 1.95 Hz, 1H), 6.72 (dd, J= 8.2, 1.95 Hz, 1H), 6.56 (d,J= 2.15 Hz, 1H), 6.46 (d, J= 2.15 Hz, 1H), 4.28-4.36 (m, 1H), 3.99 (s, 3H), 3.95 (m, 3H), 3.82-3.95 (m, 1H), 3.65-3.77 (m, 1H), 3.22-3.42 (m, 2H), 2.81-2.89 (m, 1H), 2.11-2.19 (m, 2H), 1.54-1.67 (m, 2H), 1.15 (d, J= 6.7 Hz, 6H); ESI MS m/z 4*S and 487 [M + H]+. Example 35: 2^2^(l-Benzylpiperidin-4-yl)amino)-4-methoxyphenyl)-5,7- dimetfaoxyqainazoliii-4(3H)-one
Figure imgf000092_0001
[000195] Lithium bis(trimethylsilyl)ainide (1 M in THF, 18 raL, 18 mmol) was added to a stirred suspension of 2-(2-fiuoro-4-methoxyphenyl)-5,7-dimeto^
(2.0 g, 6.0 mmol) and 1 -benzylpiperidin-4-axnine (2.28 g, 12.0 mmol) in anhydrous THF (100 mL). After the addition was complete, the reaction was heated to reflux with stirring for 72 h. After that time'the reaction was cooled to rt, diluted with ice cold water (100 mL) and concentrated under reduced pressure. The resulting solids were collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol to 90:10 dichloromethane/methanol) to give 2-(2-((l- benzylpiperidm-4-yl)amino)^methox (0.9 g,
30%) as a yellow solid: Ή NMR (400 MHz, DMSO-4 δ 11.50 (s, 1H), 9.50 (d, J= 6.6 Hz, 1H), 7.82 (d, J= 9.0 Hz, 1H), 7.27-7.36 (m, 5H), 6.59 (s, 1H), 6.51 (s, 1H), 6.21 (br s, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.78 (s, 3H), 3.52-3.61 (m, 2H), 3.49 (s, 2H), 2.60-2.72 (m, 2H), 2.40 (br s, 2H), 1.93-2.05 (m, 2H), 1.51-1.66 (m, 2H); ESI MS mlz 501 [M + H]+.
Example 36: 2^(l-IsobutyryIpiperidiji-4-yl)amino)pyridin-2-yI)-5,7- dimethoxyquinazolin-4 3i )-one
Figure imgf000093_0001
[000196] Lithium bis(trimethylsilyl)amide (1 M in THF, 8 mL, 8 mraol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5 ^imemoxyquinazolin-4(3H)-one (0.390 g, 1.30 mmol) and 1 -(4-aminopiperidin- 1 -yl)-2-methylpropan- 1 -one (0.828 g, 4.0 mmol) in anhydrous THF (IS mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 4.0 mL, 4.0 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (3.0 mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined organic layers were dried (MgSC ) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 90:10 ethyl acetate/methanol) followed by prep. HPLC to give 2^-((l-isobutyiylpiperidm^-yl)ammo)pyri
dimethoxyquinazolin-4(3H one (0.095 g, 16%) as a yellow solid: lH NMR (400 MHz, CDCI3) δ 10.92 (br s, 1H), 9.61 (d, J= 6.6 Hz, 1H), 7.94 (d, J= 3.5 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 6.59 (d, J= 2.0 Hz, 1H), 6.47 (s, lH), 4.28-4.39 (m, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.88 (br s, 1H), 3.75 (br s, 1H), 3.26-3.45 (m, 2H), 2.86 (sept, 6.6 Hz, 1H), 2.14 (br s, 2H), 1.58-1.77 (m, 2H), 1.16 (d, J= 6.6 Hz, 6H); ESI MS m/z 452 [M + H]+.
92 Example 37: 2-(3-((l-Acetylpiperidiii-4-yI)amijio)pyridine-2-yl)-5,7- diinethoxyqainazoljji-4(3JN)-one
Figure imgf000094_0001
[000197] A mixture of 2^3-fluoropyridin-2-yl)-5 -^UmethoxyquiDazoUn^3H)-one (0.150 g, 0.5 mmol), l-(4-aixdnopiperidm-l-yl)ethanone (0.142 g, 1.0 mmol) and K2CO3 (0.207 g, 1.5 mmol)in DMF (5.0 mL) was heated to 110 °C with stirring for 48 h. After that time the reaction mixture was cooled to rt and concentrated under reduced pressure. The residue was dissolved in CH2CI2 (20 mL), washed with water (10 mL) then brine (10 mL), dried ( gS0 ) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 90:10 ethyl acetate methanol) to give 2-(3-((l- acetylpiperidm^-yl)ammo)pyri^ (0.020 g,
10%) as a yellow solid: 1H NMR (400 MHz, CDCl3) δ 10.90 (br s, lH), 9.59 (d, J= 7.0 Hz, 1H), 7.87-7.98 (m, 1H), 7 0-7.32 (m, 1H), 7.11 (d, J = 8.6 Hz, 1H), 6.57 (s, 1H), 6.46 (s, 1H), 4.26-4.36 (m, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.68-3.86 (m, 2H), 3.23-3.46 (m, 2H), 2.07-2.20 (m, 5H), 1.58-1.74 (m, 2H); ESI MS m/z 424 [M + H]+.
93 Example 38: N-(c«^^(2^5,7-Dimethoxy- >xo-3,4-^ihydroquinazolin-2-yI)-5- methoiypyridin-3-yl)aniino)cyclohexyI)isobutyramide
Figure imgf000095_0001
[000198] A solution of 5-bromo-2-chloro-3-fluoropyridine (8.90 g, 42.3 ramol) in anhydrous toluene (100 mL) was cooled to -78 °C. A solution of n-butyl lithium (2.5 M solution in he anes, 18.6 mL, 46.5 mmol) was added dropwise over a period of 15 min. After the addition was complete, the reaction was stirred at -78 °C for an additional 5 min. After that time trimethyl borate (5.6 mL, 50.7 mmol) was added dropwise at -78 °C over a period of 5 min. After the addition was complete, the reaction was stirred at -78 °C for an additional 15 min, then allowed to warm to rt and stirred for 16 h. The reaction mixture was cooled to 0 °C and aqueous NaOH solution (8 M, 60 mL) was added, followed by hydrogen peroxide (30 wt%, 40 mL). The mixture was stirred at rt for 2 h, then cooled to 0 °C and saturated aqueous sodium thiosulfate solution was added carefully until clear solution was obtained (about 40 mL). The resulting mixture was neutralized to pH 7 using 1 HC1 and extracted with ethyl acetate (2 x 200 mL). The combined organics were washed with water then brine, dried
(Na2S04) and concentrated under reduced pressure to give 6-chloro-5-fluoropyridin-3-ol (5.61 g, 90%) as a brown solid: 1H NMR (D SO-<¾) δ 10.79 (s, 1H), 7.86 (d, J= 2.5 Hz, 1H), 7.33 (dd, J= 10.2, 2.5 Hz, 1H).
[000199] A suspension of 6-chloro-5-fiuoropyridin-3-oi (5.50 g, 37.2 mmol), methyl iodide (4.64 mL, 74.5 mmol) and potassium carbonate (10.3 g, 74.5 mmol) in acetone (300 mL) was heated to reflux with stirring for 16 h. After that time the reaction was cooled to rt and partitioned between water and ethyl acetate. The organic phase was separated, washed with water and brine, dried over Na2SO-j, and concentrated under reduced pressure to give 2- cWoro-3-fmoro-5-memoxypyridine (5.05 g, 84%) as a brown oil: 1H NMR (CDC13) δ 7.94 (d, J = 2.7 Hz, 1H), 7.07 (dd, J= 9.4, 2.7 Hz, lH), 3.88 (s, 3H).
94 [000200] A solution of 2-cWoro-3-fluoro-5-me oxypyridine (5.05 g, 31.2 mmol) , triethylainine (13.0 mL, 93.6 mmol) and Pd(dppf)Cl2 (1.14 g, 1.56 mmol) in methanol (150 mL) was purged with carbon monoxide three times and then heated in an autoclave with stirring at 110 °C for 6 h under a carbon monoxide atmosphere (200 psi). After that time, the mixture was cooled to it, filtered through a pad of Celite and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 50:50 ethyl acetate/hexanes) to give methyl 3-fluoro-5-methoxypicolinate (4.52 g, 78%) as a white solid: Ή NMR (CDC13) δ 8.26 (d, J== 2.3 Hz, lH), 7.01 (dd, J= 11.7, 2.3 Hz, 1H), 3.99 (s, 3H), 3.94 (s, 3H); ESI MS m/z 186 [M + H]+.
[000201] A solution of 3-fluoro-5-methoxypicolinate (2.00 g, 10.8 mmol) in a mixture of anhydrous toluene (30 mL) and THF (25 mL) was cooled to -78 °C. A solution of DIBAL- H (1.0 M in toluene, 32.4 mL, 32.4 mmol) was added dropwise at -70 °C over a period of 30 min and the resulting mixture was stirred at -70 °C for 30 min. The reaction was then allowed to warm to -5 °C over a period of 2 h and stirred at -5 °C for an additional 1 h. The mixture was cooled to -70 °C and isopropanol (10 mL) was carefully added followed by water (10 mL). The mixture was stirred at rt for 16 h and filtered through a pad of Celite. The solids were washed with CH2C12 and then ethyl acetate. The combined filtrates were concentrated under reduced pressure to give (3-fluoro-5-memoxypyridm-2-yl)methanol (1.68 g, 99%) as an off-white solid: 1H NMR (CDCI3) 6 8.11 (s, 1H), 6.98 (dd, J= 10.5, 2.3 Hz, 1H), 4.76 (d, J= 5.3 Hz, 2H), 3.88 (s, 3H), 3.61 (t, J= 5.3 Hz, 1H); ESI MS m/z 158 [M + H]+.
[000202] A solution of (3-fluoro-5-methoxypvridin-2-yl)methanol (1.85 g, 11.8 mmol) and IBX (3.30 g, 11.8 mmol) in DMSO (20 mL) was stirred at rt for 2 h. After that time water (100 mL) was added and the precipitated solid was collected by filtration. The solid was washed with ethyl acetate (200 mL) and the filtrate was washed with brine, dried over Na2S04 and concentrated under reduced pressure to give 3-fluoro-5- methoxypicolinaldehyde (1.66 g, 91%) as a pale yellow solid: Ή NMR (CDC13) δ 10.12 (s, 1H), 8.32 (d, J= 1.6 Hz, 1H), 7.01 (dd, J= 11.7, 2.3 Hz, 1H), 3.97 (s, 3H).
[000203] A solution of 3-fiuoro-5-memoxypicolinaldehyde (1.57 g, 10.1 mmol), 2- ammo-4,6-dimethoxybenzamide (1.99 g, 10.1 mmol NaHSC (58.5 wt%, 2.75 g, 15.2 mmol) and -toluenesulfomc acid monohydrate (0.39 g, 2.02 mmol) in N^-dimethyl acetamimde (30 mL) was stirred at 120 °C for 16 h. After that time the reaction was cooled to rt and concentrated under reduced pressure. Water was added and the precipitated solid was collected by filtration, washed with water, then diethyl ether and dried under reduced pressure. The product was purified by flash column chromatography (silica gel, 97:3
95 dichloromethane/methanol) followed by trituration (50:50 diethyl ether/ethyl acetate, 50 mL) to give 2-(3-fluoro-5-meftoxypyridm-2-yl)-5,7 (0.51 g,
15%) as a yellow solid: 1H NMR (CDCI3) 6 10.42 (br s, 1H), 8.22 (d, J= 2.3 Hz, 1H), 7.12 (dd, J= 12.1, 2.3 Hz, 1H), 6.85 (d, J= 2.3 Hz, 1H), 6.50 (d, J= 2.3 Hz, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 3.94 (s, 3H); ESI MS m/z 332 [M + H]+.
[000204] Isobutyryl chloride (0.945 g, 8.87 mmol) was added drop wise to a vigorously stirred solution of terf-butyl (c«^armno<^clohexyl)cajrbamate (2.0 g, 9.33 mmol) and N,N-diisopropylethylarnine (2.41 g, 18.66 mmol) in anhydrous dichloromethane (20 mL) at 0 °C. After the addition was complete, the reaction mixture was allowed to warm to rt, stirred for 17 h and then diluted with ethyl acetate (300 mL). The organic phase was washed with 0.5A citric acid solution (50 mL), followed by saturated NaHCOj solution (50 mL) and brine, dried over Na2S04 and concentrated under reduced pressure to give terf-butyl (cty-4- isobutyramidocyclohexyi)cari>amate (2.5 g, 98%) as a white solid: 1H NMR (400 MHz, CDC ) δ 5.30-5.45 (m, 1H), 4.48-4.60 (m, 1H), 3.83-3.94 (m, 1H), 3.56-3.69 (m, 1H), 2.23-2.39 (m, 1H), 1.68-1.82 (m, 4H), 1.46-1.62 (m, 4H), 1.45 (s, 9H), 1.15 (d, 7= 7.0 Hz, 6H); ESI MS m/z 285 [M + H]+.
[000205] Concentrated HC1 (37%, 3.4 mL, 41 mmol) was added slowly to a stirred mixture of tert-butyl (cis^isobutyramidocyclohexyl)carbamate (2.33 g, 8.19 mmol) in methanol (50 mL) at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 17 h. After that time the reaction was concentrated under reduced pressure to give N-(cis- - ammocyclohexyl)isobutyramide hydrochloride (1.83 g, >99%) as a white solid: Ή NMR (400 MHz, DMSO-<¾) 6 8.15 (br s, 3H), 7.57 (d, J= 5.5 Hz, 1H), 3.63 (br s, 1H), 2.95-3.11 (m, 1H), 2.40-2.50 (m, lH), 1.59-1.81 (m, 6H), 1.42-1.58 (m, 2H), 0.98 (d, J- 6.6 Hz, 6H).
[000206] Lithium bis(trimethylsilyl)amide (1 M in THF, 12.1 mL, 12.1 mmol) was added to a stirred suspension of 2-(3-fluoro-5 -methoxypyridin-2-yl)-5 ,7- dimethoxyquinazolin-4(3H)- ne (0.402 g, 1.21 mmol) and N-{«s-4- amlnocyclohexyl)isobutyramide hydrochloride (0.803 g, 3.64 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 5 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (10 mL) and concentrated under reduced pressure. The residue was diluted with water (50 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/ methanol to 97:3 dichloromethane
96 methanol) to give N-(cis-4-((2-(5 J-^imethoxy-4^xo ,4^mydroquinazolin-2-^^ methoxypyridm -yl)anuOo)cycloh^ (0.160 g, 27%) as a yellow solid: mp
285°C dec.; Ή NMR (400 MHz, DMSO-ifc) δ 10.56 (s, lH), 9.72 (d, J= 7.4 Hz, 1H), 7.74 (d, J = 7.4 Hz, 1H), 7.64 (d, J= 1.95 Hz, 1H), 6,72 (d, J= 1.6 Hz, 1H), 6.66 (d, J= 1.95 Hz, 1H), 6.55 (d, J= 1.6 Hz, 1H), 3.89 (s, 6H), 3.78-3.86 (m, 4H), 3.62-3.74 (m, 1H), 2,28-2.42 (m, 1H), 1.83-1.93 (m, 2H), 1.71-1.81 (m, 4H), 1.51-1.66 (m, 2H), 0.97 (d, J= 6.6 Hz, 6H); ESI MS w z494 [M - HJ-.
Example 39: 2^2 (l-Acetylpiperidin-4-yl)ainino)-4-inethoxyphenyI)-5,7- dimethoxyqumazolin-4(5/i)-one
Figure imgf000098_0001
[000207] A mixture of 2-(2-((l-benz lpiperidiJn-4-yl)amino)-4-nΊethoxyphenyI)-5,7- dimethoxyq^JiIlazolin-4(3H)-one (3.9 g, mmol) and Pd/C (6 g, 10% Pd, wet) in THF (25 mL) and ethanol (25 mL) was hydrogenated at rt under hydrogen pressure (50 psi) for 18 h. After that time, the mixture was filtered through celite and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/ methanol to 90:10 dichloromethane/ methanol) to give 5,7-diinethoxy-2-(4-methoxy-2- (pipOTdm^ylanuno)pheny^ (0.55 g, 17%): 1H NMR (400 MHz,
DMSO-<4) δ 9.57 (br s, 1H), 7.83 (d, J= 9.0 Hz, 1H), 6.52 (d, J = 9.0 Hz, 2H), 6.16-6.25 (m, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.52-3.64 (m, 1H), 3.40-3.45 (m, 1H), 2.91- 3.00 (m, 2H), 2.61-2.71 (m, 2H), 1.89-2.00 (m, 2H), 1.35-1.49 (m, 2H).
[000208] Acetic anhydride (0.0248 g) was added at 0 °C to a solution of 5,7- dimemoxy-2-(4-meAoxy-2-fcipe^ (0,100 g, 0.24 mmol) and triemylarnine (0.243 g, 2.4 mmol) in dichloromethane (25 mL). The reactrion was allowed to warm to rt and then stirred for 30 min. After that time the reaction was
concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/ methanol to 90:10 dichloromethane/
97 methanol) to give 2^2-((l-ac«tylpipeiidin^yl)mmo)^me1hoxyphenyl)-5,7- diraethoxyquinazolin-4(3H)-one (0.10 g, 92%) as white solid: 1H N R (400 MHz, DMSO- <¾) δ 11.51 (s, 1H), 9.50 (d, J= 7.4 Hz, 1H), 7.83 (d, J= 8.6 Hz, 1H), 6.47-^.56 (ra, 2H), 6.30 (s, 1H), 6.18-6.26 (m, 1H), 3.94-4.06 (m, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.65-3.77 (m, 2H), 3.37-3.45 (m, 1H), 3.09-3.21 (m, 1H), 2.02 (s, 3H), 1.93-1.99 (m, 2H), 1.34-1.47 (m, 1H), 1.48-1.62 (m, 1H); ESI MS mlz 453 [M + H]+.
Example 40: 5 -Dimethoxy-2-(5-methoxy-3-((l-methy^
yl)quinazolin-4(3J9)-one
Figure imgf000099_0001
[000209] Lithium bis(trimethylsi)yl)amide (1 M in THF, 6.0 mL, 6.0 m ol) was added to a stirred suspension of 2-(3-iluoro-5-methoxypyridin-2-yl)-5,7- d¾iemoxyquinazo -4(3/- ^ne (0.331 g, 1.0 mmol) and 1 -methylpiperidin-4-amine (0.343 g, 3.0 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 5 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (10 mL) and concentrated under reduced pressure. The residue was diluted with water (40 mL) and the resulting suspension was stirred at rt for 20 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/7N ammonia in methanol to 98:2 dichloromethane /7N ammonia in methanol) followed by trituration with methanol to give 5,7-dimeihoxy-2-(5-meAoxy-3-((l-m
yl)quinazolin-4(3H)-one (0.080 g, 19%) as an off-white solid: mp 191-193°C; Ή NMR (400 MHz, DMSO-<4) δ 10.55 (s, 1H), 9.55 (d, J= 7.0 Hz, 1H), 7.65 (d, 7= 2.3 Hz, 1 H), 6.76 (d, J = 2.3 Hz, 1H), 6.66 (d, J= 2.15 Hz, 1H), 6.55 (d, J= 2.15 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.85 (s, 3H), 3.67-3.77 (m, 1H), 2.55-2.64 (m, 2H), 2.28-2.38 (m, 2H), 2.22 (s, 3H), 1.93- 2.03 (m, 2H), 1.59-1.69 (m, 2H); ESI MS m/z 426 [M + H]+.
98 Example 41: 5 -Dimethoxy-2^3^((l-methylpyirolidin-3-yl)methyl)amino)pyri yl)quinazolin-4(3/-')-one
Figure imgf000100_0001
[000210] Lithium bis(trimemylsilyl)amide (1 M in THF, 5.6 mL, 5.6 mmol) was added to a stirred suspension of 2^3-fluoropyridm-2-yl)-57- imethoxyquin
(0.420 g, 1.39 mmol) and (l-methylpynOUdin-3-yl)methariam (0.478 g, 4.18 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 3 h. After that time the reaction was cooled to it, diluted with saturated aqueous N¾C1 (5 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane 7N ammonia in methanol to 97:3 dichloromemane /7N ammonia in methanol) to give 5,7-«limethoxy-2-(3-(((l- methylpyrrolidin-3-yl)me^yl)amino)^ (0.160 g, 29%) as a yellow solid: mp 157-159 °C; 1H NMR (400 MHz, CDCI3) δ 10.90 (br s, lH), 9.43 (br s, lH), 7.89-7.93 (m, 1H), 7.22-7.29 (m, 1H), 7.10 (d, J= 7.8 Hz, 1H), 6.65 (d, J = 1.95 Hz, 1H), 6.46 (d, J= 1.95 Hz, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.25-3.30 (m, 2H), 2.76-2.83 (m, 1H), 2.54-2.75 (m, 3H), 2.49 (dd, J= 8.8, 5.3 Hz, 1H), 2.39 (s, 3H), 2.12-2,23 (m, 1H), 1.65-1.75 (m, 1H); ESI MS m/z 396 [M + H]+.
99 Example 42: 4-((2-(5,7-Dimethoxy-4^xo-3,4-dihydroquinazolin-2-yI)pyridin-3- yl)amino)-N^^ijmethylpiperidine-l-carboxaniide
Figure imgf000101_0001
[000211] Lithium bis(trimethylsilyl)amide (1 M in THF, 3.5 mL, 3.5 mrao ) was added to a stirred suspension of 2-{3-fluoropyridijn-2-yl)-5,7-diraethoxyqiiinazolin-4(3H)-one (0.352 g, 1.17 mmol) and 4-amino-^,N^imethylpiperidine-l-carix>x (0.500 g, 2.92 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 6 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH CI (5 mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and the resulting suspension was stirred at rt for 30 rnin. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichlororaethane/methanol to 97:3 dichloromethane/methanol) to give 4-((2-(5,7-dimemoxy-4^xo-3,4-dihydroqumazolin- 2-yl)pyridm-3-yl)anmio)--V,N-dimemylpiperi (0.180 g, 34%) as a yellow solid: mp 195-197 °C; Ή NMR (400 MHz, CDC13) δ 10.91 (br s, lH), 9.59 (d, J= 7.4 Hz, 1H), 7.90-7.94 (m, 1H), 7.24-7.27 (m, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.65 (d, J= 2.15 Hz, 1H), 6.46 (d, J= 2.15 Hz, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.61-3.71 (m, 3H), 3.09-3.18 (m, 2H), 2.86 (s, 6Ή), 2.08-2.17 (m, 2H), 1.65-1.76 (m, 2H); ESI MS m/z 453 [M + H]+. Example 43: 2^3^(3^Isopropylamino)propy amino)pyridin-2-yl)-5,7- dimethoxyquinazolin-4(3H)-one
Figure imgf000102_0001
[000212] Lithium bis(trimethylsilyl)amide (1 M in THF, 3.6 mL, 3.6 mmol) was added to a stirred suspension of 2-{3-fluoropyridin-2-y])-5,7-dimethoxyquina2X)lin-4(3H)-one (0.361 g, 1.20 mmol) and JV1 -isopropylpropane- 1 ,3 -diamine (0.50 mL, 3.60 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 2 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 12 mL, 1.2 mmol) was added and reflux with stirring was continued for an additional 2 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH CI (3 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 97:3 dichloromethane methanol then 97:3
di chloromethane/7N ammonia in methanol) to give 2-(3-((3-
(isopropylarnmo)propyl)ammo)pyridm-2-yl)-5,7-diraem (0.229 g,
48%) as a yellow solid: mp 121-122 °C; 1H NMR (400 MHz, CDC13) δ 9.32 (t, J = 4.7 Hz, 1H), 7.90 (d, J= 3.1 Hz, 1H), 7.21-7.27 (m, 1H), 7.12 (d, J= 8.6 Hz, 1H), 6.65 (d, J= 2.3 Hz, lH), 6.45 (d, J= 2.3 Hz, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.33-3.42 (m, 2H), 2.78-2.88 (m, 3H), 1.92-2.00 (m, 2H), 1.07 (d, J= 6.25 Hz, 6H); ESI MS m/z 398 [M + H]+.
Example 44: 5,7-Dimethoxy-2^3^(l-methylpiperidin-^yl)amino)pyridine-2- yl)qumazolm-^3/i)-one
Figure imgf000103_0001
[000213] Lithium bis(trimeraylsUyl)amide (1 M in THF, 4.0 mL, 4.0 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5 -^iimethoxyquina-Mljn^Si-^ne (0.350 g, 1.16 mmol) and 1 -methylpiperidine-4-amine (0.400 g, 3.5 mmol) in anhydrous THF (15 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(t½iethylsilyl)amide (1 M in THF, 3.0 mL, 3.0 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (3 mL) and concentrated under reduced pressure. The product was purified by flash column
chromatography (silica gel, 97:3 dichloromethane/methanol then 97:3 dichloromethane/7N ammonia in methanol) to give 5,7-Klimethoxy-2-(3-((l -methy 1 pi peridin-4-yl)amino)pyricline- 2-yl)quinazoUn-4(3i -one (0.100 g, 22%) as a yellow solid: mp 186-188 °C; 1H MR
(CDCI3) δ 10.91 (br s, 1H), 9.55 (d, J= 7.4 Hz, lH), 7.89 (d, J= 4.3 Hz, IH), 7.19-727 (m, lH), 7.11 (d, J= 8.2 Hz, IH), 6.65 (s, IH), 6.46 (s, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.53 (br s, 1H), 2.83 (br s, 2H), 2.36 (s, 3H), 2.31 (br s, 2H), 2.08-2.18 (m, 2H), 1.70-1.82 (m, 2H); ESI MS /«/z 396 [M + H]+.
Example 45: c&4^(2^5,7-Dimedio:xy^
metfaoxypyridin-3-yI)amino)-N-isopropylcyclohexane-l-carboxainide
Figure imgf000104_0001
[000214] l-Ethyl-3^3-dimethylaminopropyl)carbodiiniide (2.10 g, 11.0 mraol) was added to a solution of cw^[(fe^butoxycarbonyl)a acid (2.43 g,
10 mmol) and hydroxybenzotriazole (1.44 g, 11.0 mmol) in DMF (30 mL) and the reaction was stirred at rt for 20 min. After that time, isopropylamine (4.2 mL, 50 mmol) was added and the reaction mixture was stirred at rt for 18 h. After that time the reaction was concentrated under reduced pressure and the residue dissolved in CHCI3 (80 mL). The organic phase was washed with aqueous saturated NaHC03 (2 * 40 mL) then brine (2 * 40 mL), dried ( a2S04) and concentrated under reduced pressure to give terf-butyl-cts- (4- (isopropylcarbamoyl)cyclohexyl)carbamate (1.9 g, 67%) as an off-white solid: Ή NMR (400 MHz, CDCI3) 5 5.29 (br s, lH), 4.76 (br s, 1H), 4.08 (dq, J= 13.9, 6.7 Hz, 1H), 3.75 (br s, IH), 2.04-2.14 (m, 1H), 1.72-1.81 (m, 2H), 1.65-1.72 (m, 4H), 1.54-1.65 (m, 2H), 1.44 (s, 9H), 1.14 (d, J= 6.3 Hz, 6H).
[000215] Cone. HC1 (4,0 mL, 40 mmol) was added to a solution of tert-buty\-cis- (4- (isopropylcarbamoyl)cyclohexyl)carbamate (1.9 g, 6.7 mmol) in methanol (30 mL) and the reaction was stirred at rt for 18 h. After that time the reaction was concentrated under reduced pressure to give cis-4-amino-N-isopropylcyclohexane- 1 -carboxamide hydrochloride (1.4 g, 95%) as an off-white solid: Ή NMR (400 MHz, DMSO-ifc) δ 8.10 (br s, 3H), 7.62 (d, J= 7.8 Hz, 1H), 3.80 (dq,J = 13.6, 6.7 Hz, lH), 3.09 (br s, 1H), 2.11-2.27 (m, 1H), 1.78-1.92 (m, 2H), 1.58-1.77 (m, 4H), 1.40-1.52 (m, 2H), 1.01 (d, J= 6.6 Hz, 6H); ESI MS m/z 185 [M + H]+.
[000216] Lithium bis(trimemylsilyl)amide (1 M in THF, 6.0 mL, 6.0 mmol) was added to a stirred suspension of 2-(3-fluoro-5-methoxypyridin-2-yl)-5,7- dimethoxyquinazolin-4(3H)-one (0.400 g, 1.2 mmol) and cw-4-amino-N- isopropylcyclohexanecarboxamide hydrochloride (1.10 g, 5.0 mmol) in anhydrous THF (IS mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimemylsilyl)amide (1 M in THF, 3.3 mL, 3.3 mmol) was added and reflux with stirring was continued for an additional 5 h. After mat time the reaction was cooled to rt, diluted with saturated aqueous NH CI (3 mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 97:3 dichlorornethane/methanol) then triturated with methanol to give cis-4-((2-(5 - dimethoxy-4-oxo-3, -dihydroquinazolin-2-yl)-5-methoxypyr^
isopropylcyclohexane-l-carrx>xamide (0.025 g, 4%) as a light yellow solid: *H NMR (400 MHz, CDCI3) 6 10.72 (br s, 1H), 9.82 (d, J= 7.8 Hz, 1H), 7.63 (s, lH), 6.89 (s, 1H), 6.49 (s, IH), 6.42 (s, 1H), 5.22 (d, J= 7.0 Hz, 1H), 3.99-4.12 (m, 1H), 3.96 (s, 6H), 3.90 (s, 3H), 3.84 (br s, 1H), 3.49 (d, J= 5.8 Hz, 1H), 2.14-2.24 (m, IH), 1.92-2.09 (m, 4H), 1.81-1.91 (m, 2H), 1.64-1.78 (m, 2H), 1.08 (d, J = 6.6 Hz, 6H); ESI MS m/z 496 [M + H]+.
Example 46: 5,7-Dimethoxy-2-(3^(l-(2^,2-tiifluoroaceryl)pip€ridin-4- yt)ammo)pyridm-2-yl)qumazotin-4(5J?)-one
Figure imgf000105_0001
[000217] A suspension of 2-(3 -fluoropyridin-2-yl)-5 ,7-dimethoxyquinazo lin-4(3H)- one (1.0 g, 3.3 mmol), 1 -benzyl piperidin-4-amine (1.25 g, 6.6 mmol), lithium
bis(trimethylsilyl)amide (13.2 mL, 13.2 mmol,) and THF (25 mL) was heated at 70 °C in a sealed tube for 3 h. After this time, the reaction was cooled to rt, quenched with cold water (100 mL) and concentrated under reduced pressure. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dichloromethane methanol) to give 2- (3^(l-benzylpiperidin-4-yl)ammo)pyridm (0.92 g,
60%) as a yellow solid: 1H NMR (400 MHz, DMSO-i^) 6 10.80 (d, J= 1.6 Hz, IH), 9.34- 9.47 (m, 1H), 7.93 (d, J= 1.95 Hz, lH), 7.37-7.43 (m, 2H), 7.29-7.37 (m, 4H), 7.21-7.28 (m, 1H), 6.73 (s, 1H), 6.61 (s, 1H), 3.94 (s, 3H), 3.87 (s, 3H), 3.59-3.73 (m, 1H), 3.51 (s, 2H), 2.61-2.77 (m, 2H), 2.26-2.40 (m, 2H), 1.88-2.08 (m, 2H), 1.56-1.72 (m, 2H); ESI MS m/z 472 [M + H]+.
[000218] A mixture of 2-(3-((l -benzylpipericun^yl)amino^^^
dimeuioxyquinazolin-4(3//)-one (0.7 g, 1.5 mmol) and Pd/C (2.1 g, 10% Pd, wet) in THF (20 raL) and ethanol (10 mL) was hydrogenated at rt under hydrogen pressure (50 psi) for 18 h. After that time, the mixture was filtered through celite and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel,
dichloromethane to 70:30 dichloromethane/methanol) to give 5 -dimethoxy-2^3^iperidin- 4-ylammo)pyria¾-2-yl)quina2»lin^3 )-one (0.20 g, 35%) as a yellow solid: ¾ NMR (400 MHz, DMSO-<¼) δ 9.43 (d, J= 7.4 Hz, 1H), 7.92 (s, 1H), 7.38 (s, 2H), 6.66 (s, 1H), 6.60 (s, lH), 3.93 (s, 3H), 3.87 (s, 3H), 3.58-3.73 (m, 1H), 3.14-3.26 (m, 1H), 2.90-3.06 (m, 2H), 2.59-2.76 (m, 2H), 1.88-2.06 (m, 2H), 1.39-1.58 (m, 2H); ESI MS m/z 382.1 [M + H]+.
[000219] Trifluoroacetic anhydride (0.032 g, O.lSmmol was added to a solution of 5,7- iimeAoxy-2-(3^iperidin^ (0.070 g, 0.18 mmol) and triethylamine (0.182 g, 1.8 mmol) in THF (15 mL) at 0°C. The resulting mixture was allowed to warm to rt and stirred for 30 min. After that time the mixture was
concentrated under reduced pressure. The product was purified by flash column
chromatography (silica gel, dichloromethane to 70:30 dichloromethane/methanol) to give 5,7- iimethoxy-2-(3-((l-(2,2,2-trifluoroacety^
4(3H>one (0.032 g, 39%) as a light yellow solid: mp 218-219 °C; 1H NMR (400 MHz, DMS s) 8 10.79 (br s, lH), 9.40 (d, J= 7.4 Hz, 1H), 7.94 (d, J = 3.5 Hz, 1H), 7.33-7.54 (m, 2H), 6.70 (s, 1H), 6.57 (s, 1H), 4.04-4.20 (m, 1H), 3.89 (s, 3H), 3.77-3.87 (m, 3H), 3.44- 3.57 (m, 2H), 3.08-3.25 (m, 2H), 2.03-2.19 (m, 2H), 1.54-1.75 (m, 2H); ESI MS m/z 478 [M + H]+, Example 47: 4^(2^5,7-Dimethoxy- H>xo-3,4^ihydn>quinazolin-2-yI)pyridin-2^ yl)amino)-N-isopropylpiperidijie-l-carboxamide
Figure imgf000107_0001
[000220] 2-Isocyan atopro pan e (0.016 g, 0.18 mmol) was added to a solution of 5,7- dimemoxy-2^3^iperidin^ylam^ (0.070 g, 0.18 mmol) and triethylamine (0.182 g, 1.8 mmol) in THF (15 mL) at 0°C. The resulting mixture was allowed to warm to rt and stirred for 30 min. After that time the mixture was
concentrated under reduced pressure. The product was purified by flash column
chromatography (silica gel, dichloromethane to 70:30 dichloromethane/methanol) to give 4- ((2-(5,7-dimethoxy-4-oxo-3,4-dihydroquina^^
isopropylpiperidme-l-carboxamide (0.060 g, 71%) as a light yellow solid: mp 198-199 °C; 1H NMR (400 MHz, DMSO-<¾) δ 10.77 (br s, lH), 9.39 (d, J= 8.2 Hz, 1H), 7.92 (d, J= 2.7 Hz, 1H), 7.32-7.50 (m, 2H), 6.64 (s, 1H), 6.57 (s, 1H), 6.21 (d, J= 7.4 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.69-3.80 (m, 4H), 3.00-3.14 (m, 2H), 1.88-2.00 (m, 2H), 1.38-1.55 (m, 2H), 1.03 (d, J = 6.3 Hz, 6H); ESI MS mlz 467 { + H .
Example 48: 5,7-Dimethoxy-2^3^(l-pivaloylpiperidin^yl)amino)pyridin-2- yI)quinazolin-4(3H)-one
Figure imgf000108_0001
o
[000221] Pivaloyl chloride (0.016 g, 0.13mraol) was added to a solution of 5,7- dime1hoxy-2-(3-{piperidin-4-ylainin^^ (0.050 g, 0.13 mmol) and triethylamine (0.131 g, 1.3 mmol) in THF (15 mL) at 0 °C. The reaction was allowed to warm to rt and stirred for 30 min. After that time the mixture was concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dichloromethane methanol) to give 5,7-dimethoxy-2-(3-((l- pivaloylpiperidm^-yl)animo)pyridm-2-yl)quina^ (0.044 g, 72%) as a yellow solid: mp 209-210 °C; Ή MR (400 MHz, DMSC s) δ 10.77 (br s, 1H), 9.43 (d, J= 7.4 Hz, 1H), 7.92 (d, J= 1.6 Hz, 1H), 7.35-7.48 (m, 2H), 6.64 (s, 1H), 6.57 (s, 1H), 3.95-4.07 (m, 2H), 3.88 (s, 3H), 3.84-3.87 (m, lH), 3.84 (s, 3H), 3.24-3.27 (m, 2H), 1.93-2.07 (m, 2H), 1.43-1.56 (m, 2H), 1.19 (s, 9H); ESI MS mlz 466 [M + H]+.
Example 49: 5 -Dimethoxy-2^3^(2-morpholino€thyI)amino)pyridine-2-yl)quinazolin- 4(3HH>ne
Figure imgf000109_0001
[000222] Lithium bis(trimethylsilyl)amide (1 M in THF, 5.0 mL, 5.0 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5,7-dimethoxyquinazolin-4(3/ )-one (0.400 g, 1.33 mmol) and 2 moφhol ^yl)ethanamine (0.520 g, 4.0 mmol) in anhydrous THF ( 5 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 3.0 mL, 3.0 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (3 mL) and concentrated under reduced pressure. The product was purified by flash column
chromatography (silica gel, 97:3 dichloromethane methanol) followed by recrystalization from chloroformhexanes to give 5,7-dimethoxy-2~(3~((2-moTpholinoet yl^
yl)quitiazolin-4(3H)-one (0.110 g, 20%) as a yellow solid: mp 168-170 °C; ¾ NMR (CDCI3) δ 10.91 (br s, lH), 9.38 (br s, lH), 7.93 (d, J= 3.5 Hz, 1H), 7.29 (br s, 1H), 7.10 (d, J= 8 Hz, 1H), 6.75 (s, lH), 6.44-6.51 (m, 1H), 4.00 (s, 3H), 3.93 (s, 3H), 3.74-3.80 (m, 4H), 3.40 (q, J= 5.6 Hz, 2H), 2.80 (t, J= 6.0 Hz, 2H), 2.59 (br s, 4H); ESI MS m/z 412 [M + H]+.
Example 50: 2^3 (l-IsopiOpylpiperidm^yI)ammo)-5 (l^op o yl iperidm^ yl)aniino)ethoxy)pyridta-2-yl)-5,7-dimethoxyqum
Figure imgf000110_0001
[000223] ButyUithium (1.6 M in hexanes, 82 mL, 130 mntol) was added dropwise to a suspension of 3 -bromo-6-chloro-5-fl uoropyridine (25.0 g, 119 mmol) in anhydrous toluene (280 mL) cooled to -78 °C. After the addition was complete the reaction was stirred for 10 min. After that time, trimethyl borate (14.82 g, 1 3 mmol) was added dropwise while maintaining the temperature at -78 °C. After the addition was complete, the reaction was allowed to warm to rt and stirring was continued for 17 h. After that time the reaction was re- cooled to -5 °C and carefully treated with 8JVNaOH solution (18 mL) followed by 30% hydrogen peroxide (37.6 g, 1105 mmol). The reaction was warmed to rt and stirred an additional 2 h. After that time the reaction was re-cooled to 10 °C and carefully quenched with sat Na2S203 (60 mL). The organic phase was reserved. The aqueous phase was extracted with ethyl acetate (3 * 150 mL). The combined organics were washed with sat NaCl (200 mL), dried (MgSC ), filtered and concentrated under reduced pressure. This product was triturated with hexanes (3 x 100 mL) and dried to give 6-chloro-5-fluoropyridin- 3-ol (14.2 g, 80%) as a white solid: 1H NMR (400 MHz, DMSO-<fc) 6 10.78 (br s, lH), 7.86 (d, J= 2.4 Hz, 1H), 7.32 (dd, J= 10.4, 2.4 Hz, 1H).
[000224] A suspension of K2CO3 (19.8 g, 143 mmol), 6-chloro-5-fluoropyridin-3-ol (14.1 g, 95 mmol) and 2-/er/-butyldimethylsilyloxyethyl bromide (25.1 g, 105 mmol) in anhydrous DMF (120 mL) was stirred at rt for 65 h. After that time the reaction mixture was diluted with ethyl acetate (200 mL), washed with water (4 * 100 mL), dried (MgS<¼) and concentrated under reduced pressure to give 5-(2-((/^/-butyldimethylsilyl)oxy)ethoxy)-2- chloro-3-fluoropyridine (26.3 g, 90%) as a yellow solid: Ή NMR (400 MHz, CDC13) δ 7.94 (<L J= 2.6 Hz, 1H), 7.11 (dd, J= 9.5, 2.6 Hz, 1H), 4.10 (t J= 4.8 Hz, 2H), 3.98 (t J= 4.8 Hz, 2H), 0.90 (s, 9H), 0.09 (s, 6H). [000225] A mixture of 5-[2-(tm-butyldimethylsilyloxy)ethoxy]-2-chloro-3- fluoropyridine (11.6 g, 38 mmol), Pd(dppf)Cl2 (1.39 g, 1.9 mmol) and triethylamine (11.5 g, 114 mmol) in methanol (200 mL) was placed under a CO atmosphere (200 psi) and heated with stirring at 90 °C for 4h. After that time the reaciton was cooled to rt, filtered through a pad of celite and concentrated under reduced pressure. The product was suspended in diethyl ether (600 mL), filtered through a pad of silica gel and concentrated under reduced pressure to give methyl 5^2-((ter^butyldimemylsilyl^ (11.6 g, 94%) as a white solid: 1H NMR (400 MHz, CDC13) δ 8.26 (d, J= 2.4 Hz, 1H), 7.07 (dd, J= 11.7, 2.4 Hz, 1H), 4.17 (t, J =4.4 Hz, 2H), 4.00 (t, .7=4.4 Hz, 2H), 3.99 (s, 3H), 0.89 (s, 9H), 0.09 (s, 6H).
[000226] Sodium borohydride (7.S7 g, 200 mmol) was added portionwise to a suspension of methyl 5-[2^/^butyldimemykttyloxy)em^^ (16.47 g,
50 mmol) in ethanol (135 mL) cooled to 10 °C and stirred for 15 h. After that time the reaction was concentrated under reduced pressure and dissolved in ethyl acetate (300 mL). The solution was washed with water (2 * 100 mL), sat NaHC<¼ (100 mL) and sat. NaCl (100 mL), dried (MgS04) and concentrated under reduced pressure to give (5-(2-((ter/- butyldimemylsilyl)oxy)emoxy)-3-f^^^ (14.91 g, 98%) as a white solid: lH NMR (400 MHz, CDC13) 5 8.12 (d, J= 2.4 Hz, 1H), 7.02 (dd, 7= 11.2, 2.4 Hz, 1H), 4.77-4.75 (m, 2H), 4.10 (t, .7=4.8 Hz, 2H), 3.98 (t, J=4.8 Hz, 2H), 3.57 (t, J= 4.8 Hz, 2H), 0.90 (s, 9H), 0.10 (s, 6H).
[000227] 2-Iodoxybenzoic acid ( 18.0 g, 64 mmol) was added in one portion to a solution of (5-(2-((re^butyldimethylsUyl^^ (14.91 g, 50 mmol) in DMSO (82 mL) and stirred at rt for 18 h. After that time the reaction was diluted with water (500 mL). The precipitated solids were collected by filtration and washed with water (2 * 200 mL) and air-dried The solids were triturated with diethyl ether (3 x 200 mL) to remove the product. The combined ether extracts were washed with sat. NaHCCh (100 mL), sat. NaCl (100 mL), dried (MgS04) and concentrated under reduced pressure to give 5-(2-(ie^butyldimemylsilylox (11.36 g, 77%) as a white crystaline solid: 1H NMR (400 MHz, CDC13) δ 10.12 (s, 1H), 8.32 (d, J= 2.4 Hz, 1H), 7.07 (dd, J= 11.8, 2.4 Hz, 1H), 4.20 (t, J= 5.2 Hz, 2H), 4.02 (t, J= 5.2 Hz, 2H), 0.90 (s, 9H), 0.09 (s, 6H).
[000228] A suspension of 2-amino-4,6 limethoxybenzamide (7.37 g, 37.9 mmol) and 5-(2-(fe^butyldimethylsilyloxy)e^ (11.36 g, 38 mmol) in nitrobenzene (77 mL) was heated to 137 °C with stirring for 24 h. After mat time, the reaction was cooled to it and diluted with hexanes (600 mL). The dark tar-like precipitate was separated and purified by flash column chromatography (silica gel, 85:15 dichloromethane/ ethyl acetate) to give 2-[5-(2-ftm-butyldimethylsilyloxy) ethoxy)-3-fluoropyridin-2-yl)-5,7- dimemoxyquiriazolm-4(3H)-one (4.26 g, 24%) as a yellow solid: Ή NMR (400 MHz, CDC13) 5 10.43 (s, lH), 8.22 (d, J = 2.4 Hz, lH), 7.17 (dd,J= 12.4, 2.4 Hz, 1H), 6.85 (d,J= 2.4 Hz, 1H), 6.49 (d, 7= 2.4 Hz, 1H), 4.20 (t, J= 4,8 Hz, 2H), 4.02 (t, J= 4.8 Hz, 2H), 3.99 (s, 3H), 3.94 (s, 3H), 0.91 (s, 9H), 0.11 (s, 6H).
[000229] Triethylamine trihydrofluoride (4.33 g, 26.9 mmol) was added in one portion to a suspension of 2-[5-(2-(te^butyldimemy^
dimethoxyquinazolin-4(3 H)-one (4.26 g, 8.96 mmol) in anhydrous THF (85 mL) and stirred at it for 14 h. After that time the reaction was concentrated under reduced pressure and the solid was treated with saturated aqueous solution of NaHC03 (100 mL). The precipitated solids were collected by filtration and washed with water (3 x 100 mL), diethyl ether (3 * 100 mL) and dried to give 2-3-fluoro-5-(2-hydroxyet oxy)pyridin-2-yl)-5,7- dimethoxyquinazoIin-4(3 H)-one (3.15 g, 97%) as a yellow solid: Ή NMR (400 MHz,
DMSO-40 δ 11.37 (s, 1H), 8.29 (s, 1H), 7.63 (d, J= 11.5 Hz, 1H), 6.70 (s, 1H), 6.56 (s, 1H), 4.99 (t, J= 4.6 Hz, 1H), 4.18 (t, J= 4.6 Hz, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.74 (q, J= 4.6 Hz, 2H).
[000230] Phosphorus tribromide (4.72 g, 17.4 mmol) was added in one portion to a suspension of 2-(3-fluoro-5-(2-hydroxye&oxy)py^
one (3.15 g, 8.7 mmol) in anhydrous DMF (66 mL) and heated at 60 °C with stirring for 1 h. After that time the reaction was cooled to rt and concentrated under reduced pressure. The solids were dissolved in chloroform (130 mL) and the solution was washed with sat. NaHCC^ (220 mL), dried (MgS04) and concentrated under reduced pressure. The product was triturated with diethyl ether (3 * 30 mL) and dried to give 2-(3-fluoro-5-(2- brojmoethoxy)pyri din-2-yl)-5 ,7-dimethoxyquinazolin-4(3H)-one (3.41 g, 92%) as a yellow solid: 1H NMR (400 MHz, CDC13) δ 10.40 (s, 1H), 8.24 (d, J= 2.4 Hz, lH), 7.15 (dd, J= 12.4, 2.4 Hz, 1 H), 6.86 (d, J= 2.4 Hz, 1H), 6.50 (d, J= 2.4 Hz, 1H), 4.44 (t, J= 5.6 Hz, 2H), 3.99 (s, 3H), 3.94 (s, 3H), 3.71 (t, J= 5.6 Hz, 2H).
[000231] l-Isopropyl-4-aminopiperidine (0.711 g, 5 mmol) was added in one portion to a suspension of 2-(3-fluoro-5-(2^romc>emoxy)pyridm-2-yl 5,7^imetho
4(3H)-one (0.212 g, 0.5 mmol) in anhydrous DMSO (2 mL) and heated at 80 °C with stirring for 17 h. After that time the reaction was cooled to rt, diluted with chloroform (15 mL), washed with sat. NaHC03 (20 mL), water (2 x 15 mL), dried (MgS04) and concentrated under reduced pressure. The product was triturated (diethyl ether, 3 x 5 mL) and dried to give 2^3^(1 -isorflopylpiperidin^yl)am^
yl)amino)e&oxy)pyridm-2-yl)-5,7^ (0.252 g, 83%) as a yellow solid: Ή N R (400 MHz, CDC13) δ 9.57 (d, J= 7.2 Hz, 1H), 7.62 (d, J= 2.0 Hz, IH), 6.60 (d, J= 2.0 Hz, 1H), 6.50 (d, 7= 2.0 Hz, 1H), 6.41 (d, J= 2.0 Hz, 1H), 4.16 (t, J= 4.8 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.44 (br s,lH), 3.07 (t, J= 4.8 Hz, 2H), 2.91-2.70 (m, 6H), 2.54-2.40 (m, 3H), 2.21-2.13 (m, 4H), 1.96-1.93 (m, 2H), 1.78-1.74 (m, 3H), 1.45- 1.37 (m, 2H), 1.10 (d, J= 6.4 Hz, 6H), 1.04 (d, J= 6.4 Hz, 6H); ESI MS m/z 608 [M + H]+.
Example 51: 2^4^(2-(5,7-Dimethoxy^oxo-3,4-dihydr«quina¾olin-2-yl)pyridin-3- yl)amino)piperidiA-l- l)- ,AΓHlimethyl·2^xoacetamide
Figure imgf000113_0001
[000232] N,N'-dicyclohexylcarbcKiiiiiiide (0.081 g, 0.39 mmol) was added at room temperature to a solution of 2-(dimethylamino 2-oxoacetic acid (0.046 g, 0.39 mmol) in DMF (15 mL), followed by 1 -hydroxy- 1 H-benzo†riazole (0.053 g, 0.39 mmol). The reaction was stirred for 1 h and then 5,7<limeraoxy-2^3^piperidm^y
yl)quinazolin-4(3 /)-one (0.050 g, 0.13 mmol) was added. The reaction was then stirred at rt for 16 h, concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dichloromethane/methanol) to give 2- (4^(2^5>7 hmemoxy^-oxo-3,4-o^ydrc umazolin-2-yl)p^
N.V-^imethyl^-oxoacetamide (0,015 g, 24%) as yellow solid: mp 261-262 °C; Ή NMR (400 MHz, DMSO- ) δ 10.78 (br s, 1H), 9.41 (d, J= 7.4 Hz, 1H), 7.95 (br s, 1H), 7.37-7.49 (m, 2H), 6.67 (s, 1H), 6.59 (s, 1H), 4.04-4.14 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.43-3.52 (m, 2H), 3.15-3.24 (m, 2H), 2.91 (s, 3H), 2.86 (s, 3H), 2.00-2.12 (m, 2H), 1.48-1.65 (m, 2H); ESI MS m/z 479 [M - H]'. Example 52: 4^(2^5,7-dimethoxy-4M)xo-3,4^ihydn)quma2olin-2-yl)pyridin-3- y^amino^A'-etfaylpiperidiiie-l-car oxaniide
Figure imgf000114_0001
[000233] Ethyl isocyanate (0.016 g, 0.18 mmol) was added to an ice-cold solution of 5,7-dimetoox -2^3^ ipOTdin^ylamm^ (0.070 g, 0.18 mmol) and triethylamine (0.182 g, 1.8 mmol) in THF (IS mL). The reaction was allowed to warm to rt and stirred for 30 min. After that time the reaction was concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dicUoromethane/methanol) to give 4-((2-(5 -dimethoxy-4-oxo- 3,4KlmydiOquinazoUn-2-yl)pyri (0.060 g,
78%) as yellow solid: mp 151-152 °C; *H NMR (400 MHz, DMSO-<¼) 6 10.80 (br s, 1H), 9.42 (d, J= 7.4 Hz, 1H), 7.95 (br s, 1H), 7.38-7.48 (m, 2H), 6.66 (s, 1H), 6.60 (s, 1H), 6.51- 6.56 ( , lH), 3.91 (s, 3H), 3.86 (s, 3H), 3.73-3.82 (m, 3H), 3.00-3.16 (m, 4H), 1.91-2.02 (m, 2H), 1.43-1.57 (m, 2H), 1.01 (t, .7= 7.2 Hz, 3H); ESI MS mlz 453 [M + H]+.
Example 53: c&-4-((2-(5,7-Dimethoxy-4-<)x(>-3,4^
yI)ainino)-N^-dimethylcyclohexane-l-carboxanijde
Figure imgf000115_0001
[000234] l-Erayi-3-(3-dimemylain oprop (2.10 g, 11.0 ramol) was added to a solution of cw-4-[(teri-butoxycarbonyl)amino]cyclohexanecait>oxylic acid (2.43 g, 10 mmoi) and hydroxybenzotriazole (1.436 g, 11.0 mmol) in DMF (30 mL). The reaction was s birred at rt for 20 min. After that time dimethylamine (2 M solution in THF, 25 mL, SO mmol) was added and the reaction mixture was stirred at rt for 18 h. After that time the reaction was concentrated under reduced pressure and the residue was dissolved in chloroform (80 mL). The organics were washed with sat. NaHC03 (2 x 40 mL), sat. NaCl (2 x 40 mL), dried (Na2SQ«) and concentrated under reduced pressure to give tert-b\xty\-cis- (4- (dimemyl<»rlwnoyl)cyclohexyl)cari)amate (2.2 g, 82%) as an off-white solid: lH NMR (400 MHz, CDCb) 54.82 (br s, 1H), 3.81 (br s, lH), 3.04 (s, 3H), 2.94 (s, 3H), 2.52-2.63 (m, 1H), 1.74-1.86 (m, 2H), 1.64-1.77 (m, 2H), 1.51-1.64 (m, 4H), 1.44 (s, 9H).
[000235] Concentrated hydrochloric acid (4.0 mL, 40 mmol) was added to a solution of te/i-butyl-ci_ 4-(dime^ (2.2 g, 6.7 mmol) in methanol
(30 mL) and stirred at rt for 18 h. After this time the reaction was concentrated under reduced pressure and dired to give cw-4-ammo-N,N-ch &ylcyclote^
hydrochloride (1.6 g, 95%) as an off-white solid: 1H NMR (400 MHz, DMSC fc) 5 8.08 (br s, 3H), 3.18 (br s, 1H), 2.99 (s, 3H), 2.80 (s, 3H), 2.73 (br s, 1H), 1.76-1.87 (m, 2H), 1.71 (dd, J= 9.4, 4.3 Hz, 4H), 1.44-1.57 (m, 2H); ESI MS m/z 171 [M + H]+.
[000236] Lithium bis(trimethy!silyl)amide (1 M in THF, 8.0 mL, 8.0 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5 J-dimemoxyqumazolin-4(3H)-one (0.400 g, 1.33 mmol) and cii-4-amino-N,N-dimemylcyclohexane-l-carboxamide
hydrochloride (0.826 g, 4.0 mmol) in anhydrous THF (15 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 4.0 raL, 4.0 mmol) was added and reflux with stirring was continued for an additional 15 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (3 mL) and concentrated under reduced pressure. Hie product was purified by flash column chromatography (silica gel, 97:3 chloroform/methanol) followed by recrystalization from chloroform hexanes to give cis-A- ((2^5,7^iimemoxy- )xo-3,4-dmydroquinazo
dmemylcyclohexane-l-<arboxamide (0.075 g, 13%) as a light yellow solid: mp. 276-278 °C; 1H NMR (400 MHz, CDC13) δ 10.93 (br s, lH), 9.80 (d, J= 8.2 Hz, 1H), 7.87 (d, J= 3.5 Hz, 1H), 7,22 (dd, J= 8.6, 3.9 Hz, 1H), 7.05-7.17 (m, 2H), 6.46 (s, 1H), 4.04 (s, 3H), 3.97 (s, 3H), 3.91 (br s, 1H), 3.08 (s, 3H), 2.92 (s, 3H), 2.60-2.72 (m, 1H), 1.96-2.18 (m, 4H), 1.65- 1.83 (m, 4H); ESI MS m/z 452 [M + H]+.
Example 54: 4-((2^5,7-Dimethoxy-4^xo-3^Wmydroqumazolin-2-yI)pyridin-3- yl)amino)piperidine-l-carboxamide
Figure imgf000116_0001
[000237] Trimethylsilyl isocyanate (1.0 mL) was added to a solution of 5,7- dimemoxy-2^3^iperidm^ylarnino)pyridm-2-yl^ (0.050 g, 0.13 mmol) and triethyl amine (1.0 mL) in THF (15 mL) cooled to 0 °C. The reaction was allowed to warm to rt and stirred 16 h. After that time the reaction was concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dichloromethane/methanol) to give 4^(2-(5,7-dimethoxy-4-oxo- 3,4-dihydroquinazolin-2-yl)pyridin^ (0.025 g, 45%) as yellow solid: mp 265-266 °C; Ή NMR (400 MHz, DMSO-i¾) δ 10.75 (br s, lH), 9.39 (d, J= 7.4 Hz, 1H), 7.92 (br s, 1H), 7.35-7.45 (m, 2H), 6.63 (s, 1H), 6.57 (s, 1H), 5.97 (br s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 3.67-3.80 (m, 3H), 3.03-3.16 (m, 2H), 1.87-2.01 (m, 2H), 1.40- 1.54 (m, 2H); ESI MS mlz 425 [M + H]+.
Example 55: Methyl-2^4^(2 5,7^imethoxy-^
3-yl)amino)piperidin-l-yl)-2-oxoacetate
Figure imgf000117_0001
[000238] Methyl-2-chloro-2-oxoacetate (0.022 g, 0.183 mmol) was added to a solution of 5,7-Klimemoxy-2 3-(piperidm^^
(0.070 g, 0.183 mmol) and triethyl amine (0.182 g, 1.8 mmol) in THF (25 mL) cooled to 0 °C. The reaction was allowed to warm to rt and stirred 30 min. After that time the reaction was concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dichloromethane/methanol) to give methyl~2~(4-((2-(5,7-dirnet oxy-4-oxo-3,4-dihyd^
yl)amino)piperidin- 1 -yl)-2-oxoacetate (0.044 g, 72%) as yellow solid: mp 165-166 °C; Ή NMR (400 MHz, DMSO-<i¾) δ 10.79 (s, 1H), 9.38 (d, J= 7.8 Hz, 1H), 7.94 (dd, J= 3.9, 1,1 Hz lH), 7.37-7.48 (m, 2H), 6.69 (d, 7= 1.9 Hz, 1H), 6.57 (d, 7= 1.9 Hz, 1H), 4.01-4.11 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.51-3.62 (m, 1H), 3.14-3^5 (m, 2H), 1.99- 2.11 (m, 2H), 1.48-1.66 (m, 2H); ESI MS mlz 466 [M - H]\ Example 56: N-(2-((2-(5,7-Dimethoxy^oio-3,4Hiihydroquinazolin-2-yl)pyridiii-3- yI)amino)ethyl)isobutyramide
Figure imgf000118_0001
[000239] Lithium bis(trimethylsilyl)amide (1 M in THF, 10.0 mL, 10.0 mmol) was added to a stirred suspension of 2-(3-fluoropyridin-2-yl)-5 ,7 mnemoxyqutoa2»lin-4(3j¾)- one (0.300 g, 0.99 mmol) and N^2-arnmoe1hyl)isobutyramide hydrochloride (0.498 g, 2.99 mmol in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 17 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (10 mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, 97:3 dichloromethane/methanol) followed by recrystalization from chloroform hexanes to give 2-((2-(5,7-a iethoxy-4- oxo-3 ,4-di ydroquinazol in-2- l)pyridin-3 -yl)amino)ethyl)isobutyramide (0.102 g, 25%) as a yellow solid: mp 235- 237 °C; 1H NMR (400 MHz, CDC13) δ 10,80 (s, lH), 9.34 (t, J= 5.6
Hz, 1H), 7.84 (dd, J= 4.3, 1.2 Hz, lH), 7.19-7.25 (m, 1H), 7.12-7.18 (m, 1H), 6.70 (d,J = 2.3 Hz, 1H), 6.35 (d, J= 2.3 Hz, 1H), 6.25 (t, J= 5.6 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.61-3.67 (m, 2H), 3.46-3.52 (m, 2H), 2.47 (sept, J= 6.7, 1H), 1.17 (d, J= 6.7 Hz, 6H); ESI MS /n z 412 [M + H]+, Example 57: N^3^(2^5,7-Dimethoxy-4^xo-3,4^ihydn^uinazolin-2-yl)pyridin-3- yI)amino)propyI)isobutyramide
Figure imgf000119_0001
[0002401 Lithium bis(trimethylsilyl)amide (1 M in THF, 9.6 mL, 9.6 mmol) was added to a stirred suspension of 2^3-fluoropyrid -2-yl)-5,7-dime^
one (0.361 g, 1.20 mmol) and N^3-am opropyl)isobutyramide (0.65 g, 3.60 mmol) in anhydrous THF (20 mL). After the addition was complete, the reaction was heated to reflux with stirring for 1 h. After that time a second portion of lithium bis(trimeUiylsilyl)amide (1 M in THF, 2.4 mL, 2.4 mmol) was added and reflux with stirring was continued for an additional 2 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (S mL) and concentrated under reduced pressure. The residue was diluted with water (30 mL) and the resulting suspension was stirred at rt for 30 min. The precipitated solid was collected by filtration, washed with water and air-dried. The product was purified by flash column chromatography (silica gel, dicMoromethane to 97:3 dichloromethane/methanol) followed by trituration (90:10 diethyl ether/methanol) to give iV-(3^(2-(5,7-dimethoxy-4- oxo-3,4-dihydroquiriazolm-2-yl^ (0207 g, 40%) as a yellow solid: mp 230-231 °C;Ή NMR (400 MHz, DMSO^¾) δ 10,76 (s, 1H), 9.38 (t, J= 5.7 Hz, 1H), 7.93 (dd, J= 4.3, 1.2 Hz, 1H), 7.87 (t, J= 5.7 Hz, 1H), 7.41 (dd, J= 8.6, 3.9 Hz, 1H), 7.33 (dd, J= 8., 1.2 Hz Hz, 1H), 7.10 (d, J= 2.3 Hz, 1H), 6.57 (d, J= 2.3 Hz, 1H), 3.94 (s, 3H), 3.85 (s, 3H), 3.28-3.36 (m, 2H), 3.25 (q, J= 6.6 Hz, 2H), 2.37 (sept, J= 6.6 Hz, 1H), 1.70-1.80 (m, 2H), 1.02 (d, J= 6.6 Hz, 6H); ESI MS m/z 426 (M + H . Example 58: 2^3^(148opiOpyIpiperidin^yl)amino)pyridin-2-yI)-5- methoxypyrido[3,4-rf|pyrimidin-4(Jfl)-one
Figure imgf000120_0001
[000241] Lithium bis(trimethylsilyl)amide (1 M in THF, 2.0 mL, 2.0 mmol) was added to a suspension of 2-(3-fluoropyridin-2-yl)-5-methoxypyrido[3,4-d]pyrimidm^ one (0.103 g, 0.37 mmol) and l-isopropylpiperi<lin-4-amine (0.142 g, 1.0 mmol) in anhydrous THF (10 mL). After the addition was complete, the reaction was heated to in a sealed tube at 70 °C for 3 h. After that time the reaction was cooled to rt, diluted with ice- cold water (SO mL) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol to 90:10 dichloromethane/methanol) to give 2-(3-((l-isopropylpiperidin-4-yl)^
memoxypyrido[3,4^]pyiirmdm-4(3 i one (0.025 g, 17%) as a yellow solid: mp 237-238 °C; 1H NMR (400 MHz, DMSO-<¼) δ 11.32 (br s, lH), 9.32 (d, J= 8.2 Hz, 1H), 8.67 (s, 1H), 8.40 (s, lH), 7.98 (br s, 1H), 7.45 (d, J= 2.3 Hz, 2H), 4.01 (s, 3H), 3.63-3.86 (m, 1H), 2.72- 3.17 (m, 5H), 2.01-2 3 (m, 2H), 1.58-1.89 (m, 2H), 1.0 (d, J= 7.0 Hz, 6H); ESI MS mlz 395 [M + H]+.
Example 59: 2 3 (M2-Hydroj-y-2-methylpropy
5,7^)imethoxyquinazoIm-4(JJ7)-one
Figure imgf000121_0001
[000242] A solution of 5,7-diniethoxy-2-(3-(piperidin-4-ylamino)pyridin-2- yl)quinazolin-4(3jt3 -one (0.050 g, 0.13 mmol) and 2^-dimethyloxirane (0.047 g, 0.65 mmol) in ethanol (3 mL) was heated to 140 °C with stirring in a sealed tube for 1.5 h using microwave radiation. After that time the reaction was cooled to it, concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, dichloromethane to 70:30 dichlororaethane/methanol) to give 2-{3-((l~{2-hydroxy-2- methy I propyl)piperi din-4-y l)amino)pyridin-2-yl)-5 ,7-dimethoxyqiiin^ (0.029 g, 72%) as yellow solid: mp 220-221 °C; lH NMR (400 MHz, DMSO-*fc) δ 10.79 (s, lH), 9.41 (d, J= 7.8 Hz, 1H), 7.93 (dd, J= 3.7, 1.8 Hz, 1H), 7.35-7.42 (m, 2H), 6.72 (d, J= 1.95 Hz, 1H), 6.60 (d, J= 1.95 Hz, 1H), 4.08 (s, 1H), 3.93 (s, 3H), 3.87 (s, 3H), 3.59-3.69 (m, 1H), 2.76-2.86 (m, 2H), 2.53-2.57 (m, 2H), 2^4 (s, 2H), 1.91-2.01 (m, 2H), 1.56-1.67 (m, 2H), 1.10 (s, 6H); ESI MS mlz 454 [M + H]+.
Example 60: 2-(3-{(H2-hydroxypropanoyI)piperidin^y^
dimetfaoxyquinazolin-4(JA)-one
Figure imgf000122_0001
[000243] iV,iV-Dicyclohexylcarbodiiraide (0.113 g, 0.55 mmol) and 1 -hydroxy- 1H- benzotriazole (0.074 g, 0.55 mmol) were added to a solution of 2-hydroxypropanoic acid (0.058 g, 0.55 mmol; 85% in water) in DMF (15 mL) at rt. The reaction was stirred for 1 h and then 5,7-dimethoxy-2-(3-^ipeTidm-4-ylanimo)pyridm^ (0,070 g, 0.18 mmol) was added. The reaction was stirred 18 h at rt After that time the reaction was concentrated under reduced pressure and the product was purified by prep. HPLC to give 2- (3-((l-(2-hydroxypropanoyl)piperidin-4-yl)amino)pyridin-2-yl)-5
4(3H)-one (0.010 g, 12%) as yellow solid: mp 290-291 °C; 1H NMR (400 MHz, DMSO-4,) δ 10.75 (s, 1H), 9.44 (d, 7= 7.0 Hz, 1H), 7.95-7.97 (m, 1H), 7.40-7.49 (m, 2H), 6.67 (s, 1H), 6.60 (d, 1H), 4.84-4.96 (m, 1H), 4.41-4.54 (m, 1H), 4.00-4.19 (m, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.38-3.44 (m, 1H), 3.05-3.26 (m, 2H), 1.96-2.13 (m, 2H), 1.44-1.70 (m, 2H), 1.20 (d, 7=6.25 Hz, 3H); ESI MS mlz 452 [M - Hf.
Example 61: 2^3-((l-bopropylpiperidin^yl)amino)pyridin-2-yl)-5-metho3cy-7-((4- methoxybenzyl)amiiio)quinazolin-4(3 -<>ne
Figure imgf000123_0001
[000244] A solution of 3-bromopicolinaIdehyde (5.00 g, 27 mmol), ethylene glycol (6.0 mL, 108 mmol) and /7-toluenesulfonic acid monohydrate (0.256 g, 1.35 mmol) in anhydrous toluene (120 mL) was heated to reflux for 16 h with azeotropic removal of water using a Dean-Stark apparatus. After that time the reaction was cooled to rt and diluted with ethyl acetate (100 mL). The organic phase was separated, washed with 5% aq. Na2C(¼ (120 mL), sat NaCl (100 mL), dried (Na2SC> ) and concentrated under reduced pressure to give 3- teom^ l^-dioxolan^-yl^yridine (5.36 g, 87%) as a brown oil: JH MR (CDC13) δ 8.60 (d, J= 3.5 Hz, 1H), 7.86-7.93 (m, 1H), 7.18 (dd, J= 82, 4.7 Hz, 1H), 6.31 (s, 1H), 426-4.34 (m, 2H), 4.08-4.15 (m, 2H).
[000245] Tris(dibenzylideneacetone)dipalladium (0.092 g, 0.10 mmol) was added to a de-gassed solution of 3-bromo-2-(l,3-dioxolan-2-yl)pyridine (1.15 g, 5.00 mmol), 1- isopropylpiperidin-4-amine (1.03 mL, 6.50 mmol), sodium-tert-butoxide (0.865 g, 9.00 mmol) and 22'-bis(diphenylphosphmo>-l,r-bmaphuiyl (0.187 g, 0.30 mmol) in toluene (10 mL). The misture was de-gassed again and heated at 110 °C with stirring for 3 h under nitrogen. After that time the mixture was cooled to rt, filtered through celite, and
concentrated under reduced pressure. The product was purified by flash column
chromatography (silica gel, 97:3 dichloromethane/methanol then 97:3 dichloromethane 7N ammonia in methanol) to give 2-(l,3-dioxolan-2-yl)--V-(l-isopropylpiperi
amine (1.342 g, 92%) as a brown oil: ,H MR (CDCI3) 87.89 (dd, J= 4.7, 1.2 Hz, 1H), 7.10 (dd, J= 8.4, 4.5 Hz, 1H), 6.% (d, J= 7.8 Hz, 1H), 5.79 (s, 1H), 5.10 (d, J = 7.8 Hz, 1H), 4.1 -4.18 (m, 2H), 4.02-4.10 (m, 2H), 3.24-3.38 (m, 1H), 2.69-2.87 (m, 2H), 2.26-2.38 (m, 2H), 1.99-2.11 (m, 2H), 1.46-1.59 (m, 2H), 1.06 (d, J= 6.6 Hz, 6H). [000246] A solution of 2-(1 ^ xolan-2-yl>N-(l-isopropylpiperidin^yl)pyridin-3- amine (1.32 g, 4.S3 mmol) and 2 N aqueous HC1 (10 mL) was stirred at rt for 16 h. After that time the reaction was concentrated under reduced pressure and dried to give 3-((l - isopropylpiperidin-4-yl)amino)picolinaldehyde dihydrochloride (4.53 g). The aldehyde was dissolved in N^-dimethylacetamimde (20 mL) and 2-amino-4,6-difluorobenzamide (0.64 g, 3.70 mmol) was added followed by NaHS03 (58.5 wt%, 1.01 g, 5.55 mmol) and p- toluenesulfonic acid monohydrate (0.14 g, .74 mmol). The reaction was heated at 130 °C with stirring for 16 h. After that time the mixture was cooled to rt, concentrated under reduced pressure and diluted with water (100 mL). The resulting precipitate was collected by filtration, washed with water and dried. The product was purified by flash column
chromatography (silica gel, 97:3 dichloromethane/methano 1 ) to give 5,7-difluoro-2-(3-((l- isopropylpiperiom^yl)amino)pyridm-2-yl)quina∞ (0.705 g, 48%) as yellow solid: 1H MR (CDC13) δ 11.16 (br s, 1H), 9.35 (d, J= 7.8 Hz, 1H), 7,90 (dd, J= 4.3, 1.2 Hz, lH), 7.23-7.31 (m, 1H), 7.05-7.19 (m, 2H), 6.80-^.93 (m, 1H), 3.47-3.58 (m, 1H), 2.84- 2,94 (m, 2H), 2.74-2.84 (m, 1H), 2.35-2.48 (m, 2H), 2.08-2.20 (m, 2H), 1.67-1.79 (m, 2H), 1.09 (d, J= 6.6 Hz, 6H); ESI MS m/z 400 [M + H]+.
[000247] A solution of sodium methoxide in methanol (25 wt%, 2.3 mL, 10.6 mmol) was added to a suspension of 5,7-<Muoro-2^3^(l-isopropylpiperi^
yl)quinazolin-4(3H)-one (0.703 g, 1.76 mmol) in anhydrous DMF (10 mL). The reaction was stirred at rt for 16 h under nitrogen. After that time 2N HC1 was added to quench the reaction and adjust the reaction pH to about 2. The reacion was then made strongly basic with aq. a2C03 solution. The resulting precipitate was collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 97:3
dichloromethane methanol) to give 7-fluoro-2-(3 -(( 1 -isoprop lpip<aridin-4-yl)araino)pyridin- 2-yl)-5-memoxyquinazolm^3H one (0.765 g, (>99%) as yellow solid: lH NMR (DMSO- <¼) δ 10.96 (br s, 1H), 9.28 (d, J= 7.4 Hz, lH), 7.93 (dd, J= 3.5, 2.0 Hz, lH), 7.34-7.44 (m, 2H), 6.94-7.08 (m, 2H), 3.90 (s, 3H), 3.52-3.65 (m, 1H), 2.68-2.79 (m, 3H), 2.33-2.45 (m, 2H), 1.93-2.03 (m, 2H), 1.53-1.67 (m, 2H), 0.99 (d, J= 6.3 Hz, 6H); ESI MS m/z 412 [M + Hl+.
[00024S] A suspension of 7-fluoro-2^3^(l-isopropylpiperidin^^
yl)-5-methoxyquinazolm^3 )-one (0.412 g, 1.00 mmol)) and 4-methoxybenzylamine (0.78 mL, 6.00 mmol) in DMSO (5 mL) was heated at 100 °C with stirring for 24 h. After that time the reaction was cooled to rt and diluted with water (50 mL). The resulting precipitate was collected by filtration, washed with water and dried. The product was triturated with diethyl ether and then purified by flash column chromatography (silica gel, 97:3
dichloromethane/methanol then 97:3 dichloromethane 7N ammonia in methanol) to give 2- (3-((l-isopropylpiperioUn^yl)amm^
methoxybenzyl)amino)quiim2»lin- (3H)-one (0.230 g, 43%) as yellow solid: rap 220-222 °C; Ή NMR (DMSO-<¼) δ 10.37 (br s, IH), 9.52 (d, J= 7.8 Hz, lH), 7.84-7.93 (m, 1H), 7.30-7.43 (m, 4H), 7.26 (t, J= 5.7 Hz, lH), 6.87-^.99 (m, 2H), 6.31 (d, J= 2.0 Hz, 1H), 6.22-6.29 (m, 1H), 4.32 (d, J= 5.7 Hz, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 3.53 (br.s, lH), 2.68- 2.80 (m, 3H), 2.32-2.42 (m, 2H), 1.92-2.03 (m, 2H), 1.43-1.57 (m, 2H), 0.99 (d, J= 6.6 Hz, 6H); ESI MS m/z 529 [M + H]+.
Example 62: 2-[5-(2-Hydroxyethoxy)-3-(l-isopropylpiperidm
S^-dimethox quinazolin-^S/ -one
Figure imgf000125_0001
[000249] A solution of 2-[5^2-^e^butyldimemylsilyloxy)emoxy]-3-fluoropyri yl)-5,7-dimethoxyquinazolin-4(3H)-one (0.476 g, 1.0 mmol) and 1 -isopropyl-4- aminopiperidine (0.711 g, 5 mmol) in anhydrous acetonitrile (5 mL) was heated to reflux with stirring for 26 h. After that time the reaction was cooled to it and concentrated under reduced pressure. The solids were treated with chloroform (25 mL) and the resulting mixture was filtered, washed with sat NaHCC (15 mL), dried (MgS04) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 95:5 dichloromethane methanol) followed by recrystallization from chloroform/diethyl ether to give 2-[5-(2-Hydroxyethoxy)-3-(l -isopropylpiperidm-4-ylammo)pyridin-2-yl]-5,7- dimethoxyquinazolin-4(3H)-one (0.292 g, 60%)as a yellow solid: mp 231-233 °C; JH NMR (400 MHz, CDC13) δ 10.67 (br s, 1H), 9.56 (d, J = 7.2 Hz, 1H), 7.62 (d, J = 2.4 Hz, 1H), 6.59 (d, J= 2.4 Hz, 1H), 6.50 (d, J= 2.0 Hz, 1H), 6.42 (d, J= 2.0 Hz, lH), 4.19 (t, J= 4.4 Hz, 2H), 4.02 (t, J= 4.4 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.40 (br s, 1H), 2.93-2.90 (m, 2H), 2.81-2.77 (m, 1H), 2.44-2.42 (m, 2H), 2.14-2.11 (ra, 2H), 1.79-1.74 (m, 2H), 1.10 (d, J= 6.4 Hz, 6H); ESI MS m/z 484 [M + H]+.
Example 63: ctf^((2^5,7-Dimethoxy^^xo-3,4-dihydi^uinazolin-2-yl)pyridin-3- yl)amino)--V-i8opropylcycloliexane-l-carb xamide
Figure imgf000126_0001
[000250] Lithium bis(trimethylsilyl)amide (1 M in THF, 10.0 mL, 10.0 mmol) was added to a stirred suspension of 2-(3-fluoropyrioUn-2-yl)-5,7 limemoxyqum
(0.500 g, 1.66 mmol) and cw-4-araino-N-(propan-2-yl)cyclohexanecarboxainide
hydrochloride (1.10 g, 5.0 mmol) in anhydrous THF (15 mL). After the addition was complete, the reaction was heated to reflux with stirring for 2 h. After that time a second portion of lithium bis(trimethylsilyl)amide (1 M in THF, 5.0 mL, 5.0 mmol) was added and reflux with stirring was continued for an additional 18 h. After that time the reaction was cooled to rt, diluted with saturated aqueous NH4CI (3 mL), concentrated under reduced pressure and the product was purified by flash column chromatography (silica gel, 98:2 dic oromel ane/methanol) to give cz 4-((2-(5,7-dimet oxy-4-oxo-3,4-dihydroquinazolin-2- yl)pyridm-3-yi)ammo)-J/V-isopropylcyclohexane-l-<^ (0.120 g, 16%) as a light yellow solid: mp 256-257 °C; Ή NMR (400 MHz, CDC13) δ 10.93 (br s, 1H), 9.74 (d, J = 8.2 Hz, 1H), 7.89 (d, J= 4.3 Hz, 1H), 7.23 (dd, J= 8.6, 4.3 Hz, 1H), 7.10 (d, J - 8.6 Hz, 1H), 6.95 (d, J= 2.3 Hz, 1H), 6.46 (d, J= 2.3 Hz, 1H), 5.23 (d, J= 7.0 Hz, 1H), 4.00-4.09 (m, 1H), 3.98 (s, 6H), 3.84-3.94 (m, 1H), 2.12-2.24 (m, 1H), 1.93-2.08 (m, 4H), 1.81-1.91 (m, 2H), 1.65-1.79 (m, 2H), 1.09 (d, J= 6.6 Hz, 6H); ESI MS m/z 464 [M - HJ". Example 64: 2-[5-(2-HydraKYethoxy)-3-(l-uobutyi^^
yl]-5,7-dimethoxyquinazol -4(3i/)-one
Figure imgf000127_0001
[000251] A mixture of 2-[5-(2- e^butyldimethylsUyto^
yl>5 Hiimet oxyquinazolm-^3H)-one (0.476 g, 1.0 mmol), l-isobutyroyl-4- aminopiperidine hydrochloride (1.034 g, 5.0 mmol) and K2CO3 (1.11 g, 8.0 mmol) in anhydrous DMSO (10 mL) was heated to 96 °C with stirring for 26 h. After that time the reaction was cooled to rt, diluted with chloroform (100 mL), washed with water (5 x 10 mL), dried (MgS0 ) and concentrated under reduced pressure. The oily product was triturated (diethyl ether, (S * 10 mL) to give a solid product that was purified by flash column chromatography (silica gel, 98:2 chloroform/methanol) to give 2- [5-(2-hydroxyethoxy)-3 -( 1 - isotoityroylpiperidin-4-ylammo)p^ (0.172 g,
34%) as a yellow solid: mp 173-176 °C; "H NMR (400 MHz, CDCI3) δ 10.66 (br s, 1H), 9.65 (d, J = 6.8 Hz, lH), 7.65 (d, J= 2.4 Hz, 1H), 6.52 (s, 2H), 6.43 (d, J= 2.4 Hz, 1H), 4.13-4.28 (m, 1H), 4.22-4.20 (m, 2H), 4.05-4.03 (m, 2H), 3.98 (s, 3H), 3.93 (s, 3H), 3.90-3.86 (m, 1H), 3.66-3.63 (m, lH), 3.41-3.28 (m, 2H), 2.88-2.82 (m, 1H), 2.34 (t, J= 6.4 Hz, 1H), 2.12 (br s, 2H), 1.72-1.58 (m, 2H), 1.16 (d, 7= 7.2 Hz, 6H); ESI MS m/z 512 [M + H]+.
Example 65: 7-ammo-2-<3-{(l-Isopropylpiperidin^yl)amino)pyridin-2-yI)-5- methoiyquinazolin-4(3H)-one
Figure imgf000128_0001
[000252] A solution of 2^3^(1 -isopropylpiperidin^yl)aimno)pyridm
me1hoxy-7-((4-raethoxybenzyl)amino)quinazolin-4(3H>^ne (0.200 g, 0.37 mmol) and trifluroacetic acid (2 mL) in dichloromethane (18 mL) was stirred at rt for 48 h. After this time the reaction was concentrated under reduced pressure, diluted with water (20 mL) and made basic with sat. NazCC^. The precipitated solids were collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 97:3 dichloromethane methanol then 97:3 dichloromethane 7N ammonia in methanol) to give 7-ammo-2^3^(l -isopropyipiperia^
4(3H one (0.023 g, 15%) as yellow solid: 1H N R (DMSO-<¼) 6 10.72 (s, 1H), 8.74 (d, J= 7.8 Hz, lH), 7.99 (t, J= 2.7 Hz, 1H), 7.44 (d, J= 2.7 Hz, 2H), 624 (s, 1H), 5.92 (br s, 2H), 4.41 (s, 1H), 3.72 (s, 3H), 3.40-3.52 (m, 1H), 2.62-2.77 (m, 2H), 2.57 (sept, J = 6.3 Hz 1H), 2.14-2.29 (m, 2H), 1.91-2.04 (m, 2H), 1.27-1.38 (m, 2H), 0.84 (d, J= 6.3 Hz, 6H); ESI MS /n/z 409 [M + H]+.
Example 66: 2-{3^1-l8opropylpiperidin^ylamino)-5-[2-^yiTolidin-l- yl)ethoxy]pyridin-2-yl}-5,7-dimethoxyqiiinazolin-4(3H)-one
Figure imgf000129_0001
[000253] Carbon tetrabromide (1.33 g, 4.0 mmol) and triphenylphosphine (1.10 g, 4.2 mmol) were added to a stirred suspension of 2-[5^2-hydroxyethoxy)-3^1-isopropylpiperidin- 4-ylamino)pyridin-2-yl]-5,7-<limeA^ (0.967 g, 2.0 mmol) in dichloromethane (60 xnL). The reaction was stirred for 2 h at rL After that time the reaction was concentrated under reduced pressure. The residue was suspended in anhydrous DMSO (10 mL) and pyrrolidine (7.11 g, 100 mmol) was added. The reaction mixture was heated to 80 °C with stirring for 14 h. After that time the reaction was cooled to rt, diluted with chloroform (100 mL), washed with sat. NaHCC (20 mL), water (4 x 20 mL), dried (MgS04) and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 90:10 chioroform/methanol) followed by trituration (diethyl ether) to give 2-{3-(l-isopropylpiperidto^ylaiiun^
yl}-5,7^memoxyquinazolin-4(3H)-one (0.520 g, 48%) as a yellow solid: mp 166-169 °C;
1H NMR (400 MHz, CDC13) δ 10.69 (br s, 1H), 9.57 (d, J = 7.2 Hz, lH), 7.64 (d, J = 2.4 Hz, 1H), 6.60 (d, J= 2.0 Hz, 1H), 6.54 (d, J= 2.0 Hz, 1H), 6.41 (d, J= 2.4 Hz, 1H), 4.21 (t, 7= 5.6 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.45 (br s, 1H), 2.97-2.93 (m, 3H), 2.84-2,80 (m, 1H), 2.67 (br s, 4H), 2.46-2.44 (m, 2H), 2.17-2.15 (m, 2H), 1.86-1.77 (m, 6H), 1.12 (d, J= 6.4 Hz, 6H); ESI MS m/z 537 [M + Hj+. Example 67: 2-{5-[2^sopropylamino)€thoxy]-3-<l-isopropylpiperidiii-4- ylamino)pyridin-2-yl}-5,7-dimethoxyquiniUM)lin-4{3 )-one
Figure imgf000130_0001
[000254] Carbon tetrabromide (1.79 g, 5.4 mmol) and triphenylphosphine (1.49 g, 5.7 mmol) were added to a stirred suspension of 2-[5^2-hydroxyethoxy 3^1-isoprop
4-ylammo)pyridin-2-yl]-5,7-&me (1.303 g, 2.7 mmol) in dichloromethane (80 mL). The reaction was stirred for 2 h at rt and was then concentrated under reduced pressure. The residue was suspended in anhydrous DMSO (10 mL) and isopropylamine (7.98 g, 135 mmol) was added. The reaction mixture was heated to 60 °C with stirring for 18 h. After that time the reaction was cooled to it, diluted with chloroform (100 mL), washed with sat NaHCC (20 mL), water (4 x 20 mL), dried (MgS04) and concentrated under reduced pressure. The product was purified by flash column
chromatography (silica gel, 90:10 chloroforra/methanol) followed by recrystallization from chloroform/diethyl ether to give 2-{5-[2^isopropylammo)emoxy3-3^1-isopropylpiperidm ylamino)pyridin-2-yl}-5,7-dimethoxyquina7 )lin-4(3/^-one (0.742 g, 52%) as a yellow solid: mp 178-181 °C; Ή NMR (400 MHz, CDC13) δ 9.58 (d, J = 8.0 Hz, 1H), 7.63 (<L J = 1.6 Hz, 1H), 6.60 (d, J = 1.6 Hz, 1H), 6.51 (d, J= 2.2 Hz, 1H), 6.42 (d, J= 2.2 Hz, 1H), 4.17 (t, J= 5.2 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.45 (br s, 1H), 3.05 (t, J= 5.2 Hz, 2H), 2.94-2.79 (m, 4H), 2.48-2.44 (m, 2H), 2.17-2.13 (m, 2H), 1.80-1.76 (m, 2H), 1.14-1.10 (m, 12H); ESI MS m/z 525 [M + HJ+, Example 68: 2^3^(Hl-Hydrojy-2-me&ylpropan-2-yI)piperi
yl)-5,7^.methoxyqumazolin-4(3i/)-one
Figure imgf000131_0001
[000255] A solution of tert-butyl piperidin-4-ylcarbamate (5.0 g, 25 mmol), ethyl 2- bromo-2-methylpropanoate (7.30 g, 37 mmol) and potassium carbonate (8.60 g, 62 mmol) in anhydrous acetonitrile (80 mL) was heated to reflux for 17 h. After that time the reaction was cooled to rt, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography (silica gel, 80:20 hexanes/ethyl acetate to 60:40 hexanes/ethyl acetate) to give ethyl 2-(4-((fer/-butoxycarbonyl)an^
(3.20 g, 41%) as a white solid: ¾ NMR (400 MHz, CDC13) δ 4.40 (br s, IH), 4.18 (q, J= 6.8 Hz, 2H), 3.44 (br s, 1H), 2.84-2.92 (m, 2H), 2.27 (td, J= 11.5, 2.3 Hz, 2H), 1.87-1.96 (m, 2H), 1.44 (s, 9H), 1.34-1.49 (m, 2H), 1.30 (s, 6H), 1.24-1 9 (m, 3H); ESI MS m/z 3\5 [M + H]+.
[000256] A solution of diisobutylaluminum hydride (1M in toluene, 36 mL, 36 mmol) was slowly added to a vigorously stirred solution of ethyl 2^4-((/t?ri-butoxycarbonyl)amino) piperidin- 1 -yl)-2-meth lpropanoate (2.80 g, 8.9 mmol) in anhydrous dichloromethane (120 mL) at -78 °C. The reaction was stirred at -78°C for 15 min and then warmed to 0 °C and stirred an additional 45 min. After this time the reaction was quenched by addition of saturated aqueous NH4CI (40 mL). The resulting mixture was diluted with ethyl aceate (150 mL) and chloroform (150 mL), dried (MgSCv), concentrated under reduced pressure and dried in vacuum to give /erf-butyl ( 1 -( 1 -hydroxy-2-met ylpropan-2-yl)piperidin-4- yl)carbamate (2.17 g, 89%) as a white solid: ]H NMR (400 MHz, CDC13) δ 4.46 (br s, 1 H), 3.39-3.55 (m, 1H), 3.35 (s, 2H), 2.85-2.97 (m, 2H), 2.22-2.38 (m, 2H), 1.94-2.05 (m, 2H), 1.44 (s, 9H), 1.36-1.51 (m, 2H), 1.05 (s, 6H); ESI MS m/z 273 [M + H]+. [000257] Concentrated HC1 (3.3 mL, 39.8 mmol) was added slowly to a stirred solution of tert-butyl (l-(l-hydroxy-2-memylpropan-2-yl^^ (2.17 g,
7.97 mmol) in methanol (50 mL). The reaction mixture was then stirred at rt for 17 h. After that time the reaction was concentrated under reduced pressure, triturated with diethyl ether and dried to give 2-(4-aminopiperidin- 1 -yl)-2-methylpropan- 1 -ol dihydrochloride (1.71 g, 87%) as a white solid: 1H NMR (400 MHz, DMSO-<¾) δ 9.64 (t, J= 9.0 Hz, 1H), 8.49 (br s, 3H), 5.78 (br s, 1H), 3.55 (s, 2H), 3.39-3.55 (m, 2H), 3.19-3.37 (m, 1H); 3.00-3.15 (m, 2H), 1.93-2.20 (m, 4H), 1.27 (s, 6H); ESI MS m/z 173 [M + H]+.
[000258] A mixture of 2 3-fluoropyridin-2-yl)-5,7-di^^
(0.300 g, 0.99 mmol), 2-(4-aminopiperidin- 1 -yl)-2-methylpropan- 1 -ol dihydrochloride (0.624 g, 2.54 mmol) and potassium carbonate (1.38 g, 9.96 mmol) in anhydrous DMF (15 mL) was heated at 100 °C for 40 h. After that time the reaction was cooled to rt and concentrated under reduced pressure. Water (50 mL) was added and the resulting suspension was stirred at rt for 20 min. The precipitated solid was collected by filtration and air-dried. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane 7N ammonia in methanol to 97:3 dic oromethane/7N ammonia in methanol) to give 2-(3-((l -(1 -hydroxy-2- memylpropan-2-yl)piperidm-4-yl)amino)pyridm
(0.218 g, 48%) as a yellow solid: mp 223- 225 °C; 1H NMR (400 MHz, DMSO-dfe) δ 10.78 (s, 1H), 9.37 (d, J= 7.0 Hz, 1H), 7.92 (d, J= 2.7 Hz, 1H), 7.30-7.44 (m, 2H), 6.71 (<L J= 2.15 Hz, 1H), 6.59 (d, J= 2.15 Hz, lH), 4.23 (t, J= 4.7 Hz, lH), 3.93 (s, 3H), 3.86 (s, 3H), 3.60 (br s, 1H), 3.29 (d, J = 4.7 Hz, 2H), 2,79-2,90 (m, 2H), 2.46-2.57 (m, 2H), 1.92-2.03 (m, 2H), 1.52-1.66 (m, 2H), 0.97 (s, 6H); ESI MS m/z 454 [M + H]+.
Example 69: 7^Ethylamino)-2^3^(l-isopropyIpiperi^
methoxyquinazolin-4(3H)-one
Figure imgf000133_0001
[000259] Ethylamine (2.0 M solution in THF, 10 mL, 20.0 mmol) was added to a suspension of 7-fluoro-2-(3^(1 sopropylpiperidin^
methoxyquiiiazolin-4 (3H)-one (0.284 g, 0.69 mmol) in DMSO (5 mL). The reaction heated under microwave conditions at 100 °C with stirring for 10 h. After that time the reaction was cooled to it, concentrated under reduced pressure and diluted with water (50 mL). The resulting precipitate was collected by filtration, washed with water and dried. The product was purified by flash column chromatography (silica gel, 97:3 chloroform/methanol then 97:3 chloroform/7N ammonia in methanol) to give 7^emylamino)-2-(3-((l- isopropylpiperidin-4-yl)ammo)pyridin-2-yl)-5^ (0.106 g, 35%) as yellow solid: mp 219-221 °C; 1H NMR (400 MHz, CDCI3) δ 10.73 (s, IH), 9.62 (d, J=* 7.4 Hz, 1H), 7,87 (dd, 7= 3.9, 1.2 Hz, 1H), 7.20 (dd, J= 8.6, 4.3 Hz, 1H), 7.08 (d, J= 8.2 Hz, 1H), 6.32 (d,J= 2.0 Hz, 1H), 6.08 (<L J = 2.0 Hz, 1H), 4.10-4,19 (m, 1H), 3.95 (s, 3H), 3.41-3,56 (m, 1H), 3.23-3.36 (m, 2H), 2.85-2.97 (m, 2H), 2.71-2.84 (m, 1H), 2.38-2.47 (m, 2H), 2.07- 2.19 (m, 2H), 1.67-1.82 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H), 1.10 (d, J = 6,6 Hz, 6H); ESI MS m/z 437 [M + H]+.
Example 70: Inhibition of tetra-acetylated histone H4 binding individual BET
Bromodomains
[000260] Proteins were cloned and overexpressed with a N-terminal 6xHis tag, then purified by nickel affinity followed by size exclusion chromatography. Briefly, Exoli BL21(DE3) cells were transformed with a recombinant expression vector encoding JV- terminally Nickel affinity tagged bromodomains from Brd2, Brd3, Brd4. Cell cultures were incubated at 37°C with shaking to the appropriate density and induced overnight with IPTG. The supernatant of lysed cells was loaded onto Ni-IDA column for purification. Eluted protein is pooled, concentrated and further purified by size exclusion chromatography.
Fractions representing monomelic protein were pooled, concentrated, aliquoted, and frozen at -80°C for use in subsequent experiments.
[000261] Binding of tetra-acetylated histone H4 and BET bromodomains was confirmed by a Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) method. N-terminally His-tagged bromodomains (200 nM) and biotinylated tetra-acetylated histone H4 peptide (2S-50 nM, Millipore) were incubated in the presence of Europium Cryptate-labeled streptavidin (Cisbio Cat. #610SAKLB) and XL665-labeled monoclonal anti-His antibody (Cisbio Cat. #61HISXLB) in a white 96 well microtiter plate (Greiner). For inhibition assays, serially diluted test compound was added to these reactions in a 0,2% final concentration of DMSO. Final buffer concentrations were 30 mM HEPES pH 7.4, 30 ra NaCl, 0.3 mM CHAPS, 20 mM phosphate pH 7.0, 320 mM KF, 0.08% BSA). After a 2- h incubation at room temperature, the fluorescence by FRET was measured at 665 and 620 nm by a SynergyH4 plate reader (Biotek). Illustrative results with the first bromodomain of Brd4 are shown below. The binding inhibitory activity was shown by a decrease in 665 nm fluorescence relative to 620 nm. ICso values were determined from a dose response curve.
[000262] Compounds with an ICso value less than 30 uM were deemed to be active.
Table 2: Inhibition of Tetra-acetylated Histone H4 Binding to Brd4 bromodomain 1 (BRD4(1) as Measured by FRET
Figure imgf000134_0001
Figure imgf000135_0001
Example 71: Inhibition of c-myc expression in cancer cell lines
[000263] MV4-11 cells (2.5X10* cells) were plated in 96 well U-bottom plates with test compound or DMSO (0.1%), and incubated for 3 h at 37°C. Cells were then harvested by centrifugation, lysed, and mRNA was isolated using the mRNA catcher plus kit
(Invitrogen). Reverse transcription of the mRNA and duplex amplification of the c-myc and cyclophilin cDNAs was performed using the RNA Ultrasense kit (Invitrogen) and a ViiA7 real-time PCR machine (Applied Biosystems). IC5o values were determined from a dose response curve.
[000264] Compounds with an IC50 value less than 30 u were deemed to be active.
Table 3: Inhibition of c-myc Activity in Human AML MV4-11 cells
Figure imgf000136_0001
Example 72: Inhibition of cell proliferation in cancer cell lines
[000265] MV4-11 cells: 96-well plates were seeded with SxlO4 cells per well of exponentially growing human AML MV-4-11 (CRL-9591) cells and immediately treated with two-fold dilutions of test compounds, ranging from 30 uM to 0.2 uM. Triplicate wells were used for each concentration, as well as a media only and three DMSO control wells. The cells and compounds were incubated at 37 °C, 5% CC¾ for 72 h before adding 20 μΐ, of the CellTiter Aqueous One Solution (Promega) to each well and incubating at 37°C, 5% C<¾ for an additional 3-4 h. The absorbance was taken at 490 nm in a spectrophotometer and the percentage of proliferation relative to DMSO-treated cells was calculated after correction from the blank well. IC50 were calculated using the GraphPad Prism software.
[000266] Compounds with an IC50 value less than 30 μΜ were deemed to be active.
Table 4: Inhibition of Cell Proliferation in Human AML MV-4-11 cells
Figure imgf000137_0001
Figure imgf000138_0001
Example 73: Inhibition of hIL-6 mRNA Transcription
[000267] In this example, hIL-6 mRNA in tissue culture cells was quantitated to measure the transcriptional inhibition of bJL-6 when treated with a compound of the present disclosure.
[000268] A human leukemic monocyte lymphoma cell line (U937) was plated (3.2xl04 cells per well) in a 96-well plate in 100 uL RPMI-1640 containing 10% FBS and penicUtin/streptomycin, and differentiated into macrophages for 3 days in 60 ng/mL PMA (phorbol- 13 -myristate- 12-ace ate) at 37°C in 5% CO2 prior to the addition of the compound of interest. The cells were pretreated for 1 h with the test compound prior to stimulation with 1 ug/mL lipopolysaccharide from Escherichia colt The cells were incubated at 37°C for 3 h before the cells were harvested. At time of harvest, the spent media was removed from the cells and the cells were rinsed in 200 uL PBS. Cell lysis solution (70 uL) was added the cells in each well and incubated for 5-10 min at room temperature, to allow for complete cell lysis and detachment. mRNA was then prepared using the "mRNA Catcher PLUS plate"
(Invitrogen), according to the protocol supplied. After the last wash, as much wash buffer as possible was aspirated without allowing the wells to dry. Elution buffer (E3, 70 uL) was then added to each well. mRNA was then eluted by incubating the mRNA Catcher PLUS plate with Elution Buffer for 5 min at 68°C and then immediately placing the plate on ice.
[000269] The eluted mRNA isolated was then used in a one-step quantitative real-time PCR reaction, using components of the Ultra Sense Kit together with Applied Biosystems primer-probe mixes. Real-time PCR data was analyzed, normalizing the Ct values for hIL-6 to an internal control, prior to determining the fold induction of each unknown sample, relative to the control. [000270] Compounds with an IC50 value less than 30 μ were deemed to be active.
Table 5: Inhibition of hIL-6 mRNA Transcription
Figure imgf000139_0001
Example 74: Inhibition of IL-17 mRNA Transcription
[000271] In this example, hIL-17 mRNA in human peripheral blood
mononuclear cells was quantitated to measure the transcriptional inhibition of hIL-17 when treated with a compound of the invention.
[000272] Human peripheral blood mononuclear cells were plated (2.0x10s ce) Is per well) in a 96-well plate in 45 μΐ, OpTimizer T Cell expansion media containing 20 ng/ml IL-2 and penicillin/streptomycin. The cells were treated with the test compound (45 uL at 2x concentration), and then the cells were incubated at 37°C for 1 h before addition of 1 Ox stock OKT3 antibody at 10 ug/ml in media. Cells were incubated at 37°C for 6 h before the cells were harvested. At time of harvest, cells were centrifuged (800 rpm, 5 min). Spent media was removed and cell lysis solution (70 uL) was added the cells in each well and incubated for 5- 10 min at room temperature, to allow for complete cell lysis and detachment. mRNA was then prepared using the "mRNA Catcher PLUS plate" (Invitrogen), according to the protocol supplied. After the last wash, as much wash buffer as possible was aspirated without allowing the wells to dry. Elution buffer (E3, 70 μί) was then added to each well. mRNA was then eluted by incubating the mRNA Catcher PLUS plate with Elution Buffer for 5 min at 68°C and then immediately placing the plate on ice.
[000273] The eluted mRNA isolated was then used in a one-step quantitative RT-PCR reaction, using components of the Ultra Sense Kit together with Applied Biosystems primer-probe mixes. Real-time PCR data was analyzed, normalizing the Ct values for hIL-17 to an internal control, prior to deterrnining the fold induction of each unknown sample, relative to the control.
[000274] Compounds with an IC50 value less than 30 μΜ were deemed to be active. Table 6: Inhibition of hIL-17 mR A Transcription
Figure imgf000140_0001
Example 75: Inhibition of hVCAM mRNA Transcription
[000275] In this example, hVCAMmRNA in tissue culture cells is quantitated to measure the transcriptional inhibition of hVCAM when treated with a compound of the present disclosure.
[000276] Human umbilical vein endothelial cells (HUVECs) are plated in a 96-well plate (4.0 x1ο3 cells/well) in 100 μΙ> EGM media and incubated for 24 h prior to the addition of the compound of interest. The cells are pretreated for 1 h with the test compound prior to stimulation with tumor necrosis factor-a. The cells are incubated for an additional 24 h before the cells are harvested. At time of harvest, the spent media is removed from the HUVECs and rinsed in 200 μL PBS. Cell lysis solution (70 uL) is then added the cells in each well and incubated for -5-10 min at room temperature, to allow for complete cell lysis and detachment. mR A is then prepared using the "mRNA Catcher PLUS plate" (Invitrogen), according to the protocol supplied. After the last wash, as much wash buffer as possible is aspirated without allowing the wells to dry. Elution buffer (E3, 70 μί) is then added to each well. mRNA is then eluted by incubating the mRNA Catcher PLUS plate with elution buffer for 5 min at 68°C and then immediately placing the plate on ice.
[000277] The eluted mRNA so isolated is then used in a one-step quantitative realtime PCR reaction, using components of the Ultra Sense Kit together with Applied
Biosystems primer-probe mixes. Real-time PCR data is analyzed, normalizing the Ct values for hVCAM to an internal control, prior to determining the fold induction of each unknown sample, relative to the control.
[000278] Compounds with an ICJO value less than 30 μΜ are deemed to be active.
Example 76: Inhibition of hMCP-1 mRNA Transcription
[000279] In this example, hMCP-1 mRNA in human peripheral blood mononuclear cells is quantitated to measure the transcriptional inhibition of hMCP-1 when treated with a compound of the present disclosure.
[000280] Human Peripheral Blood Mononuclear Cells are plated (1.Ox 105 cells per well) in a 96-well plate in 45 uL RPMI-1640 containing 10% FBS and
penicillin streptomycin. The cells are treated with the test compound (45 uL at 2x
concentration), and then the cells are incubated at 37°C for 3 h before the cells are harvested,. At time of harvest, cells are transferred to V-bottom plates and centrifuged (800 rpm, 5 min). Spent media is removed and cell lysis solution (70 μί) is added to the cells in each well and incubated for 5-10 min at room temperature, to allow for complete cell lysis and detachmen mRNA is then prepared using the "mRNA Catcher PLUS plate" (Invitrogen), according to the protocol supplied. After the last wash, as much wash buffer as possible is aspirated without allowing the wells to dry. Elution buffer (E3, 70 μL) is then added to each well. mRNA is then eluted by incubating the mRNA Catcher PLUS plate with Elution Buffer for 5 min at 68°C and men immediately placing the plate on ice.
[000281] The eluted mRNA isolated is then used in a one-step quantitative real-time PCR reaction, using components of the Ultra Sense Kit together with Applied Biosystems primer-probe mixes. Real-time PCR data is analyzed, normalizing the Ct values for hMCP-1 to an internal control, prior to determining the fold induction of each unknown sample, relative to the control.
MO [000282] Compounds with an IC50 value less than 30 μΜ are deemed to be active.
Example 77: Up-regulation of hApoA-1 mRNA Transcription.
[000283] In this example, ApoA-I mRNA in tissue culture cells was quantitated to measure the transcriptional up-regulation of ApoA-I when treated with a compound of the present disclosure.
[000284] Huh7 cells (2.5 xlO5 per well) were plated in a 96-well plate using 100 μΐ. DMEM per well, (Gibco DMEM supplemented with penicilHn streptomycin and 10% FBS), 24 h before the addition of the compound of interest After 48 h treatment, the spent media was removed from the Huh-7 cells and placed on ice (for immediate use) or at -80°C (for future use) with the "LDH cytotoxicity assay Kit II" from Abeam, The cells remaining in the plate were rinsed with 100 uL PBS.
[000285] Then 85 μΐ, of cell lysis solution was added to each well and incubated for 5-10 min at room temperature, to allow for complete cell lysis and detachment. mRNA was then prepared using the "mRNA Catcher PLUS plate" from Life Technologies, according to the protocol supplied. After the last wash, as much wash buffer as possible was aspirated without allowing the wells to dry. Elution Buffer (E3, 80 μL) was men added to each well. mRNA was then eluted by incubating the mRNA Catcher PLUS plate with Elution Buffer for 5 min at 68°C , and then 1 min at 4°C. Catcher plates with mRNA eluted were kept on ice for use or stored at -80°C.
[000286] The eluted mRNA isolated was then used in a one-step real-time PCR reaction, using components of the Ultra Sense Kit together with Life Technologies primer- probe mixes. Real-time PCR data was analyzed, using the Ct values, to determine the fold induction of each unknown sample, relative to the control (that is, relative to the control for each independent DMSO concentration).
[000287] Compounds with an ECno value less than 30 μΜ were deemed to be active.
Table 8: Up-regulation of hApoA-1 mRNA Transcription.
Examples 78: In vivo efficacy in athymic nude mouse strain of an acute myeloid leukemia xenograft model using MV4-11 cells:
[000288] MV4-11 cells (ATCC) are grown under standard cell culture conditions and (NCr) nu/nu fisol strain of female mice age 6-7 weeks are injected with 5x106 cells/animal in 100 uL PBS + 100 uL Matrigel in the lower left abdominal flank. Bysapproximately day 18 after MV4-11 cells injection, mice are randomized based on tumor volume (L x Wx H)/2) of average -120 mm3. Mice are dosed orally with compound at 75 mg kg b.i.d and 120 mgkg b.i.d in EA006 formulation at 10 mL kg body weight dose volume. Tumor measurements are taken with electronic micro calipers and body weights measured on alternate days beginning from dosing period. The average tumor volumes, percent Tumor Growth Inhibition (TGI) and % change in body weights are compared relative to Vehicle control animals. The means, statistical analysis and the comparison between groups are calculated using Student's t-test in Excel.
Example 79: Evaluation of Target Engagement
[000289] MV4-11 cells (ATCC) are grown under standard cell culture conditions and (NCr) nu/nu fisol strain of female mice age 6-7 weeks were injected with 5xl06 cells/animal in 100 μΐ, PBS + 100 uL Matrigel in the lower left aMominal flank. By approximately day 28 after MV4-11 cells injection, mice are randomized based on tumor volume (L x Wx H) 2) of average -500 mm3. Mice are dosed orally with compound in EA006 formulation at 10 mL kg body weight dose volume and tumors harvested 6 hrs post dose for Bcl2 and c-myc gene expression analysis as PD biomarkers. Example 80: In Vivo Efficacy in Mouse Endotoxemia Model Assay.
[000290] Sub lethal doses of Endotoxin (E. Coli bacterial lipopolysaccharide) are administered to animals to produce a generalized inflammatory response which is monitored by increases in secreted cytokines. Compounds are administered to C57/B16 mice at T= 4 hours orally at 75 mg/kg dose to evaluate inhibition in IL-6 and IL-17 and MCP-1 cytokines post 3-h challenge with lipopolysaccharide (LPS) at T=0 hours at 0.5 mg kg dose
intraperitoneally.
Example 81: In Vivo Efficacy in Rat Collagen-Induced Arthritis
[000291] Rat collagen-induced arthritis is an experimental model of polyarthritis that has been widely used for preclinical testing of numerous anti-arthritic agents. Following administration of collagen, this model establishes a measurable polyarticular inflammation, marked cartilage destruction in association with pannus formation and mild to moderate bone resorption and periosteal bone proliferation. In this model, collagen is administered to female Lewis strain of rats on Day 1 and 7 of study and dosed with compounds from Day 11 to Day 17. Test compounds are evaluated to assess the potential to inhibit the inflammation
(including paw swelling), cartilage destruction and bone resorption in arthritic rats, using a model in which the treatment is administered after the disease has been established.
Example 82: In Vivo Efficacy in Experimental autoimmune encephalomyelitis (EAE) Model of MS
[000292] Experimental autoimmune encephalomyelitis (EAE) is a T-cell-mediated autoimmune disease of the CNS which shares many clinical and histopathologic^ features with human multiple sclerosis (MS). EAE is the most commonly used animal model of MS. T cells of both Thl and Thl7 lineage have been shown to induce EAE. Cytokines 1L-23, IL- 6 and IL-17, which are either critical for Thl and Thl 7 differentiation or produced by these T cells, play a critical and non-redundant role in EAE development. Therefore, drugs targeting production of these cytokines are likely to have therapeutic potential in treatment of MS.
[000293] Compounds of Formula I or Formula la are administered to EAE mice to access anti-inflammatory activity. In this model, EAE is induced by MOG35-55/CFA
immunization and pertussis toxin injection in female C57B1/6 mice. Example 83: Ex Vivo effects on T cell function from Splenocyte and Lymphocyte cultures stimulated with external MOG stimulation
[000294] Mice are immunized with MOG/CFA and simultaneously treated with the compound for 11 days on a b.i.d regimen. Inguinal Lymph node and spleen are harvested and cultures set up with external MOG stimulation for 72 hours. Supernatants from these cultures are analyzed for TH1, Th2 and Th17 cytokines using a Cytometric Bead Array assay.
Example 84: In vivo efficacy in athymic nude mouse strain of multiple myeloma xenograft model using MMl.s cells
[000295] MMl.s cells (ATCC) are grown under standard cell culture conditions and (NCr) nu/nu fisol strain of female mice age 6-7 weeks are injected with 10*106 cells/animal in 100 μL PBS + 100 uL Matrigel in the lower left abdominal flank. By approximately day 21 after MM1.s cells injection, mice are randomized based on tumor volume (L x Wx H)/2) of average -120 mm3. Mice are dosed orally with compound at 75 mg kg b.i.d in EA006 formulation at 10 mL/kg body weight dose volume. Tumor measurements are taken with electronic micro calipers and body weights measured on alternate days beginning from dosing period. The average tumor volumes, percent Tumor Growth Inhibition (TGI) and % change in body weights are compared relative to Vehicle control animals. The means, statistical analysis and the comparison between groups are calculated using Student's t-test in Excel.
[000296] Other embodiments of the present disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the present disclosure disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the present disclosure being indicated by the following claims.

Claims

What is claimed is:
1 t A compound according to Formula I:
Figure imgf000146_0001
Formula I
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:
Wi is selected from N and CRi;
W2 is selected from N and CR2;
W3 is selected from N and CR3;
W is selected from N and CR*;
X is selected from N and CH;
Y is selected from -S(0>, -C(0)-, -NH-, - HCH2-, -NHCH2CH2-, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(C]-C3), halogen, hydroxyl, or amino;
Ri, R2, R3, and R4 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amino, aryloxy, aminoalkyl, aryl, hydroxyl, and halogen;
two adjacent substituents selected from R\, R2, R3, and R4 may be connected in a 5- or 6-membered ring to form a bicyclic carbocycle or bicyclic heterocycle;
R5 is selected from amino and 5- and 6- membered carbocycles and heterocycles;
R¾ is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl; and
R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
2. The compound of claim 1 , according to Formula la: R7
Re
H
Figure imgf000147_0001
Formula la
or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:
X is selected from N and CH;
Y is selected from -S(0)-, -C(0 , -NH-, -NHCH2-, - HCH2CH2-, and - NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with alkyl(CpC3), halogen, hydroxyl, or amino;
Ri and R3 are independently selected from hydrogen, alkyl, alkenyl, alk nyl, alkoxy, amino such as, e.g., aminoalkyl, aryloxy, aryl, hydroxyl, and halogen;
R5 is selected from amino, aminoalkyl, 5- and 6- membered carbocycles and heterocycles optionally substituted with halogen, amino, amide, alkyl(Ci-C6), or alkoxy(Ci- C$) for example, the structures
Figure imgf000147_0002
wherein Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, - C(0)Pr, -C(0)iPr, benzyl, -C(0)CF3, -C(0 tBu, -C(0)NHiPr, -C(0) Me2, -C(0)NHEt, - C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2(¾amino, and - CH2CH2C(Me)20H;
R<5 is selected from hydrogen, alkoxy, alkyl, halogen, aminoalkyl, and thioalkyl; and R7 is selected from hydrogen, alkyl, alkoxy, thioalkyl, aminoalkyl, and halogen.
3. The compound of claim 1 , wherein each of Ri, R2> R3, and R4, if present, are independently selected from hydrogen, alkyl, alkoxy, amino, and halogen.
4. The compound of claim 2, wherein each of Ri and R3 are independently selected from hydrogen, alkyl, alkoxy, amnio, and halogen.
5. The compound of claim 1 or claim 3, wherein each of Rj , R2, R3, and Rj, if present, are independently selected from hydrogen, alkyl, and alkoxy, each of which may be optionally substituted with hydroxyl, amino, or halogen,
6. The compound of claim 2 or claim 4, wherein each of Rj and R3 are independently selected from hydrogen, alkyl, and alkoxy, each of which may be optionally substituted with hydroxyl, amino, or halogen.
7. The compound of any one of claims 1, 3, or S, wherein each of Ri, R2, R3, and R4, if present, are independently selected from aryl and aryloxy, each of which may be optionally substituted with halogen, alkoxy, and amino.
8. The compound of claim 2, wherein each of Rj and R3 are independently selected from aryl and aryloxy, each of which may be optionally substituted with halogen, alkoxy, or amino.
9. The compound of any one of claims 1 , 3, 5, or 7, wherein
Wi is CRi;
W3 is CR3; and
Ri and R3 are each independently an alkoxy group.
10. The compound of any one of claims 1 , 3, 5, 7, or 9, wherein the alkoxy group is selected from methoxy, ethoxy, isopropoxy, and propoxy.
11. The compound of claim 2, wherein Ri and R3 are each independently an alkoxy group, for example methoxy, ethoxy, isopropoxy, and propoxy.
12. The compound of claim 11, wherein Ri and R3 are each methoxy.
13. The compound of any one of claims 1, 3, 5, 7, 9, or 10, wherein Wj is CR|, W2 is CR2, W3 is CR3, W4 is CR , and Ri and R3 are each alkoxy and R2 and R4 are each hydrogen.
14. The compound of any one of claims 1 , 3, 5, 7, 9, 10, or 13, wherein Wj is CRi, W2 is CR2, W3 is CR3, W4 is CR4, and Rj and R3 are each methoxy and R2 and R4 are each hydrogen.
15. The compound of claim 1, wherein Wj is CRi, W2 is CR2, 3 is CR3, W4 is CR4, R] is methoxy, R3 is amino or aminoalkyl, and R2 and R> are each hydrogen.
16. The compound of claim 2, wherein Rt is methoxy and R3 is amino or aminoalkyl.
17. The compound of claim 1 or 2, wherein R5 is aminoalkyl.
18. The compound of any one of claims 1 to 16, wherein Y is selected from -NH-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring, and one or more hydrogens may be optionally substituted with F, Me, OMe, and CI.
19. The compound of any one of claims 1 to 18, wherein Y is -NH-.
20. The compound of any one of claims 1 to 19, wherein X is N.
21. The compound of any one of claims 1 to 20, wherein R5 is selected from amino and 5- and 6- membered carbocycles and heterocycles optionally substituted with halogen, amino, urea, ester, carbamate, amide, alkyl(Ci-C6); alkoxy(Cj-C6), and aryl.
22. The compound of any one of claims 1 to 21, wherein R5 is selected from - NHRa, and 5- and 6-membered carbocycles and heterocycles optionally substituted with halogen, amino, urea, ester, carbamate, amide, alkyl(Ct-C6), alkoxyiCi-Ce), or aryl selected from the group
Figure imgf000149_0001
, where Ra is selected from hydrogen, alkyl, alkenyl, aryl, -C(0)Alkyl(Ci-C4), -C(0)Amino, -C(0)Oalkyl(Ci-C4), and benzyl.
23. The compound of any one of claims 1 to 22, wherein R5 is selected from - NHRa, and 5- and 6-membered carbocycles and heterocycles optionally substituted with halogen, amino, amide, alkyl(Ci-C6), or alkoxy(Ci-Ci) selected from the group
Figure imgf000150_0001
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0>tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH CH2OH, -CH2CH2arnino, and -CH2CH2C(Me)20H.
24. The compound of any one of claims 1 to 23, wherein R$ is selected from hydrogen, alkyl, alkoxy, aminoaikyi, and thioalkyl, each of which may be optionally substituted with halogen, amino, hydroxyl, or alkoxy.
25. The compound of any one of claims 1 to 24, wherein R« is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
26. The compound of any one of claims 1 to 25, wherein R is selected from hydrogen, methyl, and methoxy.
27. The compound of any one of claims claims 1 to 23, wherein Re is selected from groups represented by Formula Π:
Figure imgf000150_0002
wherein:
D and E are independently selected from O, N, and S;
Rg is selected from hydrogen and alkyl, and Re is present only if D is N;
R9 and Rio are independently selected from hydrogen, alkyl, and cycloalkyl, and only one of R and Rio is present if E is O or S;
R9 and Rio may be connected to form a carbocycle or a heterocycle containing one or more heteroatoms; and
n is selected from 1, 2, and 3.
28. The compound of claim 27, wherein
D is O and E is N; n is l; and
R and Rio are independently selected from hydrogen, alkyl, and carbocycle.
29. The compound of claim 27 or claim 28, wherein ¾ is selected from:
Figure imgf000151_0001
30. The compound of any one of claims 1 to 29, wherein R7 is selected from hydrogen, methoxy, ethoxy, propoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, and -
OCF3.
31. The compound of claim 1 , wherein
Wi is CRi;
W2 IS CR2;
W3 I CR3;
W4 is CR4;
Ri and R3 are each alkoxy;
R2 and RA are each hydrogen
Y is selected from-NH-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring;
Rj is selected from -NHRa, and a 5- or 6-membered carbocycle or heterocycles selected from
Ra
Figure imgf000151_0002
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -0(Ο)Ν <¾, -C(0)NHEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2CH2amino, and -C CH^iMefcOH; and
R<5 is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
32. The compound of claim 1 , wherein
W, is CRi;
W2 is Cl¾;
W3 is CR3;
W4 IS CR4;
Ri is alkoxy;
R3 is amino or aminoalkyl;
R2 and * are each hydrogen;
Y is selected from-ΝΗ-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring;
R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
Ra
Figure imgf000152_0001
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0) HiPr, -C^ e -C(0) HEt, -C(0)NH2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, -CH2CH2amino, and -CH2CH2C(Me)2OH; and
¾ is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxyl or amino.
33. The compound of claim 2, wherein
Ri is alkoxy;
R3 is amino or aminoalkyl;
Y is selected from-NH-, -NHCH2-, -NHCH2CH2-, and -NHCH2CH2CH2-, with the nitrogen attached to the B ring; R5 is selected from -NHRa and 5- or 6-membered carbocycle or heterocycles selected from
Figure imgf000153_0001
, where Ra is selected from hydrogen, methyl, ethyl, propyl, isopropyl, t-butyl, -C(0)Me, -C(0)Pr, -C(0)iPr, benzyl, - C(0)CF3, -C(0)-tBu, -C(0)NHiPr, -C(0)NMe2, -C(0)NHEt, -C(0) H2, -C(0)CH(OH)CH3, -C(0)C(0)OMe, -CF3, -CH2CH2OH, ¾CH2amino, and -CH^HzCiMe^OH; and
Re is selected from hydrogen, methyl, methoxy, ethoxy, and alkoxy optionally substituted with a hydroxy! or amino.
34. A compound selected from:
5,7-Dimethoxy-2-(4-methoxy-2-((l-methylpiperidin-4-yl)amino)
4(3H)-one;
5 ,7-Dimethoxy-2-(4-me hoxy-2-(4-methylpiperazm 1 -carbonyl)phenyl) quinazolin- 4(3H)- ne;
2^2^(l-isopropylpiperidm^-yl)ani^^
4(3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-((l-methylpyn-olidm-3-yl)ainm
4(3H one;
5,7-Dimethoxy-2-(4-methoxy-2-(methyl(l-m
quinazolin-4(3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-((( 1 -memylpiperi<iin-4-yl)methyI)amino)phenyl) quinazoli -^SH)"0116?
5,7-Dime oxy-2^4-me&oxy-2^((lHme^
quinazolin-4(3i/)-one;
2-(2-((2-(Isopropylamino)ethyl)aniino)-4-methoxyphenyl)-5,7-cUmethoxyqui
4(3H)-one; 5 ^iniethoxy-2^4-Methoxy-2^(teti^
phenyl)quinazolin-4(3H)-one;
2^2^(1 -Isopropylpiperidin^yi)a^
5 -Dimethoxy-2^4-me1 oxy-2-((2^ynOUdin-l-yl)eth
4(3H one;
5,7-Diraethoxy-2-(4-methoxy-2-((2-(piperidin-l-yl)ethyl)amino
4(3H)-one;
5 -Dimethoxy-2^4-methoxy-2-((3Hm^
4(3 i one;
5,7-Din1e hoxy-2-(4-raetho y-2-((2-nΊO holinoethyl)amino)phenyl)-quin 4(3H one;
5, 7-Dimethoxy-2-{4-inethoxy-2-<(3 -( yrrol^
4(3H)-one;
2^2^((l-Isopropylpyrrolidin -y^
dimethoxyquinazolin-4(3H)-one;
2-(2^((l-Isopropylp;yiToHdm^
dimethoxyquinazolin-4(3-H)-one;
2^3^(l-Isopropylpiperidiii^yl)a_^
4(3H)-one;
2 2^(l-l^birtyrylpiperidin^-yl)aminoH-meih
dimethoxyquinazolin-4(3 H)-one;
2-(2-((3 -(Isopropylaraino)propyl)amino)-4-methoxyphenyl)-5 ,7- dimethoxyquinazolin-4(3H)-one;
5 ,7-Dimethoxy-2-(4-methoxy-2-((3 -(methylpiperazin- 1 -yl)propyl)amino)- phenylq\iinazolin-4(3H)-one;
2-(2-((2-(4-Isopropylpiperazin- 1 -yl)ethyl)amino)-4-methoxyphenyl)-5,7- dimethoxyquinazolin-4(3H one;
5,7-Dimethoxy-2-[4-methoxy-2-(l-methylpiperidin-4-ylsulfinyl)phenyl]quinaz^ 4(3H)-one;
5J-Dimethoxy-2-(4-methoxy-2^(2^ipe^
4(3H)-one;
5,7-Dimethoxy-2-(4-methoxy-2-((2-(4-methylpiperazin-l-yl)ethyl)anim quinazolin-4(3 /)-one; 2-(2-(( 1 -Isopropylpiperidin^yl)amin^^
4(3H one;
2^3^(l-Isopropylpiperidin^-yl)^
5,7-Dimethoxy-2-(4-methoxy-2-[3-(piperazin- 1 -yl)propylamino]phenyl)quinazolin- 4(3H)-one;
2^2^(4,4-Dimethylcyclohexyl)amijio)^methoxypheny^^
4(3H)-one;
2-(3-((l-Isopropylpiperidin-4-yl)ardno)-5-methoxypyridin-2-yl)-5,7- dimethoxyquinazolin-4(3H)-one;
2^2^( ran ^2-Hy(kox propa^
dimethoxyquinazolin-4(3H)-one;
2-(3-((l-Isobutyrylpiperidin-4-yl)amino)-5-methoxypyridm^
dimethoxyqiiinazolin-4(3H)-one;
2^4^Moro-2-((1 sopropylpiperid^
4(3H one;
2^4-Chloro-2-((1 sobutyiylpiperi(Un^yl)ainin
4(3 -one;
2-(2-((l-Benzylpiperidin-4-yl)ainino)-4-met oxyphenyl)-5,7
4(3H)-one;
2 (l-Isobutyiylpiperidin^yl)amino)pyridin-2-yl^
one;
2^3^(l-Acetylpiperidin^yl)amino)pyridJ tte
one;
N-(cw-4-((2-(5 -Dimet oxy-4-oxo-3,4-d^^
yl)amino)cyclohexyl)isobutyramide;
2-(2-(( 1 -Acetylpiperidin-4-yl)amino)-4-methoxy^^
4(5 i one;
5,7-Dimethoxy-2-( 5 -methoxy-3 -(( 1 -methylpiperidin-4-yl)amino)pyridin-2- yl)quinazolin-4(3 -)-one;
5,7-Diinethoxy-2-(3-(((l-methylpynOlidin-3-yl)methyl)amino)py^
yl)qiiinazolin-4(3H)-one;
4-((2-(5J-EHmethoxy^oxo-3,4^ihydroquinazolin-2-yl)^
dimethylpiperidine- 1 -carboxamide; 2-(3-((3-(Isopropylamino)propyl)aniino^^
4(3H one;
5,7-Dimethoxy-2-(3-((l-methylpiperidiji-4-yl)araino)pyrid
one;
m-4~((2-(5,7-Dimethoxy-4-oxo-3,4-dihydr^
yl)amino)-N-isopropy lcyclohexane- 1 -carboxamide;
5,7-Dimethoxy-2-(3-((l-(2,2^-trifluoroacetyl)piperidin-4-yl)aniino^ yl)quiiiazoIin-4(5H)-one;
4-((2-(5 ,7-Dimethoxy-4-oxo-3 ,4-dihydroquinazolin-2-yl)pyridin-3 -yl^ isopropylpiperidine- 1 -carboxamide;
5 -Dimethoxy-2-(3-((l-pivaloylpipe^
one;
5 7-0^είηο^-2-(3-((2^θ ηοη^οβ^
2-(3-((l -Isopropylpiperidm-4-yl)amino 5-(2-((l -isopropylpiperidin-4- y1)airdno)ethoxy)pyridm-2-yl)-5 7-d
2-(4-((2-(5,7-Dimethoxy-4- )xo-3,4-dihydroquinazolin-2-yl)pyri yl)amino)piperidin- 1 -y1)-JV, Wimethyl-2-oxoacetamide;
4-((2-(5 -dimethoxy-4-oxo-3,4-dihydroq ina∞
ethylpiperidine- 1 -carboxamide;
cw-4-((2-(5,7-Dimethoxy-4-oxo-3,4-cUhydro^
N^-dimethylcy clohexane- 1 -carboxamide;
4-((2-(5,7-Dimethoxy-4-oxo-3,4-dihy(lrc>quirLazolin-2-yl)pyri yl)amino)piperidine- 1 -carboxamide;
Memyl-2-(4-((2-(5 -dimemoxy-4-oxo-3,4-dihydroqui
yl)amino)piperidin- 1 -yl)-2-oxoacetate;
N- 2-((2-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin yl)amino)etbyl)isobutyramide;
N-(3-((2-(5,7-I)imemoxy-4-oxo-3,4-dmydroqumazo^
yl)amino)propyl)isobutyramide;
2-(3-((l-Isopropylpiperidin-4-yl)ain^
^pyrimidin-4(5/ )-one;
2-(3-((l-(2-Hydroxy-2-memylpropyl)piperid^
dimethoxyquinazolin-4(JH)-one; 2-(3^(H24iydroxypropanoyl)piperidm^^
dimethoxyquinazolin-4(5H)-one;
2-(3-(( 1 -Isopropylpiperidin-4-yl)amino)pyridin-2-yl)-5-methoxy-7-((4- methoxybenzyl)amino)quinazoUn^3/ -Ojne;
2-[5^2-Hydroxyeihoxy)-3^1-isopropylpiperidin^-ylan^o)pyri
dimethoxyquinazolin^3H)-one;
cw-4-((2-(5,7-Dime1hoxy-4-oxcH3,4-dihydroquinazolin-2-yl)pyri^^
isopropylcyclohexane- 1 -carboxamide;
2-[5^2-Hydroxye&oxy)-3^1-isobutyroy^
dimethoxyquinaz»lin-4(3H)-one;
7-amino-2-(3-((l-Isopropylpiperidin-4-yl)amino)pyridin-2-yl)-5-m
4(3/ -one;
2-{3^1Jsopropylpiperidm^ylammo)-5-P
5,7-dimethoxyquinazolin-4(3H)-one;
2- { 5 - f 2-(Isopropylamino)ethoxy] -3 -( 1 -isopropy lpiperidin-4 -ylamino)pyridin-2-yl } - 5,7^imethoxyquijiazolin^3//)-one;
2-(3-((l-(l-Hydroxy-2-methylpropan-2-yl)piperidin-4-yl)ainino)pyri
dimethoxyquina2»lin-4(3/ )-one; and
7^Ethylamiiio)-2^3^(l Sopropylpiperidin^yl)amin
methoxyquinazolin-4{3H)-one;
or a stereoisomer, tautomer, pharmaceutical ly acceptable salt, or hydrate thereof.
35. A pharmaceutical composition comprising the compound of any one of claims 1 to 34 or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, and a pharmaceutically acceptable carrier.
36. A method for inhibition of BET protein function comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
37. A method of treating an autoimmune or inflammatory disorder associated with BET proteins comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
38. The method of claim 37, wherein the autoimmune or inflammatory disorder is selected from Acute Disseminated Encephalomyelitis, Agammaglobulinemia, Allergic Disease, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Anti-phospholipid syndrome, Autoimmune aplastic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Autoimmune myocarditis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura, Behcet's Disease, Bullous pemphigoid, Castleman's Disease, Celiac Disease, Churg-Strauss syndrome, Crohn's Disease, Cogan's syndrome, Dry eye syndrome, Essential mixed cryoglobulinemia, Dermatomyositis, Devic's Disease, Encephalitis, Eosinophlic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Giant cell arteritis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis (Wegener's), Graves' Disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, idiopathic pulmonary fibrosis, IgA nephropathy,
Inclusion body myositis, Type I diabetes, Interstitial cystitis, Kawasaki's Disease,
Leukocytoclastic vasculitis, Lichen planus, Lupus (SLE), Microscopic polyangitis, Multiple sclerosis, Myasthenia gravis, myositis, Optic neuritis, Pemphigus, POEMS syndrome, Polyarteritis nodosa, Primary biliary cirrhosis, Psoriasis, Psoriatic arthritis, Pyoderma gangrenosum, Relapsing polychondritis, Rheumatoid arthritis, Sarcoidosis, Scleroderma, Sjogren's syndrome, Takayasu's arteritis, Transverse myelitis, Ulcerative colitis, Uveitis, and Vitiligo.
39. A method of treating an acute or chronic non-autoimmune inflammatory disorder characterized by disregulation of IL-6 and/or 1L-17 comprising administering a
therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
40. The method of claim 39, wherein the acute or chronic non-autoimmune inflammatory disorder is selected from sinusitis, pneumonitis, osteomyelitis, gastritis, enteritis, gingivitis, appendicitis, irritable bowel syndrome, tissue graft rejection, chronic obstructive pulmonary disease (COPD), septic shock, osteoarthritis, acute gout, acute lung injury, acute renal failure, burns, Herxheimer reaction, and SIRS associated with viral infections.
41. The method of claim 39, wherein the acute or chronic non-autoimmune inflammatory disorder is selected from rheumatoid arthritis (RA) and multiple sclerosis (MS).
42. A method of treating a cancer associated with overexpression, translocation, amplification, or rearrangement of a myc family oncoprotein that is sensitive to BET inhibition comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
43. The method of claim 42, wherein the cancer is selected from B-acute lymphocytic leukemia, Burkitt's lymphoma, Diffuse large cell lymphoma, Multiple myeloma, Primary plasma cell leukemia, Atypical carcinoid lung cancer, Bladder cancer, Breast cancer, Cervix cancer, Colon cancer, Gastric cancer, Glioblastoma, Hepatocellular carcinoma, Large cell neuroendocrine carcinoma, Medulloblastoma, Melanoma, nodular, Melanoma, superficial spreading, Neuroblastoma, esophageal squamous cell carcinoma, Osteosarcoma, Ovarian cancer, Prostate cancer, Renal clear cell carcinoma, Retinoblastoma, Rhabdomyosarcoma, and Small cell lung carcinoma.
44. A method of treating a cancer associated with overexpression, translocation, amplification, or rearrangement of BET proteins comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
45. The method of claim 44, wherein the cancer is selected from NUT midline carcinoma, B-cell lymphoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, and colon cancer.
46. A method of treating a cancer that relies on pTEFb (Cdk9/cyclin T) and BET proteins to regulate oncogenes comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
47. The method of claim 46, wherein the cancer is selected from chronic lymphocytic leukemia and multiple myeloma, follicular lymphoma, diffuse large B cell lymphoma with germinal center phenotype, Burkitt's lymphoma, Hodgkin's lymphoma, follicular lymphomas and activated, anaplastic large cell lymphoma, neuroblastoma and primary neuroectodermal tumor, rhabdomyosarcoma, prostate cancer, and breast cancer.
48. A method of treating a cancer associated with upregulation of BET responsive genes CDK6, Bcl2, TYR03, MYB, and hTERT comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
49. The method of claim 46, wherein the cancer is selected from pancreatic cancer, breast cancer, colon cancer, glioblastoma, adenoid cystic carcinoma, T-cell prolymphocytic leukemia, malignant glioma, bladder cancer, medulloblastoma, thyroid cancer, melanoma, multiple myeloma, Barret's adenocarcinoma, hepatoma, prostate cancer, pro-myelocytic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, small cell lung cancer, and renal carcinoma.
50. A method of treating a cancer that is sensitive to effects of BET inhibition comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
51. The method of claim 50, wherein the cancer is selected from NUT-midline carcinoma (NMV), acute myeloid leukemia (AML), acute B lymphoblastic leukemia OB- ALL), Burkitt's Lymphoma, B-cell Lymphoma, Melanoma, mixed lineage leukemia, multiple myeloma, pro-myelocytic leukemia (PML), non-Hodgkin's lymphoma,
Neuroblastoma, Medulloblastoma, lung carcinoma (NSCLC, SCLC), and colon carcinoma.
52. The method of any one of claims 42 to 51 , wherein the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 is combined with other therapies, chemotherapeutic agents or antiproliferative agents.
53. The method of claim 52, wherein the therapeutic agent is selected from ABT-737, Azacitidine (Vidaza), AZD1152 (Barasertib), AZD2281 (Olaparib), AZD6244 (Selumetinib), BEZ235, Bleomycin Sulfate, Bortezomib (Velcade), Busulfan (Myleran), Camptothecin, Cisplatin, Cyclophosphamide (Clafen), CYT387, Cytarabine (Ara-C), Dacarbazine, DAPT (GSI- Q, Decitabine, Dexamethasone, Doxorubicin (Adriamycin), Etoposide, Everolimus (RADOOl), Flavopiridol (Alvocidib), Ganetespib (STA-9090), Gefitinib (Iressa), Idarubicin, Ifosfamide (Mitoxana), IFNa2a (Roferon A), Melphalan (Alkeran), Methazolastone
(temozolomide), Metformin, Mitoxantrone (Novantrone), Paclitaxel, Phenformin, PKC412 (Midostaurin), PLX4032 (Vemurafenib), Pomalidomide (CC-4047), Prednisone (Deltasone), Rapamycin, Revlimid (Lenalidomide), Ruxolitinib (iNCBO 18424), Sorafenib (Nexavar), SU11248 (Sunitinib), SU11274, Vinblastine, Vincristine (Oncovin), Vinorelbine (Navelbine), Vorinostat (SAHA), and WP1130 (Degrasyn).
54. A method of treating a benign proliferative or fibrotic disorder, selected from benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, juvenile polyposis syndrome, idiopathic pulmonary fibrosis, renal fibrosis, postoperative stricture, keloid formation, scleroderma, and cardiac fibrosis comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
55. A method of treating a disease or disorder that benefits from up-regulation or ApoAI transcription and protein expression comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
56. The method of claim 55, wherein the disease is cardiovascular disease, dyslipidemia, atheroschlerosis, hypercholesterolemia, metabolic syndeome, and Alzheimer's disease.
57. A method of treating a metabolic disease or disorder comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
58. The method of claim 57, wherein the metabolic disorder is selected from obesity- associated inflammation, type Π diabetes, and insulin resistance.
59. A method of treating a cancer associated with a virus comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
60. The method of claim 59, wherein the virus is selected from Epstein-Barr Virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Kaposi's sarcoma associated virus (KSHV), human papilloma virus (HPV), Merkel cell polyomavirus, and human
cytomegalovirus (CMV).
61. A method for treating HIV infection comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 alone or in combination with anti -retroviral therapeutic.
62. A method for treating a disease or disorder selected from Alzheimer's disease, Parkinson's disease, Huntington disease, bipolar disorder, schizophrenia, Rubinstein-Taybi syndrome, and epilepsy comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
63. A method of male contraception comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35.
64. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for the manufacture of a medicament for use in a method of for treating according to any one of claims 36 to 63.
65. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a disease or condition associated with BET by inhibiting a BET protein function.
66. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 in method of treating an autoimmune or inflammatory disorder associated with BET proteins.
67. The use according to claim 66, wherein the autoimmune or inflammatory disorder is selected from Acute Disseminated Encephalomyelitis, Agammaglobulinemia, Allergic Disease, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Anti-phospholipid syndrome, Autoimmune aplastic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Autoimmune myocarditis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura, Behcet's Disease, Bullous pemphigoid, Castleman's Disease, Celiac Disease, Churg-Strauss syndrome, Crohn's Disease, Cogan's syndrome, Dry eye syndrome, Essential mixed cryoglobulinemia, Dermatomyositis, Devic's Disease, Encephalitis, Eosinophilic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Giant cell arteritis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis (Wegener's), Graves' Disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, idiopathic pulmonary fibrosis, IgA nephropathy, Inclusion body myositis, Type I diabetes, Interstitial cystitis, Kawasaki's Disease,
Leukocytoclastic vasculitis, Lichen planus, Lupus (SLE), Microscopic polyangids, Multiple sclerosis, Myasthenia gravis, myositis, Optic neuritis, Pemphigus, POEMS syndrome, Polyarteritis nodosa, Primary biliary cirrhosis, Psoriasis, Psoriatic arthritis, Pyoderma gangrenosum, Relapsing polychondritis, Rheumatoid arthritis, Sarcoidosis, Scleroderma, Sjogren's syndrome, Takayasu's arteritis, Transverse myelitis, Ulcerative colitis, Uveitis, and Vitiligo.
68. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating an acute or chronic non-autoimmune inflammatory disorder characterized by disregulation of IL-6 and/or EL- 17.
69. The use according to of claim 68, wherein the acute or chronic non-autoimmune inflammatory disorder is selected from sinusitis, pneumonitis, osteomyelitis, gastritis, enteritis, gingivitis, appendicitis, irritable bowel syndrome, tissue graft rejection, chronic obstructive pulmonary disease (COPD), septic shock, osteoarthritis, acute gout, acute lung injury, acute renal failure, burns, Herxheimer reaction, and SIRS associated with viral infections.
70. The use according to claim 68, wherein the acute or chronic non-autoimmune inflammatory disorder is selected from rheumatoid arthritis (RA) and multiple sclerosis (MS).
71. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a cancer associated with overexpression, translocation, amplification, or rearrangement of a myc family oncoprotein that is sensitive to BET inhibition.
72. The use according to claim 71 , wherein the cancer is selected from B-acute lymphocytic leukemia, Burkitt's lymphoma, Diffuse large cell lymphoma, Multiple myeloma, Primary plasma cell leukemia, Atypical carcinoid lung cancer, Bladder cancer, Breast cancer, Cervix cancer, Colon cancer, Gastric cancer, Glioblastoma, Hepatocellular carcinoma, Large cell neuroendocrine carcinoma, Medulloblastoma, Melanoma, nodular, Melanoma, superficial spreading, Neuroblastoma, esophageal squamous cell carcinoma, Osteosarcoma, Ovarian cancer, Prostate cancer, Renal clear cell carcinoma, Retinoblastoma, Rhabdomyosarcoma, and Small cell lung carcinoma.
73. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a cancer associated with overexpression, translocation, amplification, or rearrangement of BET proteins.
74. The use according to claim 73, wherein the cancer is selected from NUT midline carcinoma, B-cell lymphoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, and colon cancer.
75. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a cancer that relies on pTEFb (Cdk9/cyclin T) and BET proteins to regulate oncogenes.
76. The use according to claim 75, wherein the cancer is selected from chronic lymphocytic leukemia and multiple myeloma, follicular lymphoma, diffuse large B cell lymphoma with germinal center phenotype, Burkitt's lymphoma, Hodgkin's lymphoma, follicular lymphomas and activated, anaplastic large cell lymphoma, neuroblastoma and primary neuroectodermal tumor, rhabdomyosarcoma, prostate cancer, and breast cancer.
77. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a cancer associated with upregulation of BET responsive genes CDK6, Bcl2, TYR03, MYB, and hTERT.
78. The use according to claim 77, wherein the cancer is selected from pancreatic cancer, breast cancer, colon cancer, glioblastoma, adenoid cystic carcinoma, T-cell prolymphocyte leukemia, malignant glioma, bladder cancer, medulloblastoma, thyroid cancer, melanoma, multiple myeloma, Barret's adenocarcinoma, hepatoma, prostate cancer, pro-rayelocytic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-celi lymphoma, small cell lung cancer, and renal carcinoma.
79. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a cancer that is sensitive to effects of BET inhibition.
80. The use according to claim 79, wherein the cancer is selected from NUT- midiine carcinoma (NMV), acute myeloid leukemia (AML), acute B lymphoblastic leukemia (B-ALL), Burkitt's Lymphoma, B-cell Lymphoma, Melanoma, mixed lineage leukemia, multiple myeloma, pro-myelocytic leukemia (PML), non-Hodgkin's lymphoma,
Neuroblastoma, Medulloblastoma, lung carcinoma (NSCLC, SCLC), and colon carcinoma.
81. The use according to any one of claims 65 to 80, wherein the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 is combined with other therapies, chemotherapeutic agents or antiproliferative agents.
82. The use according to claim 81 , wherein the therapeutic agent is selected from ABT-737, Azacrtidine (Vidaza), AZDl 152 (Barasertib), AZD2281 (Olaparib), AZD6244 (Selumetinib), BEZ235, Bleomycin Sulfate, Bortezomib (Velcade), Busulfan (Myleran), Camptothecin, Cisplatin, Cyclophosphamide (Clafen), CYT387, Cytarabine (Ara-C), Dacarbazine, DAPT (GSI-Di), Decitabine, Dexamethasone, Doxorubicin (Adriamycin), Etoposide, Everoiimus (RAD001), Flavopiridol (Alvocidib), Ganetespib (STA-9090), Gefitinib (Iressa), Idarubicin, Ifosfamide (Mitoxana), IFNa2a (Roferon A), Melphalan (Alkeran), Methazolastone (temozolomide), Metformin, Mitoxantrone (Novantrone), Paclitaxel, Phenformin, PKC412 (Midostaurin), PLX4032 (Vemurafenib), Pomalidomide (CC-4047), Prednisone (Deltasone), Rapamycin, Revlimid (Lenalidomide), Ruxolitinib (INCB018424), Sorafemb (Nexavar), SU 11248 (Sunitinib), SU11274, Vinblastine,
Vincristine (Oncovin), Vinorelbine (Navelbine), Vorinostat (SAHA), and WP1130
(Degrasyn).
83. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a benign
proliferative or fibrotic disorder, selected from the group consisting of benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, juvenile polyposis syndrome, idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma, and cardiac fibrosis.
84. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a disease or disorder that benefits from up-regulation or ApoAl transcription and protein expression.
85. The use according to claim 84, wherein the disease is cardiovascular disease, dyslipidemia, atheroschlerosis, hypercholesterolemia, metabolic syndeome, and Alzheimer's disease.
86. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a metabolic disease or disorder.
87. The use according to claim 86, wherein the metabolic disorder is selected from obesity-associated inflammation, type Π diabetes, and insulin resistance.
88. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a cancer associated with a virus.
89. The use according to claim 88, wherein the virus is selected from Epstein-Barr Virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Kaposi's sarcoma associated virus (KSHV), human papilloma virus (HPV), Merkel cell polyomavirus, and human cytomegalovirus (CMV).
90. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35, alone or in combination with an anti-retro viral therapeutic for treating HIV infection.
91. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for treating a disease or disorder selected from Alzheimer's disease, Parkinson's disease, Huntington disease, bipolar disorder, schizophrenia, Rubinstein-Taybi syndrome, and epilepsy.
92. Use of a therapeutically effective amount of the compound of any one of claims 1 to 34 or a pharmaceutical composition according to claim 35 for male contraception.
PCT/IB2014/002510 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors WO2015015318A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EA201690087A EA201690087A1 (en) 2013-07-31 2014-07-30 NEW QUINAZOLINONS AS BROMOMODENIAL INHIBITORS
JP2016530632A JP6542212B2 (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors
KR1020167005227A KR20160038008A (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors
CN201480053771.5A CN105593224B (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors
EP14832298.5A EP3027604B1 (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors
US14/908,898 US9855271B2 (en) 2013-07-31 2014-07-30 Quinazolinones as bromodomain inhibitors
AU2014298051A AU2014298051B2 (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors
CA2919948A CA2919948C (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors
IL243479A IL243479B (en) 2013-07-31 2016-01-04 Novel quinazolinones as bromodomain inhibitors
HK16106581.4A HK1218547A1 (en) 2013-07-31 2016-06-08 Novel quinazolinones as bromodomain inhibitors
US15/821,454 US10500209B2 (en) 2013-07-31 2017-11-22 Quinazolinones as bromodomain inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860403P 2013-07-31 2013-07-31
US61/860,403 2013-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/908,898 A-371-Of-International US9855271B2 (en) 2013-07-31 2014-07-30 Quinazolinones as bromodomain inhibitors
US15/821,454 Division US10500209B2 (en) 2013-07-31 2017-11-22 Quinazolinones as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
WO2015015318A2 true WO2015015318A2 (en) 2015-02-05
WO2015015318A3 WO2015015318A3 (en) 2015-07-16
WO2015015318A4 WO2015015318A4 (en) 2015-09-03

Family

ID=52432501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/002510 WO2015015318A2 (en) 2013-07-31 2014-07-30 Novel quinazolinones as bromodomain inhibitors

Country Status (11)

Country Link
US (2) US9855271B2 (en)
EP (1) EP3027604B1 (en)
JP (1) JP6542212B2 (en)
KR (1) KR20160038008A (en)
CN (1) CN105593224B (en)
AU (1) AU2014298051B2 (en)
CA (1) CA2919948C (en)
EA (1) EA201690087A1 (en)
HK (1) HK1218547A1 (en)
IL (1) IL243479B (en)
WO (1) WO2015015318A2 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104887680A (en) * 2015-05-08 2015-09-09 胡继承 New application of multi-poly ADP RNA polymerase inhibitor in treating HBV-related diseases
WO2015153871A3 (en) * 2014-04-04 2015-12-17 Constellation Pharmaceuticals, Inc. EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2016146755A1 (en) 2015-03-19 2016-09-22 Glaxosmithkline Intellectual Property Development Limited Covalent conjugates of bet inhibitors and alpha amino acid esters
WO2016189042A1 (en) * 2015-05-28 2016-12-01 Bayer Pharma Aktiengesellschaft Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels
WO2017015027A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US9663520B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017202742A1 (en) * 2016-05-24 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US9988376B2 (en) 2013-07-03 2018-06-05 Glaxosmithkline Intellectual Property Development Limited Benzothiophene derivatives as estrogen receptor inhibitors
US9993514B2 (en) 2013-07-03 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10266536B2 (en) 2013-03-14 2019-04-23 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10370356B2 (en) 2015-09-22 2019-08-06 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
US10428026B2 (en) 2015-09-02 2019-10-01 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
WO2019199816A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10471050B2 (en) 2015-10-05 2019-11-12 Glaxosmithkline Intellectual Property (No.2) Limited 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
US10517877B2 (en) 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10849897B2 (en) 2017-03-01 2020-12-01 Glaxosmithkline Intellectual Property (No.2) Limited Pyridyl derivatives as bromodomain inhibitors
US10934272B2 (en) 2016-04-07 2021-03-02 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridyl derivatives as bromodomain inhibitors
US10966961B2 (en) 2017-03-01 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited Pyrazole derivatives as bromodomain inhibitors
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2022053967A1 (en) * 2020-09-09 2022-03-17 Aurigene Discovery Technologies Limited Heterocyclic compounds as cbp/ep300 bromodomain inhibitors
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US11771703B2 (en) 2017-03-17 2023-10-03 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
EP4067352A4 (en) * 2019-11-26 2023-11-29 Benobio Co., Ltd. Novel quercetin redox derivative and use thereof as bet inhibitor
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
CN108715834B (en) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 Preparation method of platelet lysate rich in CD41+ and CD81+ microcapsules
CN109350616B (en) 2018-12-18 2020-04-21 南华大学 Application of I-BRD9 or derivatives thereof in preparation of antiepileptic drugs
US20220259200A1 (en) * 2019-04-24 2022-08-18 Convergene, Llc Small molecule bromodomain inhibitors and uses therof
WO2021107657A1 (en) * 2019-11-26 2021-06-03 주식회사 베노바이오 Novel quinazoline redox derivative, and use as bet inhibitor
CN111012786B (en) * 2019-12-16 2021-05-25 中山大学 Small molecular compound for activating inflammatory bodies and application thereof
CN113754593B (en) * 2020-06-01 2024-03-19 上海中医药大学 BRD4 protein inhibitor and application thereof
CN112546049A (en) * 2020-12-22 2021-03-26 中山大学中山眼科中心 Application of small molecule medicine (+) -JQ1 in preparation of medicine for treating pattern-collapse-type age-related macular degeneration
KR20240045472A (en) * 2022-09-30 2024-04-08 주식회사 베노바이오 Composition for treating osteoarthritis comprising quinazoline salt compound and preparing method of the same

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3508258A1 (en) 1985-03-08 1986-09-18 Bayer Ag, 5090 Leverkusen SS LACTAMANTIBIOTICS, METHOD FOR THE PRODUCTION AND THEIR USE AS AND IN MEDICINAL PRODUCTS
FR2643903A1 (en) 1989-03-03 1990-09-07 Union Pharma Scient Appl NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
DE4023369A1 (en) 1990-07-23 1992-01-30 Thomae Gmbh Dr K New 1-bi:phenylyl:methyl benzimidazole derivs.
RU1836357C (en) 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine
DE4225756A1 (en) 1992-01-22 1994-03-10 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
DE4224752A1 (en) 1992-04-11 1994-02-03 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
SI9210098B (en) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5125961A (en) 1991-08-12 1992-06-30 Monsanto Company Substituted pyridine compounds
DE4219534A1 (en) 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituted biphenylyl derivatives, pharmaceutical compositions containing them and methods for their preparation
DE4408497A1 (en) 1994-03-14 1995-09-21 Thomae Gmbh Dr K New bi:phenyl-methyl-benzimidazole derivs.
EP0804434A1 (en) 1994-08-02 1997-11-05 MERCK SHARP &amp; DOHME LTD. Azetidine, pyrrolidine and piperidine derivatives
CZ287545B6 (en) 1995-04-21 2000-12-13 Neurosearch As Benzimidazole derivatives, pharmaceutical preparation in which they are comprised and their use
JP2000072675A (en) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd Pharmaceutical composition
EP1144387A1 (en) 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
GB0002100D0 (en) 2000-01-28 2000-03-22 Novartis Ag Organic compounds
US20020019395A1 (en) 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
US20120028912A1 (en) 2000-02-22 2012-02-02 J.David Gladstone Institute Methods of modulating bromodomains
CN1474652A (en) 2000-10-27 2004-02-11 �ݶ�ũ�����޹�˾ Substituted 4,5-dihydro-1,2,4-triazin -6-ones, 1,2,4-triazin-6-ones, and their use as fungicides and insecticides
WO2002057267A1 (en) 2000-12-01 2002-07-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
US7148237B2 (en) 2001-03-01 2006-12-12 Shionogi & Co., Ltd. Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity
MXPA03008142A (en) 2001-03-09 2003-12-12 Pfizer Prod Inc Benzimidazole anti-inflammatory compounds.
ATE367814T1 (en) 2001-03-15 2007-08-15 Janssen Pharmaceutica Nv HIV-INHIBITING PYRAZINONE DERIVATIVES
DE60211317T2 (en) 2001-03-23 2007-04-12 Bayer Corp. RHO-KINASE INHIBITORS
KR20030083016A (en) 2001-03-28 2003-10-23 브리스톨-마이어스스퀴브컴파니 Novel Tyrosine Kinase Inhibitors
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2003068857A1 (en) 2002-02-15 2003-08-21 Bridgestone Corporation Rubber composition and pneumatic tire made therefrom
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
AR043063A1 (en) 2002-12-13 2005-07-13 Altana Pharma Ag 6-SUBSTITUTED BENCIMIDAZOLS AND THEIR USE AS INHIBITORS OF GASTRIC SECRETIONS
AR042956A1 (en) 2003-01-31 2005-07-13 Vertex Pharma GIRASA INHIBITORS AND USES OF THE SAME
CL2004000409A1 (en) 2003-03-03 2005-01-07 Vertex Pharma COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003902860A0 (en) 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
AU2004263190A1 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
NL1026826C2 (en) 2003-08-13 2007-01-04 Pharmacia Corp Substituted pyridinones.
US7863310B2 (en) 2004-02-03 2011-01-04 Eli Lilly And Company Kinase inhibitors
WO2005075432A1 (en) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha 1-(2h)-isoquinolone derivatives and use thereof as anticancer agents
CN1934092A (en) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 Non-nucleoside reverse transcriptase inhibitors
US20080015196A1 (en) 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
ES2604197T3 (en) 2004-06-01 2017-03-03 University Of Virginia Patent Foundation Double small molecule inhibitors of cancer and angiogenesis
WO2005121132A1 (en) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. Fused heterocyclic compound having anti-hcv effect
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
CN101142194B (en) 2005-03-14 2012-10-10 顶点制药有限责任公司 Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
JP2008545622A (en) 2005-05-03 2008-12-18 ダウ アグロサイエンシィズ エルエルシー Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-triazin-6-ones and their use as fungicides
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
RU2008112691A (en) 2005-10-03 2009-10-10 Оно Фармасьютикал Ко., Лтд. (Jp) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ITS PHARMACEUTICAL APPLICATION
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
CA2630460C (en) 2005-12-01 2013-01-08 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
CN101384593A (en) 2006-02-17 2009-03-11 辉瑞有限公司 3-deazapurine derivatives as tlr7 modulators
ES2374455T3 (en) 2006-02-17 2012-02-16 Pfizer Limited DERIVATIVES OF 3-DEAZAPURINZA AS MODULATORS OF TLR7.
EP2007750B1 (en) 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
WO2008054599A2 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
CN101636386A (en) 2006-12-14 2010-01-27 安斯泰来制药有限公司 Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents
SG144809A1 (en) 2007-01-11 2008-08-28 Millipore U K Ltd Benzimidazole compounds and their use as chromatographic ligands
CN101641339B (en) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 Compounds for the prevention and treatment of cardiovascular diseases
WO2008153701A1 (en) 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
AU2008267444A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007038957A1 (en) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-thioxo-pyridazine derivatives
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
WO2009054790A1 (en) 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
US8269009B2 (en) 2007-12-07 2012-09-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
WO2009084693A1 (en) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation Antitumor agent
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2009158258A1 (en) 2008-06-25 2009-12-30 E. I. Du Pont De Nemours And Company Herbicidal dihydro oxo six-membered azinyl isoxazolines
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
AU2009283195A1 (en) 2008-08-18 2010-02-25 Yale University MIF modulators
JP5930278B2 (en) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター MLK inhibitors and methods of use
PT2370413E (en) 2008-12-08 2015-10-23 Arena Pharm Inc Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
DE102008062826A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh pyridazinone derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
JP2012519732A (en) 2009-03-09 2012-08-30 サーフェイス ロジックス，インコーポレイティド RHO kinase inhibitor
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior Methods and compositions of treating a flaviviridae family viral infection
MX2021012876A (en) 2009-03-18 2022-06-23 Resverlogix Corp Novel anti-inflammatory agents.
ES2821018T3 (en) 2009-04-22 2021-04-23 Resverlogix Corp New anti-inflammatory agents
CN102414206B (en) 2009-05-05 2014-11-05 霍夫曼-拉罗奇有限公司 Isoxazole-pyridine derivatives
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
JP5524343B2 (en) 2009-11-05 2014-06-18 グラクソスミスクライン エルエルシー Benzodiazepine bromodomain inhibitor
ME02356B (en) 2009-11-05 2016-06-20 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
ES2549502T3 (en) 2009-11-20 2015-10-28 Sk Chemicals Co., Ltd. Gonadoliberin receptor antagonists, method of manufacture thereof, and pharmaceutical composition containing them
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
KR101165996B1 (en) 2010-04-23 2012-07-18 주식회사 녹십자 Phthalazinone derivatives, preparation method thereof and pharmaceutical composition comprising same
BR122014024883A2 (en) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. COMPOUNDS IN NEOPLASIA TREATMENT
CA2810162A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2011159926A1 (en) 2010-06-16 2011-12-22 Rutgers, The State University Of New Jersey Antimicrobial agents
US20130165426A1 (en) 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
KR101242572B1 (en) 2010-10-12 2013-03-19 한국화학연구원 Phthalazinone derivatives substituted 5-membered heterocyclic aryl, or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
CN102731409A (en) 2011-04-08 2012-10-17 中国科学院上海药物研究所 Pyridazinone compound, and pharmaceutical compositions, preparation method and use thereof
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
PT2773354T (en) * 2011-11-01 2019-07-17 Resverlogix Corp Oral immediate release formulations for substituted quinazolinones
CN103974950B (en) 2011-12-01 2016-12-21 凯莫森特里克斯股份有限公司 Substituted benzimidazole and benzopyrazoles class as CCR (4) antagonist
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
EP2888256A4 (en) 2012-08-24 2016-02-17 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
WO2014037340A1 (en) 2012-09-05 2014-03-13 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
US20150246888A1 (en) 2012-09-11 2015-09-03 Michael Johnson Enoyl reductase inhibitors with antibacterial activity
WO2014078257A1 (en) 2012-11-14 2014-05-22 Glaxosmithkline Llc Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CN104995190A (en) 2012-12-20 2015-10-21 拜耳医药股份有限公司 Bet-protein-inhibiting dihydroquinoxalinones
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US20160009725A1 (en) 2013-02-22 2016-01-14 Bayer Pharma Aktiengesellschaft Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
EP2958923A1 (en) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
WO2014128655A1 (en) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
CN105189488B (en) 2013-02-27 2018-07-24 百时美施贵宝公司 Carbazole compound as bromodomain inhibitor
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
JP2016512524A (en) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド Bromodomain inhibitor
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
TW201444843A (en) 2013-03-11 2014-12-01 Abbvie Inc Bromodomain inhibitors
WO2014165127A1 (en) 2013-03-12 2014-10-09 Abbvie Inc. Pyrrole amide inhibitors
MX2015011984A (en) 2013-03-12 2015-12-15 Abbvie Inc Dihydro-pyrrolopyridinone bromodomain inhibitors.
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors
MX367420B (en) 2013-03-14 2019-08-21 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins.
CA2901537C (en) 2013-03-14 2021-09-07 Glaxosmithkline Intellectual Property (No.2) Limited 2,3-disubstituted 1- acyl-4-amino-1 ,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
KR102244719B1 (en) 2013-03-15 2021-04-26 플렉시콘 인코퍼레이티드 Heterocyclic compounds and uses thereof
CA2904364A1 (en) 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
BR112015022942B1 (en) 2013-03-15 2022-02-22 Incyte Holdings Corporation Tricyclic heterocycle compounds, method for inhibiting bet protein in vitro and pharmaceutical composition comprising said compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
JP6370368B2 (en) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Indolinone analogs as BRD4 inhibitors
EP2978758B1 (en) 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Dihydroquinazolinone analogues as brd4 inhibitors
TWI530499B (en) 2013-03-28 2016-04-21 吉李德科學股份有限公司 Benzimidazolone derivatives as bromodomain inhibitors
WO2014170350A1 (en) 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
EP2792355A1 (en) 2013-04-17 2014-10-22 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
WO2014173241A1 (en) 2013-04-26 2014-10-30 Beigene, Ltd. Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
TWI527811B (en) 2013-05-09 2016-04-01 吉李德科學股份有限公司 Benzimidazole derivatives as bromodomain inhibitors
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (en) 2013-05-27 2016-03-01 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease.
CA2915419A1 (en) 2013-06-17 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted phenyl-2,3-benzodiazepines
CA2915622C (en) 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
AU2014284616B2 (en) 2013-06-21 2019-02-28 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
AR096758A1 (en) 2013-06-28 2016-02-03 Abbvie Inc BROMODOMINIUM CRYSTAL INHIBITORS
JP2016523964A (en) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Tricyclic heterocycles as BET protein inhibitors
CN105555786A (en) 2013-07-23 2016-05-04 拜耳制药股份公司 Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US20190055235A1 (en) 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
JP2017538721A (en) 2014-12-17 2017-12-28 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Bromodomain inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP3027604A4

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9598367B2 (en) 2012-12-21 2017-03-21 Zenith Epigenetics Ltd. Heterocyclic compounds as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9861637B2 (en) 2012-12-21 2018-01-09 Zenith Epigenetics Ltd. Heterocyclic compounds as bromodomain inhibitors
US10717739B2 (en) 2013-03-14 2020-07-21 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US10266536B2 (en) 2013-03-14 2019-04-23 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US10010556B2 (en) 2013-06-21 2018-07-03 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US9663520B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US11026926B2 (en) 2013-06-21 2021-06-08 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10363257B2 (en) 2013-06-21 2019-07-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10226451B2 (en) 2013-06-21 2019-03-12 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10166215B2 (en) 2013-06-21 2019-01-01 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US11446306B2 (en) 2013-06-21 2022-09-20 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10772892B2 (en) 2013-06-21 2020-09-15 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US9988376B2 (en) 2013-07-03 2018-06-05 Glaxosmithkline Intellectual Property Development Limited Benzothiophene derivatives as estrogen receptor inhibitors
US9993514B2 (en) 2013-07-03 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Compounds
US10500209B2 (en) 2013-07-31 2019-12-10 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
WO2015153871A3 (en) * 2014-04-04 2015-12-17 Constellation Pharmaceuticals, Inc. EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US11512083B2 (en) 2015-03-18 2022-11-29 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016146755A1 (en) 2015-03-19 2016-09-22 Glaxosmithkline Intellectual Property Development Limited Covalent conjugates of bet inhibitors and alpha amino acid esters
CN104887680A (en) * 2015-05-08 2015-09-09 胡继承 New application of multi-poly ADP RNA polymerase inhibitor in treating HBV-related diseases
WO2016189042A1 (en) * 2015-05-28 2016-12-01 Bayer Pharma Aktiengesellschaft Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels
WO2017015027A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US11554171B2 (en) 2015-08-19 2023-01-17 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10428026B2 (en) 2015-09-02 2019-10-01 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
US10927080B2 (en) 2015-09-02 2021-02-23 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
US10370356B2 (en) 2015-09-22 2019-08-06 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
US10471050B2 (en) 2015-10-05 2019-11-12 Glaxosmithkline Intellectual Property (No.2) Limited 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
US10508106B2 (en) 2015-11-25 2019-12-17 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
US11028079B2 (en) 2015-11-25 2021-06-08 Convergene, Llc Small molecule BET bromodomain inhibitors and uses thereof
EP4050005A1 (en) * 2015-11-25 2022-08-31 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
US10517877B2 (en) 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
US10934272B2 (en) 2016-04-07 2021-03-02 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridyl derivatives as bromodomain inhibitors
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017202742A1 (en) * 2016-05-24 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors
US10844015B2 (en) 2016-05-24 2020-11-24 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US10966961B2 (en) 2017-03-01 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited Pyrazole derivatives as bromodomain inhibitors
US10849897B2 (en) 2017-03-01 2020-12-01 Glaxosmithkline Intellectual Property (No.2) Limited Pyridyl derivatives as bromodomain inhibitors
US11771703B2 (en) 2017-03-17 2023-10-03 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US11759533B2 (en) 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US11834460B2 (en) 2018-01-26 2023-12-05 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2019199816A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
EP4067352A4 (en) * 2019-11-26 2023-11-29 Benobio Co., Ltd. Novel quercetin redox derivative and use thereof as bet inhibitor
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2022053967A1 (en) * 2020-09-09 2022-03-17 Aurigene Discovery Technologies Limited Heterocyclic compounds as cbp/ep300 bromodomain inhibitors

Also Published As

Publication number Publication date
JP2016527263A (en) 2016-09-08
CN105593224A (en) 2016-05-18
EA201690087A1 (en) 2016-08-31
EP3027604A4 (en) 2016-12-14
CA2919948A1 (en) 2015-02-05
WO2015015318A3 (en) 2015-07-16
KR20160038008A (en) 2016-04-06
IL243479B (en) 2019-06-30
WO2015015318A4 (en) 2015-09-03
US10500209B2 (en) 2019-12-10
US9855271B2 (en) 2018-01-02
AU2014298051A1 (en) 2016-01-28
HK1218547A1 (en) 2017-02-24
JP6542212B2 (en) 2019-07-10
EP3027604A2 (en) 2016-06-08
US20180092924A1 (en) 2018-04-05
US20160193218A1 (en) 2016-07-07
EP3027604B1 (en) 2019-02-20
AU2014298051B2 (en) 2018-11-15
IL243479A0 (en) 2016-02-29
CN105593224B (en) 2021-05-25
CA2919948C (en) 2020-07-21

Similar Documents

Publication Publication Date Title
US10500209B2 (en) Quinazolinones as bromodomain inhibitors
US11026926B2 (en) Substituted bicyclic compounds as bromodomain inhibitors
US9278940B2 (en) Cyclic amines as bromodomain inhibitors
US10231953B2 (en) Inhibitors of bromodomains
EP3230277B1 (en) Substituted heterocycles as bromodomain inhibitors
WO2016097870A1 (en) Substituted bicyclic compounds as bromodomain inhibitors
EP3227281A1 (en) Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) Substituted pyridines as bromodomain inhibitors
WO2017103670A1 (en) 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 243479

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2014832298

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201690087

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2014298051

Country of ref document: AU

Date of ref document: 20140730

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2919948

Country of ref document: CA

Ref document number: 2016530632

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14908898

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832298

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20167005227

Country of ref document: KR

Kind code of ref document: A